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Growth and development of the prostate are regulated by androgens and mesenchymal-
epithelial interactions. Prostate growth starts in the embryo, continues throughout
neonatal life, and is completed at puberty. The male and female embryonic urogenital
sinus (UGS) both contain a prostate precursor, but due to the action of testosterone only
the male will develop a prostate. Testosterone acts in concert with paracrine signalling
from inductive mesenchyme to regulate epithelial growth and branching of the prostate.
The ventral mesenchymal pad (VMP) is an area of inductive mesenchyme that is rich in
regulatory growth factors of which few have been identified at present. Recently, the
role of mesenchyme/stroma in cancer has been established and developmental factors
may be involved in mediating the effects of cancer stroma. The aim of this thesis was to
identify mesenchymal factors and characterise their expression and function in the
developing prostate, and to investigate their expression in prostate cancer stroma.
The LongSAGE technique was used to generate a comprehensive transcriptional profile
of the neonatal rat prostate rudiment. LongSAGE is an open-ended and unbiased gene-
profiling method. Two libraries were made from tissues in the female UGS; one library
was prepared from the whole female prostate rudiment and the other library was
prepared from the inductive mesenchyme (VMP) isolated from within the rudiment.
Several essential factors known to be involved in prostate development were identified
in the libraries, including low abundance cDNAs such as AR and FgflO. This suggested
that the approach had sufficient sensitivity to identify key mesenchymal factors. The
two libraries were compared, and the comparison was statistically analysed,
highlighting genes that were VMP-enriched (P<0.05). Candidate mesenchymal
transcripts were selected from the VSU and VMP Libraries by two different approaches,
either because of their status as VMP -enriched (P<0.05) transcripts, or by an 'intuitive'
approach, because the transcripts were associated with genes that are known members
of developmental pathways and/or have been associated with prostate cancer. The
expression and abundance of candidate transcripts were quantified by qRT-PCR in the
male and female neonatal UGS. Subsequently, candidate transcripts were verified as
VMP-enriched and were quantified during prostate development by Northern blot
analysis. The protein distribution of selected candidates were localised within the
neonatal rat UGS by immunocytochemistry, and the effect of testosterone treatment on
the protein distribution was studied. To test the function of one of the candidates on
prostate growth and development, recombinant protein was added to prostate rudiments
grown in vitro. Finally, candidate transcripts were investigated in human prostate
cancer associated fibroblast cells (CAFs) and normal prostate fibroblast cells (NPFs) by
RT-PCR and Northern blot analysis.
SAGE analysis, qRT-PCR and Northen blot analysis identified six candidate transcripts
as VMP-enriched; Dlkl, Notch2, Ptn Nell2, MMP2 and MMP14. The transcript
expression of each candidate was most abundant in the developing rat prostate during
the perinatal period. Proteins for Dlkl, Ptn and Notch2 were localised to mesenchymal
cells of the neonatal VMP and ventral prostate (VP). Ptn expression was also associated
with the basement membrane and cell-surface of the epithelial duct cells of the VP.
Treatment of VP organs with recombinant DLK1 in vitro increased the organ size and
epithelial branching. Also, PTN, NOTCH2, MMP2 and MMP14 transcript expression
was observed in CAFs and NPFs. PTN and NOTCH2 showed a decrease in CAFs
compared to NPFs suggesting a tumour-suppressive role.
In summary, a comprehensive gene profiling technique was used to identify
mesenchyme specific/enriched transcripts in the developing prostate. The expression,
distribution and function of candidate transcripts and proteins were investigated in the
developing prostate and in prostate cancer stroma.
iv
Acknowledgements
I would first of all like to express my gratitude to Dr. Axel Thomson, my supervisor, for
giving me the opportunity to undertake this Ph.D., and for being a constant source of
guidance, enthusiasm and motivation. Also, a huge thank-you to the other members of
the 'Prostate Group'. I am grateful to Dr. Griet Vanpoucke, for her patient teaching and
supervision as the all-knowing post-doc, her friendly support and good humour, and
the data acknowledged in this thesis. A priceless source of information and motivation!
Also, many thanks to Cathal Grace for all his help in the lab, the never -ending organ
dissections, organ culture experiments, and helping me to "take it easy", and to
Raymond Chan for the endless Mini-Preps needed to make the LongSAGE libraries.
Further individual thank-you's to Frances Collins for her being a consistent source of
molecular biology tips when I first tackled LongSAGE, to Mike Millar and Sheila
Macpherson for all the hours on the Confocal, to Arantza Esnal for embedding those
tiny organ cultures, and to Nina Hallmark for answering the wealth of "little thesis
questions", and cheering me on. Also, thank -you to the HGU Sequencing Facility,
Edinburgh, for the superhuman amount of Sequencing and to Dr. Simon Hayward,
University of Vanderbilt, USA, for supplying the CAF and NPF cells.
A collective thank-you to everyone I've worked with at the MRC and the University of
Edinburgh, too numerous to mention, who have contributed to this project, and who
have made completing a Ph.D., a happy and productive time.
Finally, a special thank-you to my family, who now know a bit too much about the
prostate. I couldn't have done it without you!
I dedicate this thesis to my aunt, Anne-Marie Andrews, to my grandmother, Laura































































deoxycytidine 5'-[32P] triphosphate triethylammonium salt
Extracellular matrix
ethylene diaminetetra -acetic acid
Epidermal growth factor








GAPDH Glyceraldehyde 3-phosphatase dehydrogenase
GDNFRal Glial derived neurorophic factor receptor alpha 1
VI
GLGI Generation of Longer cDNA fragments from SAGE tags for Gene
Identification
GnRH Gonadotrophin hormone releasing hormone
Hgf Hepatocyte growth factor
HSPG Heparin sulfate proteoglycans





Lgl 1 Late gestation lung factor 1
LH Luteinising hormone




MPSS Massively parallel signature sequencing
mRNA message ribonucleic acid
Nell2 Nel -like 2
NTP Nucleoside 5'-Triphosphate
PBS Phosphate buffered saline
PCR polymerase chain reaction
Pdgf platelet derived growth factor
PMP Peripheral myelin protein
Ptn Pleiotrophin




RT-PCR reverse transcriptase polymerase chain reaction
s sense
SAGE Serial analysis of gene expression
SAM s-adenosylmethionine
Sfrp Secreted frizzled protein
Shh Sonic hedgehog
SM Smooth muscle
SM a actin Smooth muscle alpha actin




TBS tris buffer saline
TBST tris -buffer saline tween 20
TBP TATA -box binding protein
Tfm Testicular feminized mouse strain
TF8 Transcription factor 8
TGFp Transforming growth factor beta
TGFPR Transforming growth factor beta receptor
TGFi Transforming growth factor beta induced
TIMPS Tissue inhibitors of matrix metalloproteinases
Tm melting temperature
TNFa Tumour necrosis factor alpha






VAP1 vascular adhesion protein 1
VMP ventral mesenchymal pad
VP ventral prostate






List of Abbreviations v
Table of Contents viii
List of Tables and Figures xiv
Chapter 1 Introduction
1.1 The Prostate
1.1.1 The Adult Prostate 2
1.1.2 Development of the rat prostate 3
1.2 Endocrinology of Prostate Induction and Growth 5
1.3 Mesenchymal -Epithelial Interactions During Development 8
1.3.1 The andromedin hypothesis and androgen action 12
1.3.2 Sexually dimorphic smooth muscle expression regulates
prostatic organogenesis. 12
1.4 Stromal -Epithelial Interactions in the Adult Prostate
and Prostate Cancer. 15
1.5 Molecular Control ofNormal and Neoplastic Prostate
Development 21
1.5.1 Normal prostate development 21
1.5.2 Neoplastic prostate development 25
1.6 Summary 27
1.7 Project Aims 28
Chapter 2 Materials and Methods
2.1 Materials
2.1.1 Equipment 28
2.1.2 Computer Software 30
2.1.3 Enzymes 31
2.1.4 Nucleic Acids 31
2.1.5 Chemicals 32
2.1.6 Bacterial Strain Genotypes 32
2.1.7 Bacterial Culture Media 32
2.1.8 Northern Blotting and Hybridisation Equipment 32
ix
2.1.9 Immunohistochemical Reagents 33
2.1.10 Organ Culture Media, Equipment 34
2.1.12 Standard Solutions (A to Z) 36
2.2 Methods
2.2.1 Total RNA Extraction 37
2.2.2 DNase Treatment of Total RNA 37
2.2.3 cDNA Synthesis 37
2.2.4 Polymerase Chain Reaction 38
2.2.5 qRT-PCR - LightCycler Analysis 38
2.2.6 Cloning of PCR Products 42
2.2.6.1 Preparation of Insert DNA 42
2.2.6.2 Ligation 42
2.2.7 Plasmid DNA Preparation 42
2.2.7.1 Plasmid Mini-Preparation 42
2.2.7.2 Restriction Endonuclease Digestion 42
2.2.8 Agarose Gel Electrophoresis 43
2.2.8.1 DNA 43
2.2.8.2 RNA- Formaldehyde gel 43
2.2.9 Northern Blotting and Hybridisation 43
2.2.9.1 Northern Blotting 43
2.2.9.2 In vitro transcription of 32P labelled DNA probes 44
2.2.9.3 Hybridisation of Labelled DNA Probes to RNA Blot 44
2.2.10 Immunocytochemistry 45
2.2.10.1 Paraffin Embedding of Tissue 45
2.2.10.2 Tissue Immunohistochemistry 45
2.2.10.3 Fluorescent Tissue Immunocytochemistry 46
2.2.11 In Vitro Organ Culture 46
2.3. LongSAGE 46
2.3.1. Materials 47
2.3.1.1 Tissue Samples and RNA Preparation 47
2.3.2 Method
2.3.2.1 SAGE Library Preparation 48
2.3.3 Library Analysis 52
2.3.3.1 Tag Quantification 52
2.3.3.2 Statistical analysis 53
X
2.3.3.3 Tag-to-Gene Annotation 53
2.3.3.4 Literature Mining and Candidate Selection 53
2.3.3.5 Gene Ontology Assignment 54
Chapter 3. Gene Expression Profiling and Serial Analysis of Gene
Expression (SAGE).
3.1 Introduction 55
3.1.1 Gene Expression Profiling Techniques 55
3.1.2 SAGE and LongSAGE 56
3.1.2.1 SAGE Bioinformatics 58













3.3 Discussion of Library Preparation and Analysis 72
3.3.1 VSU and VMP Library Preparation 72
3.3.2 Bioinformatics -Library Analysis 73
3.3.2.1 Extracting the Tag Data 75
3.3.2.2 Tag-to-Gene Annotation 76
3.3.2.3 Differential Tag Expression in the LongSAGE libraries 77
3.3.2.4 Gene Ontology of VMP-enriched Tags 78
3.3.2.5 Selection of Genes of Interest 79
Chapter 4. LightCycler Analysis and Selection of Candidate Genes
4.1 Introduction 80
4.2 Results 80
4.2.1 Selecting Genes for Further Analysis 80
4.2.2 Experimental Validation of LongSAGE Libraries 81
4.2.2.1 VMP-Enriched Genes Verified by LightCycler Analysis 81
4.2.2.2 LightCycler Analysis Identifies VSU-enriched Genes 82
3.2 Results
3.2.1 Library Preparation
3.2.2 The VSU and VMP LongSAGE Libraries
3.2.3 Bioinformatics -Library Analysis
3.2.3.1 Extracting the SAGE tag data
3.2.3.2 Comparison of the VSU and VMP Libraries
3.2.3.3 Statistical Analysis
3.2.3.4 Tag-to-Gene Annotation
3.2.3.5 Assignment to Gene Ontology
3.2.3.6 Developmental Pathways and Regulatory Genes
3.2.4 Summary of Results
xi
4.2.2.3 LightCycler Analysis Identifies No Difference in
Transcript Expression 83
4.2.2.4 Selection of Candidate Genes 84
4.2.3 Summary of Results 85
Chapter 5 Delta-Like 1 homolog
5.1 Introduction 87
5.2 Results 92
5.2.1 Delta-Like 1 Transcript Expression in the VMP and VSU 92
5.2.2 Dlkl transcript levels in the prostate and selected organs 93
5.2.3 Dlkl Protein Localisation in the UGS 93
5.2.4 The effect of Testosterone on Dlkl distribution 95
5.2.5 Functional Studies on Dlkl 100
5.2.6 Summary of Dlkl Results 102
Chapter 6. Notch 2
6.1 Introduction 103
6.2 Results 107
6.2.1 Notch! Transcript Expression in the VSU and VMP 107
6.2.2 Notch2 transcript levels in the prostate and selected organs 108
6.2.3 Notch 2 Protein Localisation in the UGS. 108
6.2.4 The effect of Testosterone on Notch2 distribution 110




7.2.1 Ptn Transcript Expression in the VSU and VMP 118
7.2.2 Ptn transcript levels in the prostate and selected organs 119
7.2.3 Pleiotrophin Protein Localisation in the UGS 121
7.2.4 The effect of Testosterone on Ptn distribution 125
7.2.5 Functional studies on Ptn 127
7.2.6 Summary of Pleiotrophin Results 127
xii
Chapter 8. Other Candidate Genes; Nell2, MMP2 and MMP14
8.1 Introduction 128
8.1.1 Nell2 128
8.1.2 MMP2 and MMP14 131
8.2 Results 135
8.2.1 Nell2, MMP2 and MMP14 transcript expression in the
VSU and VMP 135
8.2.2 Nell2 transcript levels in the prostate and selected organs 136
8.2.3 MMP2 transcript levels in the prostate and selected organs 138
8.2.4 MMP14 transcript levels in the prostate and selected organs 138
8.2.5 Summary of results 142
Chapter 9. Candidate Expression in Prostate Cancer Stroma
9.1 Introduction 143
9.2 Results 145
9.2.1 Expression of candidate transcripts in the human prostate 145
9.2.2 PTN protein localisation in the human prostate 148
9.2.3 Summary of results 149
Chapter 10. Discussion
10.1 LongSAGE 150
10.2 Experimental Validation of the LongSAGE Libraries 151
10.3 Delta-Like 1 (Homolog) 153
10.3.1 Dlkl transcript expression 153
10.3.2 Dlkl Protein Expression in the Neonatal UGS 155
10.3.2.1 The Effect of Testosterone on Dlkl Protein Distribution 156
10.3.3 Dlkl Functional Studies 157
10.4 Notch2 158
10.4.1 Notch2 Transcript Expression 158
10.4.2 Notch2 Protein Expression 160
10.4.2.1 The Effect of Testosterone on Notch2 Protein Distribution 160
10.4.3 Notch2 Function in the Developing Prostate 161
xiii
10.5 Pleiotrophin 163
10.5.1 Pleiototrophin Transcript Expression 163
10.5.2 Pleiotrophin Protein Expression 164
10.5.2.1 Effect of Testosterone on Pleiotrophin Protein Distribution 165
10.5.3 Pleiotrophin Functional Studies 165
10.6 NeI12 167
10.7 MMP2 and MMP14 168
10.8 Candidate Expression in Prostate Cancer Stroma 170
10.9 Project Conclusions 172
10.9.1 A Novel Approach to Studying Prostate Development 172
10.9.2 How successful was the use of LongSAGE analysis? 173
10.9.3 How could the LongSAGE data be further mined? 174
10.9.4 LongSAGE analysis is a robust, reliable and interesting approach
to gene expression profiling? 175
10.9.5 What does the LongSAGE data tell us about prostate
development and prostate cancer? 176
10.10 Final Summary 178
Chapter 11 Bibliography 180
Appendix 219
xiv







Schematic illustration of the anatomy of the prostate 3
Stages of early development of the ventral prostate lobe 5
The hypothalamic-pituitary-gonadal axis regulates prostate
development 7
Summary of tissue recombination experiments between
urogenital sinus mesenchyme and epithelium from Tfm and
wild-type embryos 10
A model of ventral prostate induction and development. 14
Interactions between the epithelial and the stromal/mesenchymal
components of the prostate during development and adulthood. 17
Table 2.1 Antibodies used for Immunohistochemistry 34
Table 2.2: Recombinant proteins used in organ culture experiments 35
Table 2.3 Table of commercial kits used 35
Table2.4: Rat Primers for RT-PCR, LightCycler Analysis and DNA probes 39
Table 2.5 Human Primers for RT-PCR, LightCycler Analysis and
DNA probes 41
Fig: 2.1 The Prostate Rudiment 47
Table 2.6 Tissue collected and RNA used for LongSAGE libraries 48
Fig 2.2: The LongSAGE method 49
Fig 3.1 Steps for data analysis of SAGE Libraries 59
Table 3.1 LongSAGE protocol modifications 62
Table 3.2: Features of the VSU and VMP LongSAGE Libraries 62
Fig 3.2: Flow -Diagram of the LongSAGE protocol 63
Table 3.3: Summary of the VSU and VMP SAGE Library Data 66
Fig 3.3: Flow-diagram of the tag-to-gene annotation process 67
Table 3.4 Full VSU Library-saved to CD and appended at end of thesis
Table 3.5 Full VMP Library-saved to CD and appended at end of thesis
Table 3.6 Comparison of rat LongSAGEmap vs. BLAST for tag-to-gene
annotation of VMP-enriched tags 69
Graph 3.1 Functional classification of VMP-enriched genes (P<0.05)
from the LongSAGE Libraries 70
Table3.7 Regulatory and developmental genes from the
LongSAGE libraries 71
Graph 4.1 SAGE Tags Verified to be VMP-enriched 82
Table 4.1 Genes identified as VSU-enriched by LightCycler analysis 83
Table 4.2 Genes that show no difference in expression between the
VSU and VMP by LightCycler analysis 84
Table 4.3 Genes associated with candidates identified in the VSU
and VMP Libraries 85
XV
Fig 5.1: Structure of the Dlkl and Delta Proteins 87
Fig 5.2 Dlkl mRNA expression in the male and female rat UGS 92
Fig 5.3: Dlkl mRNA expression during prostatic ontogeny and
expression in other selected organs (PO) 94
Fig 5.4: Dlk 1 expression in female and male rat UGS 96
Fig 5.5 Dlkl and smooth muscle alpha actin expression in
the female UGS 97
Fig 5.6 Dlkl and smooth muscle alpha actin expression
in the neonatal male UGS 98
Fig 5.7 The effect of testosterone on Dlk 1 expression 99
Fig 5.8 The effect of Dlkl on VP growth 101
Fig 6.1 Schematic diagram of the Notch2 protein 103
Fig 6.2 Notch2 mRNA expression in the male and female UGS 107
Fig 6.3 Notch2 mRNA expression during prostatic ontogeny
and expression in other selected organs (PO) 106
Fig 6.4 Notch 2 expression in Male and Female UGS and the Ovary 111
Fig 6.5 The effect of testosterone on Notch2 expression 112
Fig 7.1 Ptn mRNA expression in the male and female UGS 119
Fig 7.2 Ptn mRNA expression during prostatic ontogeny and expression
in other selected organs (PO) 120
Fig 7.3 Pleiotrophin expression in the male and female UGS 122
Fig 7.4 Pleiotrophin and (3-catenin expression in the male UGS 124
Fig 7.5 Ptn and p63 expression in the male UGS 125
Fig 7.6 The effect of testosterone on Ptn localisation 126
Fig 8.1 Schematic of NELL2 protein 129
Fig 8.2 Schematic of MMP2 and MMP14 Proteins 132
Fig 8.3 Nell 2, MMP2, MMP14 and FgflO mRNA expression
in the male and female UGS 137
Fig. 8.4 Nell2 mRNA expression during prostatic ontogeny
and expression in other organs (P0) 139
Fig. 8.5 MMP2 mRNA expression during prostatic ontogeny
and expression in other organs (P0) 140
Fig. 8.6 MMP14 mRNA expression during prostatic ontogeny
and expression in other organs (P0) 141
Fig 9.1 Summary of CAF/NPF and BPH tissue recombination
Experiments 144
Fig 9.2 Gene Expression in Human Foetal Tissues and Cells 146
Graph 9.1 PTN and NOTCH2 mRNA Expression in CAFs and NPFs. 146
Fig 9.4 Pleiotrophin protein expression in the human prostate 148
Appendix VMP-upregulated genes (P<0.05) identified by LongSAGE analysis
Chapter 1 Introduction I
1. Introduction
Growth and development of the prostate is mediated by androgens and mesenchymal
interactions, and mesenchymal factors are essential for resulting growth and
development (Cunha and Chung, 1981). The mesenchyme produces essential
paracrine factors that act on the epithelium to stimulate growth in the developing
prostate. The mesenchymal factors, fibroblast growth factor 10 (Fgf 10) (Thomson
and Cunha, 1999) and fibroblast growth factor 7 (Fgf 7) (Sugimura et al., 1996) have
been identified in prostate development, and several other possible candidates have
been proposed. A highly localised area of condensed mesenchyme at the base of the
bladder, called the ventral mesenchymal pad (VMP) has been identified as a source
of the instructive signalling, and is a tissue rich in regulatory factors (Timms et al.,
1995). The mesenchymal signals may be directly controlled by androgens, but to
date, there is little experimental evidence to support this (Peehl and Rubin, 1995).
Thomson et al., (2002) has proposed a novel mechanism by which the sexually
dimorphic expression of the smooth muscle layer in the urogenital tract of the
embryo, mediates the androgen control of signalling from the mesenchyme. This
suggests that prostatic inductive factors are constitutively expressed in the VMP.
Mesenchymal factors from the adult prostate stroma act to maintain normal prostatic
epithelial differentiation and homeostasis (Gao et al., 2001), and it has been
established that the mis-expression of factors by the stroma may be responsible for
directly epithelial mitogenesis during the early stage of prostate cancer (Tuxhorn et
al., 2002). The identification of mesenchymal factors in the growing prostate would
help to characterise a developmental pathway that may be reactivated in the disease
state. This project aimed to identify developmental mesenchymal factors and to
determine if they were expressed in neoplastic prostate development. Expression of
these factors during prostate cancer may represent markers of disease or potential
therapeutic targets.
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1.1 The Prostate
1.1.1 The adult prostate
The prostate is a male accessory gland found only in mammals and functions by
contributing secretory proteins and other factors to seminal fluid. Interest in studying
the biology of the prostate is driven both by the fascinating nature of the
developmental processes that give rise to the prostate, and by the high incidence in
humans of prostatic diseases, including prostatic adenocarcinoma and benign
prostatic hyperplasia. In the UK, BPH is found in approximately 1 in 3 men over the
age of 60 and 65,000 BPH patients per year will undergo surgical treatment for this
condition. Also, there are approximately 50,000 men living with prostate cancer,
while approximately 10,000 men per year will die of prostate cancer, and about
27,000 new cases of prostate cancer will be diagnosed.
The prostate surrounds the urethra close to the base of the bladder and is composed
of a tubuloalveolar gland arranged in lobules surrounded by stroma. Located deep
within the pelvis, the gland is rich in nerves smooth muscle, collagen and lymphatics.
In rodents the prostate (Fig 1.1, Panel B) is divided into morphologically and
biochemically distinct lobes that are named according to their position: anterior (also
called coagulating gland), dorsal, dorso-lateral and ventral. In contrast, the adult
human prostate (Fig 1.1, Panel A) is a compact gland without distinct lobes. It is
roughly the size and shape of a walnut and it exhibits three distinct zones: central,
peripheral and transitional, reflecting three distinct sets of ducts (McNeal, 1980,
1983). Comparative observations of prostatic development in rodents and humans
demonstrated that prostatic morphogenesis occurs in an analagous manner in both
humans and rodents, with several distinct sets of epithelial buds growing out of the
urethra into the UGM (Price, 1963, Timms et al., 1994). Nevertheless, compelling
molecular evidence for homology between specific rodent prostatic lobes and human
prostatic zones has yet to be identified.
Mature prostatic ducts contain three major cell types, luminal secretory epithelial
cells, basal epithelial cells and stromal smooth muscle cells. Other less common cell
types include fibroblasts, neuroendocrine cells as well as rare basal epithelial cells
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with unique marker expression profiles that are candidates for epithelial stem cells
(Collins et al., 2001, Wang et al., 2001). In both the mouse and human, the ductal
lumen is lined by tall columnar secretory epithelial cells, and the stromal layer,
although largely composed of smooth muscle, also contains fibroblastic neuronal,
lymphatic and vascular cell types (as reviewed by Marker et al., 2003).
Fig. 1.1 Schematic illustration of the anatomy of the prostate
The human prostate (Panel A) and rat perinatal prostate and associated
reproductive organs (Panel B) (adapted from Abate-Shen, 2000 and Thomson et
al., 2001, respectively).
1.1.2 Development of the rat prostate
Growth and development of the prostate begins in foetal life and are complete at
sexual maturity. In all species the prostate develops from the endodermal urogenital
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ambisexual embryonic rudiment, which develops into the prostate, prostatic urethra
and bulbourethral glands in males, and the lower vagina and urethra in females and,
and into the bladder in both sexes (Staack et al., 2003). The endodermal UGS is
surrounded by embryonic connective tissue called urogenital sinus mesenchyme
(UGM). Before sexual differentiation of the UGS, UGM expresses androgen receptor
in both sexes and thus acquires the capacity to undergo masculine development
(Cooke et al., 1991).
In response to foetal testicular androgens, epithelial buds emerge from the wall of the
UGS (~E18.5) in the rat, and grow into an area of the surrounding UGM, termed the
ventral mesenchymal pad (VMP) (Fig 1.2, Panels A and B). The prostate contains
highly branched epithelial ducts that grow at their tips during development
(Sugimura et al., 1986). Branching morphogenesis starts in the perinatal period (rats
and mice) (Fig 1.2 Panel C), and is completed by the end of puberty (Kinbara and
Cunha, 1995, Sugimura et al., 1986). It has been demonstrated that 80% of
branching morphogenesis is complete by Day 10 of neonatal life in mice (Donjacour
and Cunha, 1988). Initially, the emerging prostatic buds and ducts are solid but
undergo canalization in the neonatal period. Epithelial cells of the developing, solid
prostatic cords are characterized by co-expression of cytokeratins 5, 8, 14, and 18
and p63 (Wang et al., 2001) Ductal canalization begins at the urethra and progresses
distally towards the ductal tips. During ductal canalization the epithelial cells
differentiate into luminal and basal cells. Basal epithelial cells become localized
along the basement membrane to form a discontinuous layer of cells expressing
cytokeratins 5 and 14 and p63 in the rat and mouse. Concomitantly, tall columnar
luminal cells, which express cytokeratins 8 and 18, differentiate and line the ductal
lumina. Secretory cytodifferentiation of the epithelium occurs postnatally in rodents,
and prostate specific secretory proteins are initially detected in rats and mice at 12-20
days postnatal (Lopes et al., 1996). Prostatic epithelial differentiation is
accompanied by differentiation of the mesenchyme into smooth muscle and
fibroblasts (Hayward et al., 1996a, 1997) (reviewed by Marker et al., 2003). Growth
of the epithelium is highly regulated forming a precise spatial pattern, and thus
establish in rodents the four lobar subdivisions of the prostate. The different prostatic
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lobes each have a characteristic ductal branching pattern (Kinbara and Cunha, 1995,
Marker et al., 2003, Price, 1963, Sugimura et al., 1986), and also distinct secretions,
which may be specified due to differences in the mesenchyme.
Fig 1.2 Stages of early development of the ventral prostate lobe
The rat prostate rudiment is similar in the embryonic male and female UGS (E17.5)
(Panel A). In the male, epitheial buds emerge into the VMP in response to
androgens (~E18.5) (Panel B). The buds continue to grow and branching occurs
during early postnatal development of the rodent prostate (Panel C); 1) formation of
the epithelial duct lumen (proximal to distal, relative to the urethra) 2) epithelial cell
differentiation into basal and luminal cells (proximal to distal), 3) differentiation of
smooth muscle from mesenchyme (proximal to distal), and 4) ductal growth
localised to highly proliferative ductal tips. Androgen receptor (AR) expression is
localised to the mesenchyme until the formation of growing epithelial ducts, when
AR is also found expressed the epithelia (modified from Marker et al., 2003).
1.2 Endocrinology of Prostate Induction and Growth
The major steroids involved in induction and growth of the developing prostate, and
the adult prostate, are androgens. Androgens masculinize the reproductive tract
during the ambisexual stage to development and lead to the formation of the prostate.
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Androgens are required to initiate prostatic development, to continue embryonic and
neonatal prostatic growth, and subsequently to begin secretory activity at puberty.
The role of androgens in the prostate changes over the course of a lifetime, and
during adult life, androgens maintain the production of secretory proteins as well as
maintaining the tissue architecture of the prostate. The levels of circulating
androgens found in rats correlate with prostate development and production of
prostatic fluid during adulthood; androgen levels are relatively high towards the end
of gestation, decrease one day after birth and increase again during puberty
(Corpechot et al., 1981), and are high in adult life.
Androgen production is under the control of the hypothalamic-pituitary-gonadal
axis (Fig 1.3). GnRH from the hypothalamus acts on the pituitary gland to induce
the release of the gonadotropins follicle stimulating hormone (FSH) and luteinising
hormone (LH). In the male, LH acts on the Leydig cells of the testis to stimulate
synthesis of testosterone, the principal androgen of the testis, while FSH acts on the
Sertoli cells of the testis to induce inhibin production in the presence of testosterone.
Testosterone and inhibin exert a negative feedback regulation of LH and FSH
production at the levels of the pituitary and hypothalamus (as reviewed in Coffey,
1988).
In addition to androgens, prostatic development is sensitive to levels of oestrogenic
compounds. Most of the oestrogen in the male is derived from peripheral conversion
of oestrogens through an enzymatic aromatization reaction. During neonatal life
oestrogen levels exert many effects upon the growth and differentiation of the
prostate (Jarred et al., 2002, Prins, 1992, vom Saal, 1997). These effects might be
due to the alteration of androgen concentrations via the hypothalamic-pituitary-
gonadal axis or via direct effects upon the prostate, although inactivating mutations
in the ERa and ER|3 receptors have no affect on normal prostate development (Jarred
et al., 2002).
Testosterone functions as a prohormone in the prostate, and is converted into 5a-
dihydrotestosterone (DHT) (the active form) by 5a -reductase. DHT becomes the
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major androgen regulating the cellular events of growth differentiation and function
in the prostate. DHT is bound more efficiently by the androgen receptor and is thus
a more potent androgen; impairment of 5a-reductase reduces but does not
completely inhibit prostatic development (Imperato-McGinley et al., 1985, Marks et
al., 1999,Uygur, et al., 1998). Additionally, in a study of prostate specification in
marsupials a second testicular androgen 5a -androstane-3a, 17p-diol (5a-adiol) was
implicated as the circulating androgen that acts to specify the UGS, but further work
is required to verify this finding. In this study testosterone was also found to
contribute to epithelial growth through an action triggered by androgen receptor
binding (Foster and Cunha, 1999).
Fig 1.3 The hypothalamic-pituitary-gonadal axis regulates prostate
development
The systemic androgens produced by the foetal testis act to specify development of
the UGS into prostate. Cellular response to systemic androgens is mediated by
nuclear androgen receptors (AR), activated by testosterone (T) or
dihydrotestosterone (DHT). The requirements for and sufficiency of androgens in
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establishing prostate identity in the UGS is shown by the absence of a prostate in
mice and human that lack functional androgen receptors due to inactivating
mutations (Brown et al., 1988, Charest et al., 1991, Gaspar et al., 1991, He et al.,
1991, Lubahn et al., 1989), and by the development of a prostate in female urogenital
sinuses exposed to androgens (Takeda et al., 1986).
During prostatic induction, AR is expressed in mesenchymal cells but is absent
initially from epithelial cells (Takeda et al., 1985). AR is first observed in
mesenchymal cells, preceding the appearance of prostatic epithelial buds (see Fig
1.2, Panel A, B). Once prostatic epithelial buds have formed and begun to develop,
AR is observed in these growing epithelia (Hayward et al., 1996a)(see Fig 1.2, Panel
C). Androgen signalling is both necessary and sufficient for prostatic organogenesis
and epithelial androgen receptor is not required for development of the prostate
(Cunha and Chung, 1981).
1.3 Mesenchymal-Epithelial Interactions During
Development
In addition to androgens, mesenchymal -epithelial interactions play a key role in
directing the growth and development of the prostate, with morphogenesis and
differentiation of both the epithelium and mesenchyme aborted if the epithelium and
mesenchyme are grown separately.
Paracrine signalling from the mesenchyme to the epithelium is essential for prostatic
development. During prostatic development the UGM; (a) specifies prostatic
epithelial identity, (b) induces epithelial bud formation, (c) elicits prostatic bud
growth and regulates ductal branching, (d) promotes differentiation of a secretory
epithelium and, (e) specifies the types of secretory proteins which are expressed
(Hayashi et al., 1993, Marker et al., 2003). Also, although epithelial development is
regulated by the mesenchyme, the interaction is reciprocal, and it is likely that
epithelial signalling regulates differentiation of the mesenchyme into 'stroma',
composed of smooth muscle and fibroblasts (Hayward et al., 1996a). This has been
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demonstrated by the ability of different prostatic epithelia to elicit species-specific
patterns of stromal development (Hayward et al., 1998b). Tissue recombinants
composed of adult human prostatic epithelium and rat urogenital sinus mesenchyme
were grafted beneath the renal capsule of athymic rodent hosts. The rat
mesenchymal component differentiated into thick sheets of smooth muscle
characteristic of the human but not the rat prostate.
The action of androgen on mesenchymal cells is known to regulate epithelial
mitogenesis and morphogenesis and which is suggested to be mediated by paracrine
factors made by the mesenchyme, via an unknown mechanism. The role of
mesenchymal -epithelial interactions in urogenital development has been studied
extensively using grafting and tissue recombination methods in Tfm mice (Cunha,
1996, Cunha and Chung, 1981, Cunha et al., 1987, Cunha and Lung, 1978, Hayward
et al., 1997). Tfm mice lack a functional androgen receptor this results in loss of
prostatic development in mice carrying the mutation (Quigley et al., 1995). In tissue
recombinants made with epithelium (UGE) lacking androgen receptor function
(Tfm) combined with mesenchyme (UGM) containing "wild-type" androgen
receptor in the presence of androgens, the AR-deficient epithelium underwent
androgen -dependent ductal morphogenesis, epithelial proliferation and columnar
cytodifferentiation thus forming glandular epithelium resembling prostate (Fig 1.4).
However, tissue recombinants made with mesenchyme lacking androgen receptor
function (Tfm) and epithelium containing wild-type androgen receptor did not form
prostatic tissue. These experiments demonstrated that many androgenic effects
expressed in epithelium do not require epithelial AR, and are in fact elicited by the
paracrine action of AR-positive mesenchyme. Also, androgen receptor signalling in
mesenchymal cells is both necessary and sufficient for prostatic development (Cunha
and Chung, 1981). Further analysis of Tfm/wild-type recombinants revealed that
epithelial ARs are required for expression of AR-dependent secretory proteins
(Cunha and Young, 1991, Donjacour and Cunha, 1993)













Fig 1.4 Summary of tissue recombination experiments between urogenital
sinus mesenchyme and epithelium from Tfm and wild-type embryos.
A positive androgenic response (prostatic morphogenesis) occurs when wild-type
mesenchyme is grown in association with either wild -type or Tfm epithelium.
Conversely, no prostate structures are formed when either wild -type or Tfm
epithelium is grown in association with Tfm mesenchyme. These results
demonstrate that androgens elicit many of their effects on epithelial development via
mesenchymal androgen receptors (redrawn from Cunha et al 1983).
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The UGM, in the presence of androgens, determines epithelial identity so that
subsequent cell-cell interactions can elicit prostatic bud outgrowth, ductal branching
and prostatic differentiation. The ability of UGM to specify prostatic epithelial
identify was discovered by analysis of a tissue recombinants composed of UGM plus
epithelium of embryonic or fully differentiated adult urinary bladder, in which
bladder epithelium was induced by UGM to undergo prostatic differentiation.
Formation of prostatic tissue can be explained by two possible options; either the
adult BLE was terminally differentiated and was maintained or reprogrammed by
paracrine cues from the mesenchyme/stroma, or the BLE contained uncommitted
'stem cells' that were induced to form the prostate. Studies so far have been unable
to identify molecules produced by the UGM that induce prostatic epithelial
differentiation (reviewed by Cunha et al., 2004).
The mesenchyme involved in prostatic induction includes the peri -urethral
mesenchyme and ventral mesenchymal pad (VMP), a condensed pad of mesenchyme
peripheral to the urethral epithelium that is found in both males and females. The
VMP was initially characterized by Timms et al (1995) and has been shown to
function as an inducer of prostatic organogenesis in vivo, and is located adjacent to
the site of epithelial bud outgrowth and branching. The VMP appears to
constitutively express mesenchymal factors (i.e. not androgen-regulated) important
for prostatic growth. For example, fibroblast growth factor (FgflO), a key
mesenchymal regulator of prostate development, is expressed in the VMP of males
and females and is not directly regulated by testosterone in vitro (Thomson and
Cunha, 1999).
The finding that prostatic development involves epithelial proliferation and
differentiation has led to the hypothesis that there are mesenchymal paracrine -acting
factors that are regulated by androgens. The androgen-regulated factors are not
made in epithelial cells, despite the presence of the androgen receptor. In epithelial
cells, the function of the androgen receptor is most likely the regulator of secretory
proteins (Donjacour and Cunha, 1993) and perhaps epithelial differentiation.
Furthermore, AR expression in the mesenchyme of the early prostate prior to bud
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induction and the later appearance of AR in the growing epithelial cells supports the
idea that prostatic induction and early prostate growth are mediated by mesenchymal
signals.
1.3.1 The andromedin hypothesis and androgen action
As androgens have been proposed to regulate prostatic growth and development by
action on the mesenchyme, research has been focused on the identification of
paracrine factors that could mediate androgen action. The precise mechanism of
paracrine regulation of the prostate is not known, but a current hypothesis is that
androgens might regulate the activity of paracrine-acting factors made by the
mesenchyme, which regulates epithelial development. At present, mesenchymal
paracrine regulators of prostatic growth have been identified (e.g. Fgf7, Fgf10 and
Igfl) but androgens do not appear to directly regulate the genes for Fgf7 or FgflO
(Thomson and Cunha, 1999, Thomson et al., 1997), though other studies have
suggested that these factors may be androgen-regulated (Lu et al., 1999, Yan et al.,
1992). At present no growth factors, expressed in the mesenchyme, have been shown
unequivocally to be directly regulated by androgens (as reviewed by Thomson,
2001). Therefore, at present it appears that the expression of paracrine factors may
not be androgen -regulated and alternative mechanisms by which androgens might
control development have been investigated.
1.3.2 Sexually dimorphic smooth muscle expression regulates
prostatic organogenesis.
An alternative mechanism for androgen regulation of prostatic induction proposed by
Thomson et al (2002) has examined the role that differentiation of smooth muscle
might play in regulating prostatic induction. They proposed that androgens control
prostatic induction by regulating differentiation of smooth muscle within the UGM,
and consequently the signalling between mesenchyme and epithelium.
Smooth muscle appears in the rat UGS at ~R15 is formed by the differentiation of
mesenchymal cells, and appears to be regulated by epithelial signals. The nature of
the epithelial to mesenchymal signalling involved in SM differentiation is not fully
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understood, although members of the Tgf|3 family (Peehl and Sellars, 1998), Sonic
hedgehog (Shh) (Ramahlo -Santos et al., 2000, Sukegawa et al., 2000) and Podl
(Hidai et al., 1998, Lu et al., 1998) have been implicated.
Thomson et al., (2002) have proposed that differentiation of the smooth muscle layer
is androgen-regulated and comprises part of the mechanism regulating prostatic
induction. The hypothesis is supported by several observations. Firstly, they
demonstrated that in the developing UGS, a layer of smooth muscle differentiates
between the VMP and urethral epithelium, and there is a sexually dimorphic
difference in the development of this layer. By serial reconstruction of the
developing UGS, they showed that the SM layer forms at approximately E20.5 in
female but did not form in males. Also, testosterone was shown to reduce the
thickness of the SM layer in cultures of female UGS. Plus, rare prostatic buds
present in some female UGS were stimulated to start the process of prostatic
organogenesis by testosterone treatment, depending upon the bud position relative to
the smooth muscle layer.
A diagram of their hypothesis is outlined in Figure 1.5 and will be discussed more
fully here. During embryonic development (E17.5), the VMP is separated from the
urethral epithelia by a layer of smooth muscle in males and females (Fig 1.5, Panel
A). This smooth muscle layer is less well developed in males, and prostatic buds can
pass through a gap in the SM layer to enter the VMP (Fig 1.5, Panel B). However, in
females, after the SM layer has formed rare prostatic epithelial buds formed cannot
enter the VMP to grow and develop in response to androgens (Fig 1.5, Panel C).
Androgens have been found to partially inhibit development of the smooth muscle
layer, modulate smooth muscle differentiation and lead to sexual dimorphism of this
SM layer.






















Fig 1.5 A model of ventral prostate induction and development.
Prostate development from embryonic to adult life, outlining the smooth muscle
hypothesis (Thomson et al, 2002) for prostatic induction and highlighting specific
regulatory growth molecules involved in prostate organogenesis (as reviewed by
Marker et al., 2003). During the initial stages of prostatic induction (A), the UGS is
similar in the male and female, and the SM layer is discontinuous with signalling
between the VMP and urethra occurs. At E18.5, prostatic buds become visible, in
males. In the female at E20.5 (C), a SM layer has formed and interaction between
the VMP and urethra is prevented. Residual buds may be present, but these do not
enter the VMP and eventually regress. In the male at E20.5 the UGS has a
discontinuous SM layer, prostatic buds have emerged from the urethra and entered
the VMP, where subsequent growth and branching morphogenesis takes place (D).
Developmental factors localised to the mesenchyme and/or epithelial compartments
of the P0 prostate are important in prostate organogenesis and may be mis -
expressed during prostate carcinogenesis (modified from Thomson et al., 2002).The
smooth muscle may act as a barrier to the passage of inductive factors, or to inhibit
contact between mesenchyme and epithelium. These data suggest that smooth
muscle can act as a regulator of ductal elongation and branching morphogenesis,
and that this peri-urethral smooth muscle is a barrier of prostatic ductal elongation
and branching morphogenesis (Thomson et al., 2002).
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1.4 Stromal-Epithelial Interactions in the Adult Prostate and
Prostate Cancer.
Stromal-epithelial interactions are important, not only during prostatic growth and
development (Fig 1.6, Panel A), but also in adult life. In the adult prostate (Fig 1.6,
Panel B), under the direct or indirect action of androgens, mesenchymal factors from
the stroma/smooth muscle (which express AR) act to maintain normal prostatic
epithelial differentiation and homeostasis (Cunha et al., 1996). Homeostasis of the
adult prostate is maintained through reciprocal interactions between the stroma and
epithelium, with minimal proliferation of either cell type, (Cunha et al., 2002, Kurita
et al, 2001). However, it is proposed that disruption of this homeostatic state, by
alteration of the stromal and/or epithelial compartments, could affect their reciprocal
relationship, to initiate and promote carcinogenesis. Also, it is likely that prostatic
carcinogenesis is initiated by prostatic damage to prostatic epithelium.
It is hypothesized that prostate carcinogenesis is associated with changes in the local
interactions between the stromal microenvironment and genetically initiated incipient
tumour cells, and these changes are suggested to promote malignant tumour
progression resulting in tumorigenesis (Fig 1.6, Panels B, C and D) (Cunha et al.,
2004, Grossfield et al., 1998, Hayward et al., 1996, 1997, 1998). A model of
prostate tumorigenesis proposed (reviewed in Cunha et al., 2004) is that following a
genetic insult to the prostatic epithelium, the epithelium fails to signal appropriately
to the adjacent stroma (smooth muscle), which in turn begins to differentiate towards
a more fibroblastic phenotype (Wong and Tarn, 2002a). As smooth muscle begins to
de-differentiate, signalling from prostatic smooth muscle to prostatic epithelium
becomes anamolous, resulting in progressive loss of control, over epithelial
differentiation and proliferation. Accordingly, a "vicious cycle" is established during
progression in which both prostatic epithelium and smooth muscle de-differentiate
and proliferate. This hypothesis is supported by many observations. Firstly, the
highly differentiated growth quiescent state of the normal adult prostate is
maintained by intimate stromal-epithelial cell interactions. Also, prostatic smooth
muscle undergoes de-differentiation during carcinogenesis (Cunha et al., 2002).
Furthermore, as prostate epithelium undergoes neoplastic transformation it loses its
ability to maintain and induce smooth muscle differentiation (Wong and Tarn,
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2002b). This was demonstrated in experimental tissue recombinants in which
various normal or neoplastic prostatic epithelia were grown in combination with
UGM. It was found that only the normal (non-neoplastic) epithelia were fully
capable of inducing differentiation of smooth muscle in the UGM (Hayward et al.,
1996). This observation is consistent with the idea that one of aspect of the
carcinogenic process is a loss of the ability of the epithelium to induce and maintain
smooth muscle differentiation. It is now evident that smooth muscle-epithelial
interactions play key roles in regulating epithelial differentiation, proliferation and
carcinogenesis (reviewed by Cunha et al, 2004)
Prostate carcinogenesis is regulated not only by stromal-epithelial interactions but
also by the action of steroid hormones (Fig 1.6, Panels C and D). The pivotal role of
androgens and oestrogens will not be discussed in detail, and is included only to
provide a more comprehensive picture of the factors involved. The importance of
androgens in prostate carcinogenesis has been determined conclusively by the fact
that prostate tumours do not develop in the absence of testosterone, as in eunuchs
castrated early in life. Also, with relevance to the action of stromal factors in
prostate tumorigenesis, there is strong supportive evidence that some of the stromal
signals are likely to be mediated by androgens, and the presence of stromal AR has
been verified (Cunha et al., 2003, Wang et al., 2001b).
Therefore, prostatic stroma plays a key role in the regulation of prostatic growth and
differentiation, and also prostate cancer (Cunha et al., 1996, Cunha et al., 2002,
Cunha et al., 2003). The importance of the stroma in human prostatic tumorigenesis
has been clearly established, and human and rodent models of stromal effects upon
prostatic neoplasia have been developed (reviewed in Hayward, 2002, Matrisian et
al., 2001). However, the mechanisms by which stromal cells influence
tumorigenesis are poorly understood, although it is proposed that prostatic stroma
may affect prostatic carcinogenesis in many different ways, for example, by adopting
a wound-like phenotype or by stimulation of angiogenesis (reviewed in Tuxhorn et
al., 2001).











Fig 1.6 Interactions between the epithelial and the stromal/mesenchymal
components of the prostate during development and adulthood.
During prostatic development (A) low levels of androgens, acting through the
mesenchymal androgen receptor (AR), stimulate proliferation and differentiation of
prostatic epithelium. Concurrently, the epithelium induces differentiation of the
mesenchyme into smooth muscle. In the normal adult (B) high levels of circulating
androgens, acting through AR located in the smooth muscle, maintain the
morphology of growth-quiescent adult epithelium. Secretory function is elicited by
direct androgenic stimulation of AR in the differentiated columnar epithelium.
Epithelial and smooth muscle differentiation is maintained by reciprocal paracrine-
acting homeostatic factors. In early tumors it is hypothesized that following genetic
insult to the epithelium (C), signaling between the epithelium and the adjacent
smooth muscle begins to become abnormal, leading (D) to the formation of a
fibroblastic "tumor stroma", which responds to androgenic stimulation by producing
paracrine-acting mitogens, fueling a cycle of tumor proliferation and stromal de -
differentiation, (redrawn from Cunha et at., 2002).
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Tumour stroma is histologically different from normal stroma (Ronnov et al., 1996,
Tisty and Hein, 2001) and shows enhanced proliferation and migratory behaviour in
vitro (Schor et al., 1985, 1988). Also, the constituents of the ECM and the
vasculature in tumour stroma are also different from that associated with normal
epithelia (Carmeliet and Jain, 2000). The tumour stromal cells are known to produce
a variety ofMMPs, which may affect tumour initiation, growth, migration,
angiogenesis, apoptosis, invasion and metastasis (Lynch and Matrisian, 2002). In
comparison to normal stromal cells, tumour stromal cells exhibit alterations in their
cell-surface molecules (Chaudhuri et al., 1975, Oishi et al, 1981), altered expression
of growth factors (Ellis et al., 1994, Frazier et al., 1997, Nakamura et al., 1997,
Ponten et al., 1994, Uan et al., 1993, Yee et al., 1989), expression of prostaglandin
synthase enzyme (Shattuck- Brandt et al., 1999, 2000) and alterations in the ECM
(Pupa et al., 2002, Werb et al., 1996).
The first studies to demonstrate that stroma could regulate neoplastic prostate
epithelia were conducted over a decade ago, and showed that embryonic
mesenchyme could regulate epithelial proliferation and differentiation of rat Dunning
tumour (Hayashi and Cunha, 1991, Hayashi et al., 1990). Tissue recombination
experiments combined perinatal UGM or neonatal seminal vesicle mesenchyme
(SVM) or neonatal bulbourethral mesenchyme (BLM) or with androgen -dependent
Dunning prostate carcinoma (DT). The resultant issue combinations were grown as
subcapsular renal grafts. Grafts of the slow growing DT increased only marginally in
size in their hosts and comprised tubules with simple undifferentiated epithelium.
When grown in association with BLM, the DT continued to show it s characteristic
differentiation and showed little growth. By contrast, tissue combinations of UGM
+DT, SVM +DT and BUG-M + DT enlarged many fold in size. DT carcinoma cells
in combination with UGM, SVM and BUG-M, were induced to undergo
morphogenetic changes by forming larger more regularly organized ducts, b)
differentiated in tall polarized columnar epithelial cells, and c) produced secretion
which accumulated in the lumen when grown in male hosts. These results
demonstrated a continued responsiveness of carcinoma cells to mesenchymal
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inductors that can induce secretory cytodifferentiation and elicit reduction in growth
rate and loss of tumorigenesis (Hayashi et al., 1990).
More recently, data indicate that stromal signals play a key role in directing epithelial
mitogenesis during early (Olumi et al., 1999, Tuxhorn et al., 2002) and late stages of
prostate cancer (as reviewed in Bhowmick et al 2004b and Cunha et al., 2004). To
demonstrate this, cultured human fibroblast cells from normal or tumour prostate
were cultured together with immortalized epithelial cells derived from benign
prostatic hyperplasia. Tumour fibroblasts but not normal prostatic fibroblasts were
found to stimulate epithelial proliferation and malignant transformation. However,
tumour fibroblasts were found not to stimulate the growth of normal epithelial cells
under identical conditions, suggesting that cancer associated fibroblasts express
ECM proteins and growth factors that influence the incipient tumour cells and
promote the angiogenesis necessary to maintain epithelial transformation (Olumi et
al., 1999, Tuxhorn et al., 2002).
-Factors produced by the cancer associated stroma may be involved in prostate cancer
by stimulating epithelial mitogenesis in at least two ways; either by aberrant re -
expression in the stroma (paracrine action (eg Tuxhorn et al., 2002)) or by mis -
expression in epithelia (autocrine action (eg Gao et al., 2001)). Gao et al., (2001),
showed that mis-expression of mesenchymal genes in epithelia may contribute to a
switch from paracrine (normal) growth control to autocrine (cancer) growth control.
They proposed that normal adult epithelial proliferation is mediated by stroma and
that at some point during tumorigenesis, there is a direct control of epithelial
proliferation by androgens (Gao et al., 2001). Additionally, the stromal cells may
influence the incidence and growth rate of prostatic tumour cells through direct
interaction and recruitment of endothelial cells, regulating angiogenesis (Tuxhorn et
al., 2002).
Therefore, an important avenue in prostate cancer research has been the
identification of cancer-associated stromal factors. For example, in a recent study to
identify differential gene expression in breast tumour in comparison to normal breast,
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two chemokines, CXCL12 and 14, were identified as over-expressed in
myofibroblasts and myoepithelial cells, respectively (Allinen et al., 2004). CXCL12
and CXCLI4 were reported to bind to receptors, acting on adjacent epithelial cells
and causing enhanced proliferation and invasion. More recently, CXCL-I2 was
identified in prostatic stroma fibroblasts, with higher expression levels in aging men
(>63years old) in comparison to younger men, and this induced cellular proliferation
(Begley et al., 2005). This provides a more mechanistic elucidation of the role of
ageing in the etiology of prostate cancer.
In the most recent studies, it has been shown that normal epithelial cells without
genetically engineered mutations can be induced to form carcinomas by genetically
altered fibroblasts (Bhowmick et al., 2004, Kuperwasser et al., 2004). In previous
studies, epithelial cells induced to be more carcinogenic by association with
genetically altered fibroblasts (by irradiation) were already fully transformed into
carcinomas (Ohuchida et al., 2004), or had a known p53 gene mutations (Barcello -
Hoff and Ravani, 2004). This new finding of the capacity of genetically altered
fibroblasts to induce carcinomas in normal epithelial cells was demonstrated by
genetic modification of a member of the TGF(3 signalling pathway. TGF(3 has been
reported to exert both tumour suppressive and tumour promoting functions.
However, recent studies have provided further supportive evidence for a major role
for TGF|3 signalling in fibroblasts in the initiation of carcinomas. In one study, mice
were generated in which the TGF|3 type II receptor (Tgfr2) was inactivated
specifically in stromal fibroblasts, and the mice showed prostatic intraepithelial
neoplasia, a presumed forerunner of prostatic carcinoma, as well as invasive
squamous cell carcinomas of the forestomach (Bhowmick et al., 2004b). The Tgfr2
knock-out (Tgfbrfipk°) mouse model demonstrates that the TGF-(3 signalling pathway
known to suppress cell-cycle progression and tumour formation when acting on
epithelial cells can also indirectly inhibit epithelial proliferation when acting on
adjacent stromal fibroblasts in vivo. Consequently, loss of this pathway in fibroblasts
results in increased epithelial proliferation and may also promote invasive carcinoma
in some tissues. This also suggests that pre -malignant and malignant epithelial
tumours observed in the Tgfr2 knock-out (Tgfbrfspko) model can develop in tumours
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owing to mutations in fibroblasts preceding any subsequent tumorigenic changes in
the epithelial cells. Additionally, it was noted that the apart from the prostate and
forestomach, other tissues in the Tgfbrfspkmouse showed no signs of carcinogenic
transformation. Therefore, from these results it was proposed that not all fibroblasts
are created equal, and there may be differences in fibroblasts within tissues and
between tissues, which have distinct functions (as reviewed by Bhowmick et al.,
2004b).
Finally, with regard to the accumulating evidence that stromal- epithelial
interactions affects the behaviour of tumour cells, stromal therapy has been proposed
as a viable approach to cancer prevention and intervention. Targeting these
mechanisms offer a fundamental new direction and potential for future cancer
therapies. In principle three main points of attack are conceivable: 1) targeting the
tumour signals that are responsible for the development of "tumour stroma"; 2)
targeting CAF signals that initiate and promote tumour growth and facilitate invasion
and metastases; and 3) eliminating the CAFs themselves to abolish their interaction
with other fibroblast and epithelial cells. However, with the heterogeneity of
tumour-stroma interaction, it is questionable whether one single factor is the "magic
bullet" to halt tumorigenesis (as reviewed by Micke and Ostman, 2004).
1.5 Molecular Control of Normal and Neoplastic Prostate
Development
1.5.1 Normal prostate development
Several genes and gene families have been suggested to play a role in prostatic
development (reviewed by Marker et al., 2003). Functional studies of both
spontaneous and engineered mutations in mice and humans that have provided direct
evidence for the roles of specific genes in prostatic development. These genes
include those associated with epithelium-specific factors Sonic hedgehog (Shh)
(Podalesk et al., 1999 a), Nkx3.1 (Bhatia-Gair et al., 1999, Schneider et al., 2000,
Tanaka et al., 2000) and p63 (Signoretti et al., 2000), factors expressed in both the
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mesenchyme and epithelium, HoxAlO (Podalesk et al., 1999b), Hox A13 (Podalesk
et al., 1999c, Warot et al., 1997) and Hox D13 (Podalesk et al., 1997, Warot et al.,
1997), and mesenchyme -specific factors AR (Brown et al., 1988, Lubahn et al.,
1989, He et al., 1991, Charest et al., 1991 and Gaspar et al., 1991) and BMP4 (Lamm
et al., 2001).
The epithelial factor Nkx3.1 is expressed during embryogenesis and appears to
demarcate prospective prostate epithelium prior to prostate formation, and continues
to mark prostate epithelium during neonatal development. Nkx3.1 null mutants
display defects in ductal morphogenesis and secretory protein production.
Regulation of Shh expression in the epithelium is proposed to be upstream of Nkx3.1
i
since Shh -/- mice fail to express Nk3.1 transcripts (Schneider et al., 2000). Shh is
synthesised in epithelial cells and in many situations, acts as a paracrine factor
through its receptor Patched l(Ptc), that is expressed in adjacent mesenchymal cells.
The exact role of Shh on prostate development remains somewhat controversial as to
whether Shh is androgen-regulated and is required for prostatic induction (Podalesk
et al., 1999a) or whether Shh expression is not androgen-dependent and is more
important in later stages of prostate development (Freestone et al., 2003). Both
studies report that inhibition of SHH-signalling reduced growth of the prostate,
however, it has been reported that SHH is not critical for prostatic induction, but
plays important roles in prostatic growth, branching morphogenesis and epithelial
differentiation (Berman et al., 2004, Freestone et al 2003). Inhibition of SHH-
signalling in vitro led to the precocious and aberrant differentiation of epithelial
cells, resulting in lesions similar to human cribiform prostatic intraepithelial
neoplasia (PIN). The third epithelial-derived factor highlighted here, p63, has been
discussed previously, since its expression becomes restricted to the basal epithelial
cells during prostate development (reviewed in Marker et al., 2003). p63 expression
has been reported to be essential for differentiation of prostatic basal epithelial cells,
but not for differentiation of the prostatic luminal epithelial cells or neuroendocrine
cells (Kurita et al., 2004). Additionally, grafts of p63 -/- mouse embryo UGS
transplanted into adult male mice developed into prostate, demonstrating that p63 is
not essential for development and regeneration of the prostate (Kurita et al., 2004).
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The homeobox containing transcription factors HOXAIO, HOXA13 and HOXD13
are expressed in both the prostatic mesenchyme and epithelium. HOXA13 and
HOXD13 are both required for normal morphogenesis of the prostate and act in a
partially redundant fashion. Hoxal3+/- mice have small prostates with reduced
branching morphogenesis of the VP and DLP (Podalesk et al., 1999c). Hoxdl3 -/-
mice also have smaller VP and DLP with reduced DLP branching morphogenesis
(Podalesk et al., 1997). Compound Hoxal3 +/-Hoxdl3 -/- mutant mice have more
severe failure of prostate development including the absence of the AP (Warot et al.,
1997). HoxalO -/-mice have reduced AP branching and partial AP to DLP
transformation (Podalesk et al., 1999).
As for the mesenchyme, the VMP as previously mentioned, appears to constitutively
express mesenchymal factors important for prostatic growth. The VMP is present in
the embryonic UGS of both sexes but few factors specific to the mesenchyme have
been identified so far. The importance of functional AR expression in the
mesenchyme of the developing prostate has already been discussed. No prostate is
formed in the absence of functional AR expression in the Tfm mouse (Charest et air, -
1991, Gaspar et al., 1991,He et al., 1991) or in the human male with androgen
insufficiency syndrome (AIS) (Brown et al., 1988, Lubahn et al., 1989).
Additionally, signals derived from the mesenchyme have been reported to instruct of
the epithelium to grow and branch. Branching morphogenesis is a common process
in mammalian organogenesis, and gives rise not only to the excretory epithelia of the
prostate gland, but also to the salivary and mammary glands, the airways of the lungs
and urine-collecting ducts of the kidney. As branching organs exhibit many
anatomical features, matrix requirements and signalling pathways, it has been
suggested that some of the branching mechanisms are conserved. A 'consenus'
model of the mechanisms and molecules regulating branching epithelium has been
proposed (Davies, 2002), although it is recognised that it is possible that important
features of branching remain to be discovered that are quite different in different
systems.
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Some of the growth factors reported to be active in branching morphogenesis, and in
prostate development include fibroblast growth factors (FGFs) (as reviewed by
Thomson, 2001), epidermal growth factors (EGFs) (McKeehan et al., 1984),
transforming growth factors (TGFa and (3) (Lucia et al., 1998, Peehl and Sellars,
1997) and hepatocyte growth factor (HGF). Most of these factors (except for Tgf(3s
including BMPs and activins) are predominantly stimulators of proliferation, and
also have tumour-promoting functions.
Members of the Fgf family play key roles in the in development of many branched
organs and generally act to promote branching. Mammals have a multitude of FGFs
and several FGF receptors, in general branching epithelial use either FGF7 or
FGF10, and their receptor FGFR2-IIIb. The degree to which different organs
depends on these FGFs varies. Lungs for example show an absolute requirement for
FGF but in the kidney, the branching or urinary collecting duct is only reduced, not
eliminated by the loss of renal FGF (as reviewed by Davies, 2002).
During development of the prostate, Fgf7 and Fgf10 are expressed in the
mesenchyme, while their receptors are predominantly found on adjacent epithelial
cells (Finch et al., 1995, Mason et al., 1994, Orr-Utreger et al., 1993). They both
play significant roles as paracrine regulators of prostate development. Fgf7 and
FgflO both regulate the growth of the ventral prostate (Sugimura et al., 1986,
Thomson and Cunha, 1999) and seminal vesicle (Alardi et al 1994, Thomson and
Cunha, 1999). However, deletion of Fgf7 by gene knock-out does not appear to
affect the formation of the male reproductive tract (Guo et al, 1996), while the FgflO
knock-out (Fgf.10') has absent or atrophic male secondary sex organs, including the
prostate and seminal vesicle (Donjacour et al., 2003, Min et al., 1998, Sekine et al.,
1999, Suzuki et al., 2000). In the prostate, as in the lung, and other branched organs,
FgflO is restricted to the distal aspects of the organ where it is believed to act as a
chemoattractant for elongating ducts and an inducer of branching through stimulation
of cell proliferation (Bellusci et al., 1997, Thomson and Cunha, 1999). FgflO is the
first mesenchymal specifically expressed gene known to be required for prostatic
organogenesis.
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HGF, and EGF/TGFa have also been shown to promote branching. Generally, HGF
is produced by the mesenchyme and its receptor is expressed in the epithelium.
Addition of exogenous HGF or EGF/TGFa was found to stimulate the production of
branching tubules by cells derived from prostate, kidneys, mammary glands, salivary
glands and pancreas (as reviewed by Davies, 2002).
On the other hand members of the TGF(3 family, TGF(3, BMPs and activins are
proposed to inhibit branching. TGFbl is expressed in the mesenchyme of the
prostate, lungs, and mammary gland. In the prostate and the lungs, it is a potent
inhibitor of epithelial proliferation and branching (Itoh et al., 1998, Zhao et al., 1996)
and inhibits production of FGF10 (Tomlinson et al., 2004).
BMPs are involved in regulation of epithelial branching in several organs. In the
prostate, BMP4 is expressed by the mesenchyme and is suggested to restrict prostatic
ducal branching. Increased branching morphogenesis is observed in the anterior and
posterior prostatic lobes of a heterozygous BMP4 knock-out mouse (Lamm et al:,
2001). However, in the lungs, BMP4 is proposed to set up differences between
differentiation characteristic of early and late generation branching (Bellusci et al.,
1996).
An awareness of the features of different branching systems and their regulation is
very useful for hypothesising on possible similarities with the poorly characterised
prostate.
1.5.2 Neoplastic prostate development
Some molecules that regulate normal prostate development are also active during
neoplastic prostate growth. Virtually all properties of neoplasms have a counterpart
in normal prostate development. Accordingly proliferation, differentiation, invasion
and apoptosis are events especially relevant to neoplasms as well as to the
developing embryo. In the prostate these events are cardinal features of both normal
development and carcinogenesis (as reviewed by Cunha et al., 2004). Therefore, it is
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not surprising that molecules common to both processes have been reported, and of
particular interest are factors expressed by cancer associated fibroblast cells
(reviewed in Bhowmick et al., 2004). These include developmental growth factors
already identified above with relation to prostatic disease, plus members of the
developmental Wnt and MMP gene families (reviewed in Bhowmick et al, 2004b).
An important technique now for the analysis of prostate tumours is gene expression
profiling. It is hoped that the biological heterogeneity of the disease might be
reflected in expression profiles, yielding classifications for prognosis and treatment
and new diagnostic markers and therapeutic targets. Another hope from using this
technique is the identification of primary genetic changes in prostate carcinomas, by
analysis of altered gene expression patterns. Specifically, it may be able to pinpoint
transcriptional profiles for invasion, for androgen independence, or indicating the
activation of a particular "cancer pathway". More than a dozen expression profiling
studies have been published on clinical specimens and pre-clinical models, prior to
and during the course of the Ph.D. project (Bera et al., 2002, Bubendorf et al., 1999,
Xu et al., 2000, Dhansakeran, et al., 2001, Luo et al., 2001a,b, Mousses et al., 2001,
Stamey et al., 2001, Waghray et al., 2001b, Welsh et al., 2001, DePrimo et al., 2002,
Ernst et al., 2002, LaTulippe et al., 2002, Rhodes et al., 2002, Shou et al., 2002, Sing
et al., 2002, Varambally et al., 2002).
Studies using clinical samples have focused on the classification of prostate
carcinoma progression and on identification of marker genes. Two single gene
markers found reproducibly altered in prostate cancer samples; are hepsin (Luo et al.,
2001b, Magee et al., 2001) and a-methyl-acyl-coA racemase (AMACR)(Jiang et al.,
2001, Rubin et al., 2002) although at present it is uncertain if they represent good
therapeutic targets.
An inherent problem associated with gene profiling of cancer is the tissue
heterogeneity of the samples. A tumour is a complex tissue containing different
cells, and as such it has a complex transcriptome. Therefore, preparation of gene
expression profiles from whole tumour samples makes it impossible to assign the
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genes identified to a specific cell type. Furthermore, without knowledge of the
specific expression of a gene, it makes it difficult to pin-point changes in gene
expression between normal prostate tissue and prostate cancer, that are not merely
the result of alterations in the proportions of the different cell types, as the tissue
becomes tumorigenic.
Finally, gene expression profiling has also been used to identify genes that are active
during development, to investigate the regulatory mechanisms occuring during organ
formation. Several studies have been performed, including the production of a gene
expression profile of the embryonic mouse (Wagner et al., 2005) and more
specifically, profiles of individual organs such as the embryonic mouse colon (Park
et al., 2005), and testis (Shima et al., 2004), developing rat and human kidney (Dekel
et al., 2002, Stuart et al., 2001), and human foetal liver (Yu et al., 2001). Of
particular relevance to this thesis, are published transcriptome profiles, generated by
SAGE, of the developing mouse prostate (E16.5, PI and Adult) (Zhang et al (2006),
available at http://www.mouseatlas.org. In addition to contributing to the
understanding of developmental processes, identifying genes involved in
morphogenetic events taking place during development of individual tissues may
give insights into genes that function during the pathogenesis of disease in these
tissues. In cancer for instance, it is proposed that key developmental genes may be
dysregulated. Also, relating patterns of gene expression between different organs
during the development, will determine the presence of conserved developmental
mechanisms in tissues and also between species.
1.6 Summary
Development of the prostate is regulated by mesenchymal-epithelial interactions, and
is dependent on the presence of androgens, plus androgen receptor action in the
mesenchyme. Numerous molecules are involved in mesenchymal-epithelial
interactions, and have been shown to regulate prostate organogenesis. More
specifically, the ventral mesenchymal pad, an area of condensed mesenchyme has
been identified to express mesenchymal factors that are important in prostate growth.
Few mesenchymal factors have been identified so far. One hypothesis for the
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mechanism of regulation of prostate organogenesis has proposed that the production
and secretion of some mesenchymal factors are androgen-regulated, and are termed
'andromedins'. At present no growth factors, expressed in the mesenchyme have
been shown unequivocally to be directly regulated by androgens, but it is possible
that factors are constitutively expressed and their activity is indirectly regulated by
androgens. More recently, the importance of the stroma in cancer has been
established, and it has been proposed that developmental factors may be involved in
mediating the effect of cancer stroma.
1.7 Project Aims
The aims of this project were to identify mesenchymal factors involved in normal
and neoplastic prostate growth, and also to determine if these factors were androgen-
regulated. An open-ended approach was used so that the findings would not be
biased by previous assumptions.
A gene expression profile of the prostate precursor was documented, using
LongSAGE analysis. The Libraries were prepared from tissues of the neonatal
female UGS. The VMP (PO) was proposed to provide an ideal source of
homogenous mesenchymal tissue that constitutively expresses factors capable of
prostate organogenesis. The LongSAGE experiment was designed with the
knowledge that some VMP-expressed factors may be androgen-regulated in the
developing male UGS, and also that mesenchymal factors 'activated' by invading
epithelial cells were likely to be absent from the Libraries generated.
Also, the importance the role of mesenchyme/stroma in cancer has become more
established, and it was hoped to determine if regulatory developmental genes in the
developing prostate are expressed during neoplastic growth in prostate cancer, and
may represent potential molecular therapeutic targets.
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2. Materials and Methods
2.1 Materials
2.1.1 Equipment
Agarose gel electrophoresis was performed using Bio-Rad equipment
Automated sequencing gels were run using an ABI 310 Genetic Analyser by the
Human Genetics Unit, MRC, Edinburgh, UK.
Confocal Microscopy was performed on a Zeiss LSM 510 Laser scanning
microscope.
Images of immunohistochemistry were captured using a Provis microscope
(Olympus Optical Co. London, UK) equipped with a DCS330 camera (Eastman
Kodak Co., Rochester, NY).
Images of organ cultures were captured on a Leica MZ6 dissecting microscope with
attached Leica ICA camera.
Quantitative RT-PCR analysis was performed on the LightCycler from Roche
Applied Systems.
Minipreps for the SAGE libraries were performed on the Biorobot® 9600 from
Qiagen.
'x
Paraffin embedding was performed on a Leica TP1050, the tissues embedding centre
was purchased from Reichert-Jung and tissue sections were cut using the Leica
Microtome RM2135.
PCR was performed using a Peltier Thermal Cycler PTC 200 from MJ Research
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Phospho Screen and Phosphoimager Storm 860 were purchased from Molecular
Dynamics.
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RNA concentration and purity was measured using the Agilent 2100 Bioanalyser
from Agilent Biotechnologies
Vertical gel electrophoresis apparatus for large format gels (15 x 17cm) used was
from BioRad
Wallac 1450 Microbeta® Trilux, Liquid Scintillation and Luminescence Counter
2.1.2 Computer Software
SAGE2000 Version 4.5 was downloaded from http://www.invitrogen.com/sage and
used to extract the LongSAGE tags from the sequence files and generate a tag
abundance report.
The Rat LongSAGE™ map (May 2004) was downloaded from the NCBI web-site
(http://www.ncbi.nlm.nih.gov/) as a reference database for annotation of the
LongSAGE™ library tags.
Microsoft®Access was used to annotate the tags by comparison with the Rat
LongSAGEmap, and compare the tag abundances between the LongSAGE libraries.
Images were captured on a Macintosh G3/G4 and Apple computer and manipulated
with Adobe Photoshop 7.0 Power PC.
/
Organ culture images were captured using the Scion Java Package 1.1 for Image J.
Phosophimages were visualised using the Typhoon 9400 Variable Mode Imager
from Amersham Biosciences, and quantified using Image Quant Version 5.2 from
Amersham Biosciences.
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Plasmid preparations on the Qiagen Biorobot® 9600 were performed using the
Qiaprep® 96 Turbo protocol run on Qiasoft 3.0 software.
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Sequence analysis was performed using GeneJockey II Sequence Processor
(P.Taylor, BIOSOFT). Sequence searches were performed using BLAST from NCBI
(http://www.ncbi.nlm.nih.gov/) and Ensembl (http://www.ensembl.org).
2.1.3 Enzymes
£co/?l(Cat. No, R6011), Sphl (Cat. No. R6261), BamH l(Cat. No. R6021) and Xba
1 (Cat. No. 6181) were purchased from Promega
Mme 1 type II restriction endonuclease( Cat. No. B9003S) purchased from NEB
Biolabs Inc. was used with 50 pM S-adenosylmethionine and the supplied buffer.
SUPERSCRIPT™ II RNase H Reverse Transcriptase was purchased from
Invitrogen™ Life Technologies and used with the supplied buffers
T4 Polynucleotide Kinase (Cat. No. M0201S) purchased from NEB Biolabs Inc. was
supplied with lOx kinase buffer and used with 2mM ATP (Cat. No. 27-2056-01)
purchased from Pharmacia Biotech Ltd
T4 DNA Ligase (Cat. No. and Platinum Taq Polymerase (Cat. No. 10966-018) were
purchased from Invitrogen™ Life Technologies and used with supplied buffers.
2.1.4 Nucleic Acids
lOObp (Cat. No. G2101) and lkb (Cat. No. G5711) DNA ladder were purchased
from Promega Inc.
dNTP's (Cat. No. U1330) were purchased from Promega Inc.
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Radioisotope redivue deoxycytidine 5'-[32P] triphosphate triethylammonium salt
(Cat. No. AA0005) was purchased from Amersham Biosciences Inc.
Synthetic oligonucleotides were synthesised either by Sigma-Genosys Ltd or MWG-
Biotech AG.
2.1.5 Chemicals
All chemicals for standard solutions were purchased from BDH, Sigma-Aldrich or
Invitrogen™ Life Technologies and were of analytical grade.
2.1.6 Bacterial Strain Genotypes
DH5a; F- 80d/ac AZM15 A(/acZYA-argF) U169 recAl endAl
hsdRll(rk-, mk+) phoA supE44 - thi-1 gyrA96 relAl
Purchased from Invitrogen™ Life Technologies.
2.1.7 Bacterial Culture Media
Luria Broth (LB): lOg/Lbaco-tryptone, 5g/L bacto-yeast extract, 5g/L NaCl,
adjusted to pH7.0 with 5M NaOH
SOC Media: Cat. No. 46-0821 was purchased from Invitrogen™Life
Technologies.
SOB Media: 20% baco-tryptone, 0.5% baco-yeast extract, 0.05% NaCl,
2.5%mM KC1, lOmM MgCl2
2.1.8 Northern Blotting and Hybridisation Equipment
Hybond™-N+ paper (Cat. No. RPN-303B), Hybond blotting paper (Cat. No.
RPN6101M), and MicroSpin™ S—400 HR Columns (Cat. No. 27-5140-01) were
purchased from Amersham Biosciences UK Ltd.
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Hybaid boroscillicate tubes (Cat. No, HBOVBS) were purchased from Fisher
Scientific
ULTRAhyb™ Ultrasensitive Hybridisation Buffer (Cat. No. 8670) was purchased
from Ambion®
2.1.9 Immunohistochemical Reagents
ABComplex/HRP (Cat.No. K0355) and DAB+Substrate Chromagen System (Cat.
No. K3468) purchased from DakoCytomation
Table 2.1: Antibodies used for Immunohistochemistry





Goat Polyclonal 1:25 IHC
1:10 IFC
Anti-Dlk 1 Gift Dr. S.
Morley





Goat Polyclonal 1:50 IHC
Anti-Pleiotrophin RnD Systems
AF-252-PB






Goat Polyclonal 1:200 IHC
Anti -alpha actin
smooth muscle





Mouse Monoclonal 1:100 IFC
Anti-P63 Santa Cruz
SC-8431
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Topro 3 Molecular Probes 1:2,000
Santa Cruz also supplied blocking peptides to their antibodies delta-like 1(SC-
8625P), pleiotrophin (SC-1394P), and notch 2 (SC-7423P).
2.1.10 Organ Culture Media, Equipment
All incubation dishes and tubes were purchased from Falcon, NUNC™ or Corning
Inc. (COSTAR).
Dulbecco's Modern Eagle Media (DMEM) with glutamax I (Cat. No. 31966-021),
Penicillin-Streptomycin (Cat no. 15240-062), Trypsin-EDTA (Cat. No. 25300-062),
Bovine Transferrin (Cat. No. 11107) were purchased from Invitrogen™, Life
Technologies. Bovine Insulin (Cat. No. 1-0516) was purchased from Sigma.
Manipulations were carried out in statutory Class II tissue culture hoods.
Millicell CM Culture Plate Inserts (Cat. No. PICM03050) were purchased from
Millipore.
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Table 2.2: Recombinant proteins used in organ culture experiments
Recombinant
Protein
Source Cat. No. Company
Human Delta-like 1
homolog (Drosophila)






Human Pleiotrophin Sf21 insect cell line 252-PL R&D Systems
2..1.11 Kits
Table 2.3
Kit Cat. No. Source
I-SAGE kit T5001-01 Invitrogen™ Life
Technologies
Rneasy Mini Kit 74106 Qiagen
Turbo DNA-free ™ kit 1907 Ambion






DNA Master SYBR Green
1
3 003 230 Roche Applied Science













pGEM T easy Vector
System 1
A1360 Promega Inc.
Chapter 2 Method and Materials 36
Table 2.3 (cont):









2.1.12 Standard Solutions (A to Z)
(Cat. No. G190A) purchased from Promega Inc.
75ml picric acid, 25ml 40% (v/v) Formaldehyde, 5ml glacial
acetic acid.
I
0.1M Citric Acid (monohydrate), pH 5.5.
O.IM MOPS (pH7.0), 40mM sodium acetate, 5mM
EDTA(pH8.0)
200pM 3-(N-morpholino)propanesulfonic acid (MOPS),
50pM Sodium acetate, lOpM EDTA.











RNA Sample Loading Buffer: Cat. No. R-1386 purchased from Sigma®
without ethidium bromide
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SSC (20x) (Cat. No. 51233) purchased from Accugene™, Biowhittaker
Molecular Applications
TBS 0.15M NaCl in Tris pH7.4
TBST 0.15M NaCl, 0.1% Polyoxyethylenesorbitan Monolaurate
(Tween 20)
2.2 Methods
2.2.1 Total RNA Extraction
Total RNA was extracted from mammalian tissue using RNeasy™ Mini and Midi
kits (Qiagen) as per the manufacturer's instructions. RNA was eluted ddH20 in a
final volume of 30pl (Mini kit) or 120pl (Midi kit), and the RNA concentration and
purity was measured on the Agilent 2100 Bioanlayser.
2.2.2 DNase Treatment of Total RNA
Total RNA was treated with the Turbo DNA-free kit (Ambion) as per the
manufacturer's instructions to eliminate genomic DNA contamination. 4U
TurboDNase and lx DNase buffer was used in a final reaction volume of 25pl. The
reaction was incubated at 37°C for 30 minutes, and then mixed with 0.2V of DNase
Inactivation Reaction solution. The mixture was centrifuged at 10,000rpm for 1.5
minutes and the DNase-treated RNA was removed to new eppendorf tube.
2.2.3 cDNA Synthesis
500ng of DNase treated RNA was reverse transcribed in the presence of absence of
reverse transcriptase (SUPERSCRIPT™ II RNase H Reverse Transcriptase;
Invitrogen™, Life Technologies) as per the manufacturer's instructions. The
completed reactions (20 pi) were diluted with 80pl of ddH20. The quality of cDNA
was always checked by PCR using TATA-Binding Protein (TBP) primers, and also
with GAPDH primers to ensure the complete elimination of genomic DNA by
DNase treatment.
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2.2.4 Polymerase Chain Reaction
In a 50pl reaction volume 5pi of cDNA, made from 500ng DNase treated RNA, was
mixed with lx PCR buffer, 1.25 or 2.5 mM MgCl2 and, 0.2mM dNTP's, 0.5 pM of
each primer and 1.5U Platinum® Taq DNA Polymerase. The primers used are listed
in Table 2.4 and 2.5. Typically 35 cycles of PCR were performed using the
following conditions: samples were preheated to 95°C for 2 minutes, then a standard
35 cycles of 95°C for 45 seconds, Ta for 30 seconds and 72°C for 45 seconds. A final
extension of at 72°C for 15 minutes was performed and samples were incubated at 15
°C. Ta refers to the annealing temperature in °C used for the oligonucleotides based
upon the formula; Ta= 4x (No. G/C bases in the oligonucleotide) + 2x (No. A/T
bases in the oligonucleotide). PCR products were visualised by agarose gel
electrophoresis and ethidium bromide staining.
2.2.5 qRT-PCR - LightCycler Analysis
The LightCycler FastStart DNA master SYBR Green 1 Kit (Roche Applied Systems)
was used for qRT-PCR. 3pi of cDNA (synthesised from 500ng DNase Treated
RNA) was added to a reaction mixture of lx Lightcycler FastStart DNA Master
SYBR Green 1, 2mM or 3mM MgC12 and 0.625 pM of each primer in a final
volume of lOpl. The PCR products were measured against a standard curve of cDNA
diluted to 10%, 2%, 0.4%, 0.08%. The PCR was performed on a LightCycler
machine (Roche Applied Systems). Typically 45 cycles were performed using the
following conditions: samples were preheated to 95°C for 10 minutes, then a
standard 45 cycles of 95°C for 15 seconds, Ta for 5 seconds, 72°C for 22 seconds
and Tm for 1 second. Ta refers to the annealing temperature as described under
Polymerase Chain Reaction (Section2.2.4). Tm refers to the measuring temperature
at which the amount of PCR product is recorded. The PCR products were quantified
using the LightCycler software and normalised against GAPDH control primers.
The PCR products were checked by agarose gel electrophoresis and ethidium
bromide staining.
Table2.4: Rat Primers for RT-PCR, LightCycler Analysis and DNA probes.
Primers (5'-3') PCR LightCycler
Probe/constructForward Reverse Ta MgCl,Ta MgCl2 Im
Basigin CAGAGCTGATCATCAGCGAC CCTTGTCATTCAGGTGAGAC 60 1.25 60 3 86
BMP3 GGATCTTGTTGCCATTGCAG GGACCACATTCTTGTTCTCG 60 1.25 60 2 84
BMP7 CTGAAGCGTATGCTGCCTAC GCTTATCAACCACGGTGTGC 60 1.25 60 3 86
Decorin CAGTCAACTGCATCTGGATG CGAAGACACATCTGAAGGTG 60 1.25 60 3 80
Delta-like 1 AGGACTGTCAGCACAAGGCT TGGACAGGTAGCTCGTGCAC 60 1.25 60 3 88
FGF10 CAGTGGAAATCGGAGTTGTTGATGACGCAATGACACAGAGCT 60 1.25 60 3 82
FGFR2 GTCATAGTCGAATACGCATCGCCAAGTCTTCCACCAACTGC 60 1.25 65 5 84
Fibronectin GACCTACCACGTAGGAGAAC GCTGAAGCTGAGAACTTGAC 60 1.25 60 3 86
GAPDH TTAGCACCCCTGGCCAAGG CTTACTCCTTGGAGGCCATG 60 2.5
GDNFR alpha 1 CAGACACCTTTGCTGTCACT GACGTTTCTGCCAACGATAC 60 1.25 60 2 84
Hepsin GCAAGGTCTGTACAGTGACC CCAACTCTGGACTCTGGATGC 57 2.5 60 3 85
Hgf GCTTGGAATCCATGATGTCC CCTGTATCCATGGATGCTTC 60 1.25 60 2 81
Jagged 2 GAGAGGAAACAGCTCACTGC GGTAGAGTACGTCCTTGTGG 60 2.5 60 3 86
Lgll CGTCATTGTCGACGAGGTTG GCTGTCCACTCTTGTCATCC 60 2.5 60 3 86
Midkine CCTGAAGAAGGCTCGGTAC CCAGAAACTCTCTGGCCTC 60 1.25 60 2 82
MMP14 GGACAAGATTGATGCAGCTC GAGGAGGCAAAGTCCTTGTG 60 1.25 60 3 88
Ta = Annealing Temperature (°C) Tm = Measuring Temperature (°C) MgCl2= magnesium chloride (mM)
Table2.4 (cont.): Rat Primers for RT-PCR, LightCycler Analysis and DNA probes
Primers (5'-3') PCR Light
Cycler
Probe/constructForward Reverse Ta MgCl2 Ta MgClj Tm
MMP2 CCTGATGTCCAGCAAGTAGATGCTGAAGTCACCAGGTGAAGG 60 1.25 65 4 88
Nel-like 2 CACAGTTGACCTCTCCTGC GACAAGGATCGGTGACACAG 60 1.25 60 3 85
Notch 2 CTGAGGACTCTTCTGCCAAC CAGTTGATCAGCTCTGCCAC 60 1.25 60 2 88
Notch 1 CTATCAGGGTGCCAGCTTGC CCAGCAACACTTTGGCAGTC 60 1.25 60 2 86
Paralemmin GTGGAGAAGGACAAGGTGAC CGAGGTACCTTGTTGGTCTCT 60 1.25 65 4 88
Pdgf GCTGTAACACCAGCAGCGT GCACATTGGCAATGAAGCAC 60 1.25 65 4 85
Pleiotrophin GCAGTCTGAAGAGAGCTCTG CCACTGGCAGAGACAATG 60 1.25 65 3 84
PMP22 GTCTGTCATCTTCAGCGTCC GCAGGATCACGTAGATGATGC 60 1.25 60 3 82
Syntenin CACTGATCACCACATCTGTG CTCAGATAGAGTGAGGTTCC 60 1.25 60 3 80
TBP GCGGTTTGGCTAGGTTTCTG CCTAGAGCATCCTCTTATCTCCT 60 1.25 60 3 82
TGF beta 2 CCTCCACATATGCCAGCGG CAGTGGTTCCAGATCCTGG 60 2.5 60 2 86
VAP1 CCTGGAGTGTCTGTACGACA CTGAGCACAACCTTGAGGAC 60 1.25 60 3 82
Ta = Annealing 1femperature (°C) Tm = Measuring Temperature (°C) MgCl2= magnesium chloride (mM )
Table 2.5 Human Primers for RT-PCR, LightCycler Analysis and DNA probes.
Primers (5' to 3') PCR Light
Cycler
Probe/construct Forward Reverse Ta MgCl2 Ta MgCl2 Tm
Delta-like 1 CTGCCTTCACGGACTCTGT GCAGGTCTTGTCGATGAAGC 60 1.25
GAPDH TTAGCACCCCTGGCCAAGG CTTACTCCTTGGAGGCCATG 60 2.5
MMP14 GGACAAGATTGATGCAGCTC GAGGAGGCAAAGTCCTTGTG 60 1.25 60 2 87
MMP2 CCAAGCTCATCGCAGATGC CTGAAGTCACCAGGTGAAGG 60 1.25 60 3 87
Nel-like 2 GACATCACCAAGACTGCCT GGTGATGTGAGACACAGTAG 60 1.25
Notch 2 CAGAGGACTCTTCrGCTAAC GAGAGAGCAGAAGTCAACAC 60 1.25 60 3 89
Pleiotrophin CAGCTGTGGATACTGCTG GACAGTCTTCTGGCATTCG 60 1.25 60 2
TBP AGGTTAGAAGGCCTTGTGCTCGGGAGGCAAGGGTACATGAG 60 2.5 60 3.5 78
Ta = Annealing Temperature (°C) Tm = Measuring Temperature (°C) MgCl2= magnesium chloride (mM)
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2.2.6 Cloning of PCR Products
2.2.6.1 Preparation of Insert DNA
100 pi (2 x 50pl reactions) of PCR product was prepared according to the PCR
conditions outlined. lOpl of PCR product was checked by agarose gel
electrophoresis and the remaining product was purified using the Qiagen™ PCR
Purification Kit, eluting in a final volume of 30 pi. The concentration of the final
eluate was estimated by running a 5pl aliquot on a 1% agarose gel against a known
amount of DNA ladder.
2.2.6.2 Ligation
The pGEMTeasy kit from Promega was used for ligation of insert DNA into the
pGEMTeasy Vector supplied as per the manufacturer's instructions, using the
appropriate insert: vector ratios, 1XT4 DNA Ligase buffer and 0.05 U/pl in a lOpl
volume. Blunt-end ligation was performed at room temperature for 1 hour or
overnight at 16°C. 2pl of ligation mix was transformed into DH5a E.Coli as per the
manufacturer's instructions.
2.2.7 Plasmid DNA Preparation
2.2.7.1 Plasmid Mini-Preparation
A 3ml. culture of E.Coli was grown in LB, with IX ampicillin at 37°C in a shaking
incubator overnight. The culture was pelleted in a 1.5ml eppendorf tube and plasmid
DNA was prepared as described in the Qiaprep™ Mini-prep protocol.
2.2.7.2 Restriction Endonuclease Digestion
Plasmid DNA was digested using the recommended buffer and approximately 2U
enzyme per lpg DNA for 2 hours. Restriction endonuclease digestion was performed
in a water bath at 37°C.
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2.2.8 Agarose Gel Electrophoresis
2.2.8.1 DNA
Plasmid DNA was run on agarose gels of 1% at 100V, determined to give the best
possible resolution of fragments. DNA was loaded into the gels using IX
Blue/Orange Loading Dye (Cat. No. G190A) purchased from Promega, and run
using lxTBE. DNA was visualised by ethidium bromide staining and UV-light.
2.2.8.2 RNA- Formaldehyde gel
RNA was run on a horizontal 0.1% (w/v) Agarose gel containing, lx MOPS and 6%
formaldehyde, using lxFormaldehyde-gel running buffer. RNA was loaded in a
ratio of (2:1) with RNA Sample Loading Buffer without ethidium bromide (Sigma),
heated to 65°C for 15 minutes and cooled on ice prior to loading. Gels were run at 4-
5V/cm, typically 75V for a 16 cm gel. 5pg of total RNA was loaded in each gel
lane. A duplicate was performed for each gel with independent RNA samples,
except where stated.
2.2.9 Northern Blotting and Hybridisation
2.2.9.1 Northern Blotting
RNA Gels were blotted using Hybond™-N+ paper (Amersham Biosciences) and cut
to match the size of gel. 20x SSC and Hybond™ blotting paper (Amersham
Biosciences) were used for the capillary transport of RNA from the gel to the
Hybond™ N+ paper, carried out overnight. The transfer of RNA was checked by
separating and staining a lane of Hybond™ N+ paper containing transferred RNA,
with a solution of 0.5M sodium acetate (pH 5.2) and 0.04% methylene blue for 10
minutes at room temperature.
2.2.9.2 In vitro transcription of 32P labelled DNA probes
A DNA template of the probe was prepared using the relevant primers in Table, and
inserted into the pGEMTeasy vector as per the manufacturer's instructions (see
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Cloning of PCR Products). The plasmid DNA template was cut out of the
pGEMTeasy Vector by digestion with EcoRlsupplied by Promega to create a 5'
overhang. Typically, a 30pl plasmid mini-prep was digested in a reaction volume of
lOOpl. Complete digestion was confirmed by gel electrophoresis. At least 90pl of
digestion mixture was run on a 1% agarose gel and the digested DNA insert was cut
out and gel-purified using the Qiagen™ Gel Extraction Kit. The insert was eluted in
a final volume of 30pl, and 5pl of product was checked by gel electrophoresis.
In a reaction volume of 50pl ~25ng of insert DNA, typically l-3pl, was heated to
95°C for 5 minutes and cooled on ice prior to mixing with a final concentration of lx
buffer, lOpM of each dATP, dGTP, and dTTP, 40U Klenow enzyme from the
RadPrime DNA Labelling System Kit (Invitrogen™ Life Technologies) and 50pCi
32P dCTP (Amersham Biosciences). The reaction mixture was incubated for 30
minutes at 37°C. The labelled DNA probe was recovered by column purification
with MicroSpin™ S—400 HR Columns (Amersham Biosciences). The probe was
measured for 32P incorporation in a Scintillation counter (Wallacl450).
2.2.9.3 Hybridisation of Labelled DNA Probes to RNA Blot
The Northern blot was placed in a Hybaid boroscillicate tube (Fisher Scientific) with
lOmls of ULTRAhyb™ Ultrasensitive Hybridisation Buffer (Ambion®), and
incubated for at least 1 hour at 42°C in a rotating oven. The 32P DNA Labelled Probe
was heated to 95°C for 5 minutes and cooled on ice prior to adding 106CPM of probe
per ml to the hybridization buffer. The probe was hybridized to the blot overnight at
42°C. The non-hybridized probe was then discarded and the blot was washed with
solutions 2x SSC, 0.1%SDS followed by O.lx SSC, 0.1%SDS at 48°C. Hybridised
probes were visualised using a phosphor-screen (Molecular Dynamics), and
quantified using a Phosphoimager (Amersham) and normalised to a GAPDH control
probe.
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2.2.10 Immunocytochemistry
2.2.10.1 Paraffin Embedding of Tissue
Microdissected tissue or cultured VP's were fixed in Bouins fixative for 2 hours on
ice. Tissue was stored in 70% ethanol until processed. Dehydration and further
processing was performed on a Leica TP1050. Paraffin embedding was performed
on the Tissue Embedding Center and 5pm sections were cut using a microtome
(Leica RM2135).
2.2.10.2 Tissue Immunohistochemistry
Sections were dewaxed in xylene for 10 minutes and rehydrated through an ethanol
series. Sections were pressure cooked for 5 minutes in citrate buffer (0.01M) and
cooled for 20 minutes. Sections were washed two times for 5 minutes in TBS
solution, and blocked by washing in a 3% hydrogen peroxide, methanol solution for
30 minutes at room temperature. The sections were blocked in 20% normal serum
(from host species the secondary antibody was raised in) diluted in TBST with 5%
BSA, for 45 minutes. The sections were then incubated overnight at 4°C with the
primary antibody (see table) diluted in the normal blocking serum. Negative control
sections were incubated with primary antibody that had been preabsorbed with its
relevant peptide, or with normal blocking serum.
Slides were given two times 5 minute washes of TBST, followed by incubation with
the required IgG-biotinylated secondary antibody at 1:500 diluted in 20% normal
blocking serum. Sections were then washed two times 5 minutes in TBST and
incubated with ABComplex/HRP (DakoCytomation). The slides were washed again
in TBST and the antigen was finally localised using the Liquid DAB+Substrate
Chromagen System (DakoCytomation). Sections were counterstained with
haematoxylin. Images were visualised and captured using the Provis (Olympus
Optical Co.)
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2.2.10.3 Fluorescent Tissue Immunocytochemistry
Sections are prepared similarly to the protocol outlined for Tissue
Immunocytochemistry, except for the omission of the blocking step ( 3% hydrogen
peroxide, methanol solution) and the washes are made with PBS. Also, the secondary
antibody is either the required biotinylated IgG as described, or the required direct
conjugate and streptavidin fluorophore complex (diluted 1:200 in 20% normal
blocking serum). The nuclei were counterstained with Topro 3. Sections were
visualised and imaged using confocal microscopy (Zeiss LSM 510).
2.2.11 In Vitro Organ Culture
Male VP lobes (VP) were microdissected from P0Wistar rats and grown in serum-
free organ culture (DMEM/NUT.MIX F-12 supplemented with transferrin (20p/ml),
insulin (20pg/ml) and 1 x penicillin/streptomycin) (Foster and Cunha, 1999). VP's
were positioned in a drop of media on Millicell® CM filters that were floated on 1ml
of culture media in 4-well NUNCLON™ plates. Organ rudiments were cultured at
37°C in 5% C02 for up to 6 days. The VP's were imaged under lightfield
illumination using the Image J software prior to fixation. To study the effects of
recombinant proteins on the growth of the VP's, organ rudiments were cultured with
varying concentrations of each recombinant protein in the presence or absence of
testosterone (10 8M).
2.3. LongSAGE
The LongSAGE technique (Saha et al., 2002, Velculescu et al., 1995) is a genome
profiling method based on the acquisition of a 17bp sequence tag from the 3' end of
a transcript, which uniquely identifies that transcript. The method is similar to the
original SAGE approach, but uses a different type IIS restriction endonuclease
(Mmel) and incorporates other modifications to produce longer transcript tags. The
resulting 21 bp tag consists of a constant 4bp sequence representing the restriction
site at which the transcript was cleaved, followed by an adjacent sequence in each
transcript.
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2.3.1. Materials
The LongSAGE™ libraries were made using the I-SAGE™ kit purchased from
Invitrogen™ Life Technologies and an adapted form of the I-SAGE™ protocol.
An I-LongSAGE™ kit is now supplied by Invitrogen™ to make LongSAGE
libraries, but was not available at the time of making these libraries.
2.3.1.1 Tissue Samples and RNA Preparation
Two LongSAGE libraries were made with starting tissue microdissected from the
urogenital tract of PO female Wistar rats. One library was made from the whole
region comprising of the prostatic precursor, and a second library was made from
only the mesenchyme involved in prostatic induction and growth (the ventral
mesenchymal pad, VMP). The whole prostate rudiment was referred to as the VSU
as it is composed of VMP, Smooth muscle and Urethra (urethral epithelium). The
VMP library was made from microdissected VMP mesenchyme only (Fig 2.1).
RNA was prepared according to the RNA extraction method using the RNeasy Mini
Kit from Qiagen. The RNA concentration and purity was measured on the Agilent
2100 Bioanlayser.
Fig: 2.1 The Prostate Rudiment
A schematic of the female rat (PO) UGT showing the relative position of the bladder
(BL), and the two regions microdissected, and used to prepare the LongSAGE
libraries; the VSU and the condensed pad of mesenchyme (VMP).
VSU
_A_
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Table 2.6
VSU Library VMP Library
Tissue collected ~ 100 VSUs -90 VMPs
Starting Tissue Weight ~180 mg -65 mg
Total RNA Used 50 pg 21 pg
2.3.2 Method
2.3.2.1 Library Preparation
A flow -diagram of the LongSAGE protocol is included as Figure 2.2. The
following modifications were made to the I-SAGE™ protocol
(http://www.invitrogen,com), based on recommendations from an EMBO SAGE
practical course (Jan 2003), and a LongSAGE protocol released by Genzyme
Molecular Oncology in January 2003:
1) Primers for Rat EF-la were used in the PCR checks of cDNA. The EF-la
primers supplied with the kit were recommended only for human samples.
EF -IS CATGAGGCAGACAGTTGCT
EF- IAS AGCCTTCTGAGCTTTCTGG
2) Linkers containing the Mme1 recognition site were ligated to 3'cDNA ends after
Nlalll digestion. To prepare the Linkers for use, 3.15pg of LinkerlB and Linker2B
were kinased using 100 U T4 Polynucleotide Kinase, IX T4 DNA Kinase buffer,
ImM ATP in a 20 pi reaction volume, at 37°C for 30 mins. The reaction was heat
inactivated at 65°C for 10 minutes lx Linker 1A and lx Linker B was mixed with 2x
Kinased Linker IB and 2B, respectively, and hybridized at 95°C for 2minutes,
followed by 20 minutes at room temperature. The hybridised linkers were checked
by agarose gel electrophoresis and diluted to a concentration of 20ng/pl for use.
Linker 1A/B was ligated to half the cDNA population and Linker 2A/2B was ligated
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Fig 2.2: The LongSAGE method (Part 1)
Synthesis of double stranded cDNA, restriction enzyme digestion of cDNA and isolation of 3'- cDNA fragments, adaptor modification and
excision of tags (redrawn from LongSAGE protocol supplied by Invitrogen™)
TTCRACCATGXXXXXXXXXXXXXXXXXXXXDV1DD1A0VV
AAGYTGGTACXXXXXXXXXXXXXXXXXXXXOIVOOVdOll S5•o
Ugate pool 1 to pool 2 and PCR
amplifywith primers specific to
linker sequences 1 and 2
\
Tag 1 Tag2
I j I TTCRACCATGXXXXXXXXXXXXXXXXXXXX3VIOOiAOVV
I—-—I AAGYTGGTACXXXXXXXXXXXXXXXXXXXXplv°5Va01i
34 bp DITAG
Restriction digest with anchoring enzyme (Nla 01);
Isolate 34 bp ditags by PAGE gel purification;
Concatenate dltag; select size of concatemer.
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Gone Into Pzero 1 vector, Transform into E.Coli Cells.; Sequence Plasmids
Fig 2.2 (cont): LongSAGE method (Part 2)
Ditag formation followed by amplification of ditags and adaptor removal. Formation of concatemers, cloning into pZero 1 vector and
Sequencing.
o










5' TCGGACGTACATCGTTAGAAGCTTGAATTCGAGCAG Amino Modified
C7-3'
3) The Linker molecules were released from the cDNA (attached to the magnetic
beads) using 20U Mmel type IIS restriction endonuclease, IX Mmel buffer, and
50mM S-adenosylmethionine for each Linker-tag in a 100 pi reaction volume.
Digestion was performed at 37°C for 2.5 hours.
4) The LongSAGE tags created by digestion with the enzyme Mmel leaves a 2bp 3'
overhang which was not polished with a Klenow reaction. The Linker lA/B-Tag and
Linker 2A/B -Tag molecules were ligated together overnight at 16°C as per the I-
SAGE kit protocol, to create a ~130bp ditag.




7) Prior to ligation into pZero®-l Vector, the concatemer fragments were digested
with 20U of restriction endonuclease Sphl and lx required buffer purchased from
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Promega in a final reaction volume of 20pl. The reaction was incubated at 37°C for
30 minutes, giving the concatemer fragments a 5' overhang to improve their cloning
efficiency. The digest mixture was extracted with phenol/chloroform and ethanol
precipitated, as outlined in the I-SAGE protocol. Ligation of the Sphl digested-
concatemer into the pZero®-l vector was performed overnight at 16°C to improve
the efficiency of cloning longer concatemer fragments.
8) The plasmid minipreps for the LongSAGE libraries were performed by Research
Support Technician Raymond Chan on a Biorobot® 9600 from Qiagen using the
Wizard™ SV9600 Plasmid Purification System (Promega). The plasmid minipreps
were screened for inserts by double enzyme restriction digestion using recommended
enzymes Bam HI and Xba 1 (Promega) with the supplied buffer, as per the
manufacturer's instructions. The sequencing was performed by the Human Genetics




SAGE2000 Version 4.5 software, (http://www.invitrogen.com/sage) was used to
prepare a report of the tag sequences, their abundance and associated transcripts from
the raw Sequence files.
Within the sequence files each tag was ligated to another tag as a "ditag", one tag
with 5' to 3' orientation and the other in reverse. The sequence file contained a
number of the ditags ligated as a concatemer, and present as an insert in a vector.
The software was able to recognise the ditag sequences within the concatemer by the
Nla III restriction enzyme sites (CATG) at each end. The software then separated
the ditags as two individual tags and the orientation of the second tag (3' to 5') was
reversed. The tags were then listed with their frequency. Each tag should represent
a unique transcript and their quantification was a measure of the transcript abundance
in the tissue.
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2.3.3.2 Statistical analysis
The VSU and VMP libraries were compared according to the tag abundances of each
transcript using Microsoft® Access, and Microsoft® Excel. Statistical analysis of
VMP up-regulated and VSU up-regulated genes (P<0.05) was performed by Z-test
using StatView® 5.0.1 Software from http://www.statview.com, and the Bayesian
method (http://igs-server.cnrs-mrs.fr/~audic/winflat.cgiX Audic and Claverie, 1997).
2.3.3.3 Tag-to-Gene Annotation
The tags were identified according to their transcript using a reference database, the
Rat LongSAGEmap located at the NCBI web-site: http://www.ncbi.nlm.nih.gov.uk.
The tags were compared to the Rat LongSAGE map in Microsoft® Access, and a file
was created listing the LongSAGE tags, their abundance, and the tag-to-gene
annotation. Tag-to-gene annotations were verified by BLAST using Ensembl
Genome Browser (http://www.ensembl.org).
2.3.3.4 Literature Mining and Candidate Selection
The named genes in the VSU and VMP libraries were processed, to select genes of
interest that should be studied further. The aim was to validate the SAGE libraries,
and identify mesenchymal genes that may be important during prostate development.
To fully interrogate the libraries four routes of research were pursued.
1) Genes that were found to be upregulated/enriched in the VMP Library by
statistical analysis (P<0.05) (Appendix). The function of their associated proteins
had been determined previously, and secretory proteins, transcription factors and
intracellular signalling molecules were considered to be of particular interest because
of their potential activity in regulating developmental processes.
2) Genes that were found through Literature Mining using PubMed (NCBI), to be of
importance during development of branched organs such as the lung, kidney or
breast, or to be members of known developmental pathways. These genes could
also be acting in the prostate to regulate growth and development.
3) Genes that were previously found upregulated in prostate cancer by microarray
(Lapointe et al., 2004, Rhodes et al., 2002, Stuart et al., 2004). Genes robustly over-
expressed in more than one study were identified by R. Chan (research support
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technician). It is thought that genes that are present during prostate organogenesis
may also be re-expressed during disease state prostate, cancer or benign prostatic
hyperplasic. 4) Interesting development associated molecules not previously studied
in the prostate. The accuracy of the tag-to-gene annotation for genes of interest was
verified by BLAST searches using Ensembl (http://www.ensembl.org) before further
experiments.
2.3.3.5 Gene Ontology Assignment
Tags verified by BLAST were grouped according to their function. The assignments
were based on searches of Ensembl (http://www.ensembl.org) and GeneCards
(http://www.bioinfo.weizmann.ac.il/cards/) provided by the Weizman Institute. The
tag assignments were performed by Dr. G.Vanpoucke.
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3. Gene Expression Profiling and Serial Analysis of
Gene Expression (SAGE).
3.1 introduction
3.1.1 Gene Expression Profiling Techniques
Nearly all the biological events such as cell division and differentiation,
responsiveness to hormones or growth factors and ultimately cell death are
associated with changes in expression. By comparing gene expression profiles of
different tissues or tissues under different conditions, individual genes or groups of
genes can be identified that play an important role in a particular signalling cascade
or disease process. Methods for assaying gene expression can be grouped into two
major types: (1) closed methods, which measure expression levels of already
collected clones or sequences, and (2) open methods, which do not require prior
knowledge of genes being measured.
The sequencing of cDNA clones provides the first glimpse of gene expression
patterns in different human tissues (Adams et al., 1995). Techniques based on
subtractive hybridisation (Hedrick et al., 1984) and differential display (Liang and
Pardee, 1992) have been useful in identifying differences in amounts of transcript
populations. However, these techniques provide only a partial picture and may miss
transcripts expressed at low levels. Other methods such as oligonucleotide arrays
(Lockhart et al., 1996) have been used to compare the expression of thousands of
genes in a variety of tissues including small cell populations (Sgroi et al., 1999,
Mahadevappa and Warrington, 1999) but they are limited to analysing only
previously identified transcripts. Also, the methods discussed cannot be used for
accurately monitoring quantitative differences in genes expression. However,
despite the possible caveats to research using micro-arrays, they have proved a
popular method for investigation into gene markers of prostate cancer (Dhanasekaran
et al., 2001, Lapointe et al., 2004, Ernst et al., 2002, Stuart et al., 2004) and most
recently, the Institute of Cancer Research has developed a tissue microarray (TMA)
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method to be carried out on needle biopsy samples to look for multiple makers of
various genes associated with prostate cancer (Jhavar et al., 2005).
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A recent technique, called massively parallel signature sequencing (MPSS) (Brenner
et al., 2000), is able to surmount some deficiencies of the previously discussed
techniques. MPSS can perform quantitative global analysis of gene expression, and
is provided as a service by Lynx Therapeutics, Inc., (California, USA)
(http://www.lynxgen.com). This sequencing approach combines non-gel-based
signature sequencing with an in vitro cloning of millions of templates on separate
microbeads. Like other clone-and-count techniques this approach provides a digital
picture of the gene expression profile. However, the cost of MPSS can be
prohibitively expensive. In this thesis, long serial analysis of gene expression
(LongSAGE), a modified version of the gene-profiling method, Serial Analysis of
Gene Expression (SAGE) was used (Saha et al., 2002, Velculescu et al., 1995) to
investigate the "transcriptome" of the neonatal rat UGS.
3.1.2 SAGE and LongSAGE
Serial analysis of gene expression (SAGE) is a high-throughput, high efficiency
method to simultaneously detect and measure the expression levels of genes
expressed in a cell at a given time, including novel and low abundance genes
(Velculescu et al., 1995). It does not depend on the prior availability of transcript
information. The technique is comprehensive, unbiased, quantitative, sensitive and
reliable. The SAGE technique can be used in a wide variety of applications including
the definition of transcriptomes, analysis of the effect of drugs on tissues,
identification of disease-related genes and elucidation of development and disease
pathways (Tuteja and Tuteja, 2004a).
A major use of SAGE has been the identification of genetic markers of cancer (as
reviewed in Tuteja and Tuteja, 2004b). Genetic events including mutations,
chromosomal gains, losses and rearrangements, along with epigenetic alterations,
lead to significant transcriptional changes in cancer cells. Changes in the expression
of many genes associated with the onset and progression of cancer likely contribute
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to the cancerous phenotype. By characterising and comparing normal and malignant
gene expression patterns, this could yield many new diagnostic and prognostic
markers as well as therapeutic targets in cancer. The SAGE technique has been used
in prostate cancer research (Xu et al., 2001, Untergasser et al., 2002, Waghray et al.,
2001a, Waghray et al, 2001b), and more recently in a study of mouse prostate
development (Zhang et al., 2006).
The SAGE technique produces 14bp sequences or "tags" from the 3' end of each
transcript that identify one (or more) mRNAs. More recently, a modified version of
the SAGE method called long serial analysis of gene expression (LongSAGE) has
been described (Saha et al., 2002). The LongSAGE method generates 21bp tags
derived from the 3'ends of transcripts that can rapidly be analysed and matched to
genomic sequence data (Saha et al., 2002). This method is similar to the original
SAGE approach but uses different type IIS restriction endonuclease (Mmel) and
incorporates other modifications to produced longer transcript tags. The resulting
21bp tag consists of a constant 4bp sequence representing the restriction site at which
the transcript was cleaved followed by a unique 17bp sequence derived from an
adjacent sequence in each transcript. Like SAGE, these sequence tags are
concatenated serially into long DNA molecules for sequencing. The frequency of
each tag in the sequence reflects the cellular abundance of the corresponding
transcripts. This serial analysis of many thousands of gene-specific tags allows the
simultaneous accumulation of information for genes expressed in the tissue of
interest and gives rise to an expression profile for that tissue. These sequencing data
are then analysed to identify each gene expressed in the cell and the levels at which
each gene is expressed.
The benefit of using LongSAGE over SAGE is in the accuracy of tag-to-gene
annotation. LongSAGE can be used for the rapid identification of novel genes and
exons. Theoretical calculations show that >99.8% of 21bp tags are expected to occur
only once in the genomes the size of the human genome. Likewise, similar analyses
based on actual sequence information from ~ 16,000 known genes suggest that >75%
of 21bp tags would expected to occur only once in the human genome, with the
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remaining tags matching duplicated genes or repeated sequences (Saha et al., 2002).
In contrast, conventional SAGE tags of 14bp do not allow unique assignment of tags
to genomic sequences, though they do allow assignment to the much less complex
compendium of expressed sequence tags and previously characterized mRNAs
(Velculescu et al., 1995). An I-SAGE and I-LongSAGE kit is supplied by
Invitrogen™ Life Technologies to produce SAGE and LongSAGE libraries.
Since the invention of SAGE technology, a number ofmodifications have been
reported in the technique. Some of the important modifications include SAGE-lite
(Peters et al., 1999), micro-SAGE (Datson et al., 1999), mini-SAGE (Ye et al.,
2000), a SAGE adaptation for downsized extracts (SADE) (Cheval et al., 2002),
SuperSAGE (Matsumara et al., 2005), Robust LongSAGE (Gowda et al., 2004),
aRNA-LongSAGE (Heidenblut et al., 2004) and generation of longer cDNA
fragments from SAGE tags for gene identification (GLGI) (Chen et al., 2000).
3.1.2.1 SAGE Bioinformatics
The sequence data generated by a typical SAGE experiment is analysed following a
typical procedure (Fig 3.1). Invitrogen™ Life Technologies supplies SAGE2000
Version 4.5 software available for download from http://www.invitrogen.com/sage
to purchasers of the I-SAGE or I-LongSAGE kits. The core functions of the SAGE
software are: (1) extraction and tabulation of tag sequences and counts from raw
sequence files, (2) comparison of tag abundances between projects and (3) matching
tags to reference sequences in other databases.
3.1.2.2 Databases of SAGE data
SAGE is a powerful technology that has been adopted as a standard for gene
expression. SAGE has become increasingly popular and as the number of users has
increased, the size and number of SAGE databases has grown. There are presently a
number of SAGE databases available, some commercial and some public.
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Extraction & tabulation of tags"
1) Remove duplicate ditags
2) Extract tags from ditags Tag extraction andannotation
Fig 3.1 Steps for data analysis of SAGE
The SAGE clones are sequenced and the tags are extracted after removal of
duplicated ditags by SAGE software. The software also quantifies the transcript
abundance of the SAGE clones. The observed tags are then matched to known
sequences from various sources and databases. Following this, the sorting and
filtering of tags based on differential expression reveals candidates for further
investigation.
The Genzyme SAGE database is an example of a commercial database. This
database is an integral part of Genzyme's therapeutic discovery efforts, and includes
over 4 million SAGE tags, believed to represent over 100,000 genes from major
cancers and normal human tissues. Other non- commercial methods are also
available for determining gene identification from a SAGE tag, namely SAGE Genie
(http://cgap.nci.nih.gov/SAGE) and USAGE (http://www.cmbi.kun.nl/usage)(van
Kampen et al., 2000). In this thesis, a publicly available gene expression database
was used, LongSAGEmap (http://www.ncbi.nlm.nih.gov/SAGE/), for high-
throughput tag-to-gene annotation.
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3.1.2.2.1 SAGEmap
A valuable and commonly used resource for SAGE tag-to-gene mapping is NCBI's
SAGEmap (http://www.ncbi.nlm.nih.gov/SAGE/). LongSAGEmap is a variant of
SAGEmap based on 17bp (21bp-CATG) transcript sequences as opposed to lObp
sequences. Tag mapping refers to the unambiguous determination of the gene
represented by a SAGE tag. As described by Lash et al, (2000), this tag mapping is
done on the basis ofmatching SAGE data to tags extracted from Expressed Sequence
Tag (EST) and cDNA sequences found in the NCBI Unigene clusters (Schuler et al,
1997) (http//www.ncbi.nlm.nih.gov/Unigene/). The Unigene database is composed
of expressed sequences (ESTs and cDNAs) clustered on the basis of sequence
similarity to gene sequences found in Genbank. The 3' most predicted SAGE tags
are extracted from each expressed sequence, and experimentally derived tags can be
compared with these predicted tags to determine the Unigene cluster that most likely
represents the gene from which the experimental SAGE tag was derived.
Unfortunately, there are several drawbacks to this method of tag mapping, primarily
due to the underlying data. The same gene may be represented in multiple clusters,
resulting in a single tag mapping to multiple clusters, and thus being erroneously
assigned as ambiguous. The sequences in the clusters are primarily ESTs, which
have an error rate estimated at ~1% (Lash et al., 2000). This error rate will result in
tags not matching the appropriate cluster and/ or matching an incorrect cluster. As
this approach is based primarily on expressed sequences, any genes that are not
represented by ESTs or cDNAs in Genbank, will not be represented by tags in
SAGEmap, resulting in tag-to gene assignments that are missing or potentially
erroneous. As a result, tag assignments can be ambiguous, incorrect or unavailable,
leading to potentially incomplete or erroneous gene expression interpretation
(Pleasance et al., 2003).
In summary, the most reliable are tag-to-gene matches derived from well-
characterised mRNA/cDNA sequences from Genbank. Of less reliability are tags
extracted from EST sequences, which can be further partitioned into classes
depending on the presence of absence of a polyadenlylation signal and if they have a
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3' or 5' orientation. The most reliable among the EST sequences are those with a
polyadenylation signal and/or polyadeylation tail and annotated as 3' sequences.
Fortunately, it is possible to check the accuracy of tag-to gene assignments using
BLAST, which searches genomic sequences, although of course this is not feasible
for a whole Library. Originally started as a database of gene expression, SAGEmap
now accepts SAGE sequence data from any source. This database presently contains
over 3 million SAGE tags for expressed sequences from over 50 SAGE tag libraries.
By accessing SAGEmap the user can compare transcript populations between any of
the posted libraries (Lash et al., 2000).
In summary, the LongSAGE method was used in this thesis to generate a
comprehensive and quantitative gene expression profile of the prostate precursor.
LongSAGE was used because it was an open-ended method of gene profiling, does
not require prior knowledge of transcript expression, and had the potential for
identification of novel genes. LongSAGE was used in preference to SAGE because
of the improvement in the accuracy tag-to gene-annotation process.
3.2 Results
3.2.1 Library Preparation
The LongSAGE Libraries were prepared according to a modified protocol (Fig 2.2)
presented in Materials and Methods. The modifications made were recommended on
an EMBO SAGE practical course (Jan, 2003), and were also included in a
LongSAGE protocol released by Genzyme Molecular Oncology (Jan 2003). The
aims of the modifications were to increase the efficiency of the SAGE technique, and
to produce Libraries of 21bp instead of 14bp tags.
A summary of the changes made to the conventional I-SAGE protocol is presented in
Table 3.1. The LongSAGE method starts with more total starting RNA than SAGE,
and isolates a tag of 21bp (17bp +CATG) rather than 14bp (lObp +CATG) by
changing the tagging enzyme, from BsmFl to Mme 1. The action of the tagging
enzyme (Mmel) was such that no Klenow reaction was required to ligate the tags,
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and there was an additional Sphl digestion step of the concatemer fragments to
improve their cloning efficiency.
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(Velculescu et al., 1995)
Total RNA quantity 20- 50 pg 5-10pg
Tagging enzyme Mme 1 BsmF 1




3.2.2 The VSU and VMP LongSAGE Libraries
To identify mesenchymal factors involved in prostate development, two LongSAGE
libraries were made from female neonatal rat prostate rudiment (Fig 2.1). A flow-
diagram of the step-by-step preparation of the two libraries is presented in Fig 2.2.
The VSU library was generated first, followed by the VMP library. Preparation and
sequencing of each Library was completed in -9 months. The main features of the
libraries are summarised in Table 3.2.
Table 3.2: Features of the VSU and VMP LongSAGE Libraries
Library Features VSU Library VMP Library
Tissue collected ~ 100 VSU's -90 VMP's
Starting Tissue Weight -180 mg -65 mg
TotalRNA 50 pg 21 pg
130bp Template Dilution per Reaction 1:40 1:40
No. PCR Cycles 23 27
No. PCR Reactions 400 400
Concatemer fragment size insert 700- lkb 500-800bp
Number of minipreps 2,747 3,788
Number of tags per concatemer insert 24 21
Fig 3.2: Flow -Diagram of the LongSAGE protocol.
Gel 1: PCR check for cDNA synthesis from RNA (Lanes 1; dH20, 2; +ve (GAPDH), 3; +ve (EFa1)), Nla III restriction enzyme digestion of
cDNA (lanes 4; +ve, 5; no enzyme (EF1a)), and ligation of Linkers LS1A/B and LS2A/B (40bp) to cDNA pool A or B (Lanes 6; LS1A/B +
pool A cDNA, +ve, 7, dH20 (EFa1)), (Lanes 8; LS2A/2B + pool B cDNA, +ve, 9, dH20 (EFa1))
Gel2. PCR check for digestion of each pool of cDNA + linkers with Mme 1 to isolate tags (resulting in loss of EF1a sites) (Lanes 1,2
(EF1a)) and ligation of the two pools of tags plus linkers (~65bp) to form 130bp ditags (lane 3).
Gel3: PCR amplified ditags (130bp) separated from ligated Linkers (~80bp).
Ma m digestion of
130bp ditags
Separation and Purification of
34bp ditags (Hi a PAGE Gel
l
Ligation of 34bp ditags to
yield concatemers
l
Clone concatemer fragment (500-lkb)
into pZero 1 Vector,
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Fig 3.2 (cont): Flow-Diagram of the LongSAGE protocol
Gel4: Separation of 34bp ditags.,from Linkers (~40bp) and ligated Linkers (~80bp).
Gel 5: Ditags were ligated to form concatemers
Gel 6. The size of concatemer fragment insert was checked by restriction enzyme digestion
as
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The differences in the features of the library preparations will be explained more
fully here. Firstly, a greater amount of total RNA used to make the VSU (50pg) than
VMP library (21pg). Consequently, in the PCR amplification step, which was
performed to generate a minimal amount of concatemer cDNA for cloning, 27 PCR
cycles were required for the VMP library and only 23 PCR cycles were required for
the VSU library. In other words, by maximising the RNA input, this minimised the
amount of PCR amplification needed. Furthermore, minimal PCR amplification
reduced the possibility creating a transcript bias in the Libraries, where the high
abundance tags could overwhelm the low abundance tags making them more
difficult to find.
Additionally, a minor change was made to the size of concatemer fragments insert
cloned into the pZerol vector, from 700bp-lkb (VSU) to 500-800bp (VMP).
Initially it was thought that this might make the Sequencing process more efficient
because it usually returns only ~700-750bp of sequence, and therefore, any extra
sequence is lost. However, as small inserts are preferentially cloned, it was the
500bp concatemer fragments from the VMP Library that were cloned more often.
These obviously contain fewer ditags than the 700bp minimum concatemer fragment
of the VSU Library, and meant it was necessary to increase the number of minipreps
and amount of Sequencing in order to generate a VMP Library of similar size.
3.2.3 Bioinformatics -Library Analysis
3.2.3.1 Extracting the SAGE tag data
The raw sequence data from the two SAGE libraries was compiled and analysed
using SAGE 2000 version 4.5 software provided by K. W. Kinzler
(http://www.sagenet.org). The SAGE 2000 software tabulated the tags using the raw
sequence files, and quantified the tags according to their abundance. During this
process, any Linkers and duplicate dimers were removed from the sequence data by
the software. The Linkers are the ~40bp sequences containing the Mme 1 restriction
site, that are linked to the ditags during the LongSAGE protocol, and may not have
been removed from the cDNA pool by Nla III digestion and PAGE gel purification.
These sequences are not part of the ditag sequence information and were therefore
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discarded. Duplicate dimers are when two identical tags form a ditag. This
occurrence is so statistically improbable that it is considered to be a sequencing error
or a PCR artefact, and so should be discarded.
A summary of the VSU and VMP library data is presented in Table 3.3, and the full
VSU and VMP library tag lists have been saved to CD (Tables 3.4 and 3.5,
respectively), and have been appended in a pocket at the back of the thesis. The tag
lists were annotated according to the process of Tag-to-Gene Annotation (2.3.3.3).
The lists include the tag sequences, the tag abundance, tag-to-gene annotation if
found, and the relevant reference Unigene ID number from Rat LongSAGEmap
(NCBI).
Table 3.3: Summary of the VSU and VMP SAGE Library Data.
VSU Library VMP Library
Total Tags 67,833 80,008
Unique Tags 22,755 26,932
Tag Categories No. Tags % of Library No. Tags % of
Library
High 200-500+ 21 0.1 24 0.1
Med 30-199 234 1 257 1
Low 2-29 6,867 30.2 7,824 29
Singletons 15,633 68.7 18,827 69.9
3.2.3.2 Comparison of the VSU and VMP Libraries
The tag sequences and their abundances were tabulated from each library and
imported into Microsoft® Access for further analysis. Using the Microsoft® Access
software, a comparison was made between all tags in the VMP library with their
matching tags in the VSU Library. This meant that all VMP tags, but not all VSU
tags were represented, as some transcripts from the VSU library would not be present
in the VMP library. The VMP Library was found to have 2, 044 unique tags (>Itag
count), specific to the VMP but not present in the VSU Library. The converse of this
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process, comparing "all tags" in the VSU library with only matching tags in the
VMP library was also performed (data not shown).
67
3.2.3.3 Statistical Analysis
The VSU and VMP library comparisons described in Section 3.2.3.2, were analysed
for statistically significant differences in the tag abundances. The comparison
between "all tags" in the VMP and matching VSU tags as described in Section
2.3.3.2 was imported into Microsoft® Excel and manipulated to perform two
statistical tests, a Z-test and Bayesian analysis. The level of statistical significance
for both tests was set at P <0.05. Both tests produced the same list ofVMP up-
regulated genes (Appendix). Similarly, a comparison made between "all tags" in the
VSU and matching tags in the VMP was also subjected to the same statistical
analyses (data not shown).
3.2.3.4 Tag-to-Gene Annotation
The tags in the VSU and VMP libraries were processed to determine the identity of
their associated genes. By using the process described in Section 2.3.3.3 it was
attempted to match all tag sequences in each library to their associated genes using
Rat LongSAGE map (Lash et al., 2000). A modified version of rat SAGEmap (lObp
sequences) was requested from NCBI. LongSAGE map was compiled with 17bp
reference sequences to improve the tag-to-gene annotation of the LongSAGE tags.
Accurate gene assignments are essential if the named genes will be the basis of
further studies. Therefore, a more detailed analysis of the VMP-enriched genes
using BLAST was performed (Fig 3.3), to ensure the tag -to -gene annotations were
accurate. The results of the Library comparison, statistical analysis and tag-to gene
annotation is included in the Appendix..
Of the 218 VMP-enriched tags (P<0.05) (Appendix), 143 tags were identified as
"known", that is they were associated with named rat transcripts. The accuracy of
gene assignment was verified by BLAST searches of the genomic sequences
(Ensembl). The remaining 75 tags (35%) were "unknown" according to the
LongSAGE map, and could not be associated with a named transcript (Table3.4).
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To identify the "unknown" tags, BLAST searches (Ensembl) were performed. The








Unknown Unique hit in Rat genome
BLAST
19 42
Fig 3.3: Flow-diagram of the tag-to-gene annotation process
After performing BLAST searches on the 75 'unknown' tags, 42 tags were found to
give a unique hit in the rat genome, and to lie with 5kb of a gene locus and could be
identified. Using BLAST, increased the number of tag-to-gene assignments from
143 to 185, and is useful for accurately identifying smaller numbers of tags, but is
not practical for use on LongSAGE libraries. A comparison of the tag-to gene
annotation process by LongSAGEmap and BLAST is presented in Table 3.6
Finally, to name the remaining 19 'unknown' tags, it would be necessary to perform
GLGI also known as 3'RACE (Chen et al., 2002), a technique that allows the
acquisition of 50-250bp of further sequence data using the original 21bp tag. With
this extra sequence information it would be easier to identify the associated
transcripts by BLAST searches. GLGI was not undertaken as part of my research.
The process of tag-to-gene annotation was similarly performed for the VSU-
upregulated genes (P<0.05) (data not shown) and several genes of interest were
identified by genomic BLAST searches (Ensembl). Tags associated with epithelial
markers, cytokeratins 8, 19 smooth muscle markers and transgelin were found in the
list of VSU up-regulated genes (data not shown).
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Table 3.6: Comparison of rat LongSAGEmap vs. BLAST for tag-to-gene
annotation of VMP-enriched tags.












Known genes = named genes and Rat EST's with similarity to a named gene
EST's = rat EST's with no similarity to a named gene
No Match = No hit or multiple hits in the rat genome, or a hit in the wrong direction.
3.2.3.5 Assignment to Gene Ontology
The genes identified as VMP-enriched (P<0.05), were assigned a molecular function
to their proteins. The assignments were based on searches of Ensembl
(http://www.ensembl.org) and GeneCards (http://www.bionfo.weizmann.ac.il/cards/)
provided by the Weizman Institute. The assignments were performed by Dr. G.
Vanpoucke, and are presented in Graph 3.1. The proteins were divided into
categories according to their function, and 60% of the proteins were assigned a
known function. For the remaining 40% of the tags (~ 88), half were classified as
'hypothetical proteins' (20%) and half as 'unknown' function (20%). The majority of
the tags classified as "unknown" proteins (38 tags) had not been assigned to a gene.
The "hypothetical proteins", were assigned from" known" identified genes, but had














































Graph 3.1: Functional classification of VMP-enriched genes from the SAGE Libraries.
A pie chart depicting the percentage of distinct genes encoding proteins in various functional categories in the list of 218 VMP-enriched
genes (P<0.05) identified by statistical analysis of the SAGE library data.
—j
o
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3.2.3.6 Developmental Pathways and Regulatory Genes
The LongSAGE libraries were interrogated for 'genes of interest' (Table 3.7). Three
routes of investigation were pursued:
1) genes that are already known as being important during prostate development,
2) genes that are members of a known developmental pathway
3) cDNAs/transcripts associated with prostate cancer











MMP2, Paralemmin, PMP22, VAP1,
Calnexin, TF8,
Four and a half LIM domains, Hepsin
Developmental
Pathways
Notch Notch 1, Notch2, (Dlkl?) lunatic and radical
fringe
Wnt Wnt4, Wntll, Sfrp2, Frzldl, Dkk3,
Disabled2, Dishevelled 1,
TGF0 /BMP TGF02, TGFi, Ltbp4, BMP4 and 6, SMAD 1,
SMAD4 and SMAD5.
FGF FGF10, FGF13, Sproutyl, FGFR1 and 2.
Hedgehog smoothened
3.2.4 Summary of Results
The LongSAGE technique was used to prepare two libraries from the female prostate
rudiment. The VSU library was made from the whole UGS, containing the ventral
mesenchymal pad (VMP), smooth muscle and urethral epithelium, and the VMP
Library was made from the microdissected VMP only. The LongSAGE tags were
extracted from the raw sequence data, and quantified according to their tag count.
Tag -to-gene annotation was performed in a high-throughput manner on both
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Libraries, using LongSAGEmap, and the accuracy of the gene assignment was
verified by BLAST searches. The contents of the Libraries were validated by the
presence of established developmental and regulatory pathways, including FgflO, AR
and BMP4, mesenchyme-specific factors, known to be active during prostate
development. To identify genes that demonstrated VMP enriched/specific
expression, a back-comparison was made of the VSU and VMP libraries, based on
their tag counts. Statistical analysis (Z-test) of the library comparison highlighted
218 VMP-enriched (P<0.05) genes (Appendix).
3.3 Discussion of the Library Preparation and Analysis
LongSAGE is an expensive, time-consuming and multi-step technique, which is not
in common usage. Therefore, it was thought to be important to provide the reader
with a detailed insight into the preparation and analysis of the Libraries. This section
aims to provide further background on the LongSAGE method, the choice of tissue
used, and analysis process undertaken.
LongSAGE was chosen as a genome profiling method over other techniques, such as
differential display PCR, microarrays and MPSS, because they were either too time-
consuming, relied on prior knowledge of transcript expression eliminating the
possibility of identifying novel genes, or were too expensive, respectively. Also,
when this project was initiated microarrays provided poor coverage of the rat
transcriptome and there were concerns over their sensitivity and reproducibility
between different laboratories. The most efficient but expensive method, MPSS
(Jongeneel et al., 2003, Brenner et al, 2000) generates millions of signature
sequences from cells and tissues would have provided the most in-depth analysis.
The LongSAGE method was used instead of SAGE because it generated 21bp tags
instead of 14bp tags, allowing the unique identification of the associated transcripts
(Saha et al., 2002). This increased tag size helped to identify rat transcripts with
improved accuracy. However, this also created a trade-off between the need for
accurate tag-to-gene annotation, and the depth of library sampling. It is more
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expensive to generate a LongSAGE than a SAGE library of equivalent size because
the tag concatemers sequenced comprise fewer 21bp than 14bp tags.
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3.3.1 The VSU and VMP LongSAGE Libraries
The LongSAGE libraries were generated to profile the gene expression of the
mesenchyme/stroma of the prostate rudiment. The Libraries were prepared from
VSU and VMP tissue carefully microdissected from the female UGS (PO). The
quality of the tissue was paramount. Using female tissue to make the Libraries was
proposed to be valid, based on the hypothesis that females produce prostatic inducing
molecules constitutively (but that these are not 'activated' unless androgens are
present). Also, studies have shown that it is clear that females have the capacity to
form a prostate but they do not do so because of a lack of androgens (as reviewed by
Thomson, 2001). Female UGS (E16.5) can be induced to produce epithelial buds by
treatment with Testosterone in vitro (Takeda et al., 1986). Consequently, as the
'andromedin hypothesis' of prostatic induction (regulation of mesenchymal factors at
the level of gene transcription by androgens) remains controversial, it was argued
that studying the female UGS would not be a disadvantage in finding 'inductive'
molecules.
Neonatal tissue was used as opposed to embryonic tissue due to its larger size, which
was beneficial for preparing large amounts of RNA. Also, the female rat UGS had
the advantage of a homogeneous mesenchyme, the VMP (PO), with no contaminating
epithelial and smooth muscle tissue, unlike the male prostate at the same age.
An additional concern about the experimental design of this project was that in using
the VMP, any factors that are 'triggered' as a consequence of invading epithelium,
would not be expressed. A common mechanism of branching organs is for epithelial
tips to induce a local change in the mesenchyme as it invades (as reviewed by
Davies, 2002). However, alternative experimental designs that considered this
problem were also found to contain caveats.
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Two possible approaches suggested, were to compare LongSAGE libraries prepared
from male UGM and UGS (E17.5), or male UGS and female UGS (E17.5 or PO).
However, preparing libraries from embryonic tissues would have required sacrificing
a considerable number of dams, and it would be extremely technically difficult to
isolate the UGM. Zhang et al., (2006) has reported isolating E16.5 UGM in the
mouse using enzymatic and mechanical separation, but it is suggested that this may
compromise the quality of the RNA. Furthermore, it is proposed that if LongSAGE
Libraries of both male and female UGS (PO) had been generated and compared, the
heterogeneous nature of the tissues, and the developmental changes in cell
proportions between the male and female UGS, would make it very difficult to
determine transcript expression in distinct cell populations. It would not have been a
useful approach for identifying the mesenchyme-enriched genes.
It is concluded that the approach used, comparing neonatal female UGS and VMP,
has proved to be relatively successful so far, in identifying mesenchyme-enriched
molecules. However, if the project had not been aimed at identifying primarily
mesenchymal factors, and also was awarded unlimited time, funding and manpower,-
it is proposed that several Libraries would have been prepared, from embryonic to
adult prostate, including Libraries of the isolated male and female UGM, and
prostate cancer stroma. It is noted that Zhang et al., (2006) has reported preparing
several, bigger SAGE libraries to study gene expression in the developing mouse
prostate. Also, a more comprehensive picture of changes in gene expression during
prostate development could be studied with the more powerful gene profiling
technique, MPSS.
The VSU and VMP LongSAGE libraries were prepared from microdissected
neonatal female UGS, using a modified SAGE protocol (Invitrogen). It would have
been ideal to generate two VMP Libraries in addition to the VSU Library, as this
would have ensured that the data was reproducible, but limitations in tissue
collection and time available for experiments were prohibitive. It was understood
that tissue dissections are not always accurate and by preparing two VMP Libraries
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this would have acted as a 'control', and the Libraries could have been compared to
confirm if the LongSAGE technique could produce reproducible, reliable results.
Also, the 'cDNA amplification step' was highlighted as a stage in the technique that
could introduce significant errors into quantification of transcript abundance. It was
recognised that the amplification of cDNA by PCR would favour the high abundance
transcripts, exponentially increasing their expression more rapidly than the low
abundance transcripts, and could create a transcript bias within the Libraries.
Consequently, a greater amount of starting RNA was used to prepare the Libraries
than recommended, in order to minimise the number of PCR cycles necessary at the
amplification step. Also, a greater amount of RNA was used for the VSU Library
than the VMP Library because it was hypothesized that this would ensure the low
abundance tags in the more complex VSU tissue, would be adequately represented,
and because of the difficulty of obtaining a large amount of VMP tissue due to its
size. Subsequently, it was noted that the VMP Library contained more unique tags
than the VSU library even though they were sampled to a similar depth (70-80,000
tags). It was concluded that the VMP Library (26, 932 unique tags) gene profile was
-likely to be more representative of its homogenous source tissue than the VSU
Library (22,755 unique tags) prepared from the more complex VSU, and that further
sequencing would be required to generate an accurate VSU transcriptome profile.
3.3.2 Bioinformatics -Library Analysis
3.3.2.1 Extracting the Tag Data
The VSU and VMP libraries were sequenced to a depth of ~70-80,000 tags. The
VSU library had 67,833 tags, comprising 22,755 unique tags. The VMP library had
80,008 tags, comprising 26,932 unique tags. The size of the libraries was carefully
considered based on a report by Velculescu et al, (1999), who stated that a range of
50-100,000 tags in a SAGE library (of a single cell line) was optimal, and that
relatively few new tags were found with more in-depth sampling. They proposed
that ~90% of the unique tags in a SAGE library of up to 650,000 tags, were present
in a sampling of 50,000 tags. This thesis has reported that the VSU Library was not
sequenced adequately at ~80,000 tags, and recently Zhang et al., (2006) concluded
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that SAGE libraries of the developing mouse prostate required deeper sequencing
than 100,000 tags to reveal the entire transcriptome.
Fortunately, identifying the entire transcriptome of the VSU was not critical to
finding VMP-enriched genes, and it also highlighted the benefit of using the
homogeneous VMP, to prepare the second Library. Additionally, expression of
some low abundance VMP-enriched transcripts i.e. FgflO, AR and BMP4, was
confirmed in both Libraries, and therefore the LongSAGE technique and the
sampling of 80,000 tags was verified to be sensitive enough to identify similarly
expressed transcripts. Further sequencing would have been expensive and could not
be justified based on the research by Velculescu et al., (1999), that few further
unique tags would be found.
3.3.2.2 Tag-to-Gene Annotation
The tags isolated in the VSU and VMP LongSAGE libraries were used to identify
their associated transcripts/genes. Using 21bp LongSAGE tags instead of 14bp
SAGE tags improves the accuracy of the tag-to-gene annotation process (Saha et al.,
2002). However, even with the benefit of having longer tags, the data in the VSU
and VMP Libraries demonstrated that several in individual tags had been assigned to
different multiple genes. Also, conversely, in several instances, different tags had
been assigned to the same gene. The proportion of the whole Libraries that were
poorly annotated was not determined, although it was demonstrated that only 65% of
the tags were assigned in the list of 218 VMP-enriched tags (P<0.05) using the
LongSAGEmap method.
This poor rate of accurate tag-to-gene annotation can be explained by some potential
problems that had been highlighted in previous studies. 1) Rat sequences are under-
represented (particularly at the 3' end) in the Unigene database, in comparison to the
human and mouse. Therefore, a single rat tag can be wrongly matched (by
LongSAGEmap), to a sequence that is present in different transcripts, but which does
not represent the most 3' end. The tag will be assigned several gene names. 2)
Partial digestion of the cDNA by the tagging enzyme NlaHI results in heterogenous
cleavage at the poladenylation site, producing multiple tags for one transcript. 3) One
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gene can have multiple transcripts because of gene splicing, alternatively spliced or
polyadenylated mRNA sequences (Pauws et al., 2001), and therefore different tags
may represent different isoforms of the same gene. 4) 10% of SAGE tags potentially
contain a sequencing error, therefore cannot be correctly assigned to a gene (Hillier
et al., 1996, Lash et al, 2000). It is suggested here that sequencing of the longer
LongSAGE tag increases the possibility of inclusion of a sequence error. 5) Genes
that do not have a CATG (Ma III digest site) will not be included in the LongSAGE
protocol ifMa/// was used. To address this situation it is possible to use a different
"tagging" enzyme such as Sau3A.
Unfortunately, there is little that can be done to solve the several drawbacks of this
method of tag mapping, which are primarily due to the underlying data. Therefore,
until the rat genome is more fully characterised, genes that may be of interest could
unfortunately remain hidden within rat Libraries. It could be worthwhile re¬
examining the Libraries as the rat transcriptome becomes better characterised
Consequently, the tag-to-gene annotation resulting from matches to the rat
LongSAGEmap was not wholly reliable, the transcripts identified as VMP-enriched
(P<0.05) were verified by BLAST (Ensembl). BLAST uses rat genomic data, which
is more fully characterized than rat transcript data available (used to compile the rat
LongSAGEmap). BLAST was able to annotate a further 42 tags (~19%) which had
previously been classified as "unknown" by the LongSAGEmap method, and also
gave additional confidence to the accuracy of the gene assignments. BLAST was not
suitable for the high-throughput process required for annotation of whole SAGE
libraries, although it was recommended that BLAST should be used to verify the
transcript identities prior to further experimental analysis.
10.2.3 Differential Tag Expression in the LongSAGE libraries
A process of 'back-comparison' was performed between the VMP and VSU
Libraries, which highlighted 218 VMP-enriched tags (P<0.05) (Appendix A) and
103 VSU-enriched tags (P<0.05) (data not shown).
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Performing a 'back-comparison' between the VSU and VMP Libraries was proposed
because it would help to highlight the VMP-enriched low abundance transcripts. As
the VMP is only a subset of the VSU, it was thought that genes which are VMP-
specific/enriched would be likely to be represented as either very low or absent in a
VSU Library, and so will be more apparent by comparison of the Libraries.
Additionally, the list of VSU-enriched tags (P<0.05), was found to contain known
epithelial cell markers, i.e. cytokeratin 8 and 19, and smooth muscle markers, i.e
transgelin and myosin light chain. This helped to support the validity of the data in
the Libraries. Specifically it showed that there were significant differences in gene
expression depending on the tissues that had been used to make the Libraries, and
supported analysis process used. In other words, if expected gene markers could be
identified in the VSU-enriched data (P<0.05), there could be more confidence in the
accuracy of theVMP-enriched/specific transcript data (P<0.05).
However, one significant problem noted by statistical analysis of the Library
comparisons was that for a tag to be identified as demonstrating statistically
significantly different expression (P<0.05) between the Libraries, the minimum
difference in tag counts had to be at least 5 vs. 0 tags. This meant that all tags
present at ^ 4 counts in both Libraries would be discarded by statistical analysis,
even though they would be likely to contain some interesting but low abundance
genes. Consequently, the low abundance transcripts (<, 4) were analysed separately
and interrogated for possible "genes of interest". Even though candidates from this
group have not been selected in this project, some have been included other studies.
3.3.2.4 Gene ontology of VMP-enriched Tags
The proteins associated with the VMP-enriched tags (P<0.05) were assigned a
function, to assist in the selection of candidate genes for further studies.
Unfortunately, it was only possible to assign a molecular function to 60% of the tags,
while the remaining tags (40%, or ~88 tags) were evenly split between 'hypothetical'
proteins, and proteins of 'unknown' function. The poor level of assignment is
suggested to be the result of the inadequate characterisation of the rat genome. The
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groups that were highlighted as most likely to contain regulatory developmental
genes included the secreted factors (5%), transcription factors (6%) and intracellular
signalling molecules (7%). In particular, it was proposed that secreted factors would
be ideal candidates that could be active in a paracrine signalling pathway, from the
mesenchyme to the epithelium.
3.3.2.5 Selection of Genes of Interest
The Libraries were interrogated for genes that are members of known signalling
pathways expressed during prostate development, in order to validate the SAGE
data, and identify possible mesenchymal candidate genes. Also highlighted were
genes that have been reported upregulated during prostate cancer.
It was proposed that some of these genes, although not identified by the
bioinformatic and statistical analysis approach, might also represent possible
mesenchymal candidate genes. This process, described as intuitive selection, is a
recognised method of selecting candidate genes from gene profiles, which has been
extensively reported. By using an additional method of candidate selection it was
hoped to reduce the chance of 'missing' candidate genes through problems with tag
quantification in the Libraries and the subsequent bioinformatic analysis. For
example, the low abundance genes (tags counts of < 4) that were excluded as
possible mesenchymal candidates by statistical analysis of the library comparison,
but still may represent important factors.
Genes that were intuitively selected from the Libraries, included members of known
developmental and regulatory pathways i.e Notch, TGFpi/BMP, FGF, Hedgehog
and Wnt and genes associated with prostate cancer including, MMP2, Plm, PMP22
and VAP1. This provided a "snap-shot" of the likely molecular processes taking
place in these tissues, while also validating the data in the Libraries. Additionally,
identification of cancer-associated genes in a developing tissue, supports the
hypothesis that regulatory developmental genes may be active during carcinogenesis
(McNeal et al., 1969).
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4. LightCycler Analysis and Selection of Candidate
Genes
4.1 Introduction
After generating the LongSAGE Libraries, the aim of this project was to characterise
the expression and function of a small number of candidate mesenchymal genes such
that a gene identified by SAGE could be demonstrated to have a function in the
developing prostate.
Quantitative RT-PCR was used as a preliminary means of validating the LongSAGE
data by an independent technique. In other words, qRT-PCR was used as a screening
process for confirming the accuracy and reliability of the SAGE data. Unfortunately,
due to the expense of LightCycler analysis, and also insufficient time, it was not
possible to study and categorise a greater proportion of the gene expression in the
LongSAGE Libraries, as has been reported in some other cells/tissues (as reviewed
by Tuteja and Tuteja, 2004(a)). Therefore, only a few genes were selected for further
analysis, as likely mesenchymal candidates.
4.2 Results
4.2.1 Selecting Genes for Further Analysis
Genes were selected from the VMP and VSU SAGE libraries for further analysis.
The categories considered can be summarised as follows;
1) VMP-enriched transcripts (P<0.05),
2) genes found in the SAGE libraries from known developmental pathways
3) genes associated with identified developmental pathways, but not identified in the
libraries,
4) transcripts /cDNAs present in the libraries and upregulated in prostate cancer
studies (Lapointe et al., 2004, Rhodes et al., 2002, Stuart et al., 2004).
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A group of 26 transcripts were selected for further experimental studies. The
accuracy of the tag-to-gene annotation process by the rat LongSAGEmap was
verified by BLAST searches of the tags against the rat genome (Ensembl).
4.2.2 Experimental Validation of LongSAGE Libraries
Initial analysis of the selected genes was performed by the LightCycler (qRT-PCR),
to determine if they were VMP-enriched, by an independent technique. Levels of
transcript expression in VSU and VMP tissue were normalised by housekeeping
gene levels (TBP), and then compared. The experiment was repeated on at least two
individual batches of VSU and VMP cDNA, synthesised from their own freshly
prepared RNA samples. The primers designed for normal PCR were also used for
the LightCycler reaction (Table 2.4). When LightCycler analysis was performed on
genes that had not been identified in the SAGE libraries, transcript expression in the
VSU and VMP was initially tested with general RT-PCR. LightCycler analysis was
performed on the relative transcript expression levels of 26 genes in the VSU and
VMP. The results divided the transcripts into three groups; 1) VMP-enriched
transcripts (6), 2) VSU-enriched transcripts (9) and 3) transcripts with no difference
in expression levels in the VSU and VMP (11).
4.2.2.1 VMP-Enriched Genes Verified by LightCycler Analysis.
LightCycler analysis identified 6 of the 26 genes tested as 'VMP-enriched', that is
showed at least a 1.5 fold higher level of expression in the VMP in comparison to the
VSU. The fold-difference in VMP /VSU transcript expression for the six 'VMP
enriched' genes, according to the LongSAGE and LightCycler analysis results are
presented in Graph 4.1. Three of the genes were identified as VMP-enriched; Dlkl
(2.4-, 1.5 -fold), Notch2 (6-, 1.8 -fold), Nell2 (5-, 1.7-fold) by SAGE tag counts
(P<0.05) and LightCycler analysis, respectively. The 3 remaining genes {MMP14,
FgflO and Ptn) were not identified as VMP -enriched (P<0.05) by SAGE analysis
and were analysed by LightCycler after intuitive selection from the Libraries.
MMP14 (1.5 -fold), FgflO (2.4-fold) and Ptn (1.6-fold) were identified as VMP-
enriched according to LightCycler analysis. FgflO was included as an internal
control, a low abundance VMP-specific gene, known to have an important role in
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prostate organogenesis (Thomson and Cunha, 1999). Therefore, identification of
FgflO as VMP-enriched gene validated the LightCycler as a reliable technique to
quantify even low abundance transcripts.
Tag count
VSU 17 0 0 2 3 63
VMP 41 6 5 10 4 74
Graph 4.1: SAGE Tags Verified as VMP-enriched by LightCycler Analysis
A graph of the SAGE and LightCycler analysis data, showing the fold-difference of
transcript expression in the VMP in comparison to the VSU. LightCycler analysis
classified a difference in transcript expression of s1.5-fold in the VMP, as VMP-
enriched
4.2.2.2 LightCycler Analysis Identifies VSU-enriched Genes.
Of the remaining genes tested, some were found to be VSU-upregulated (>1.5 fold)
in comparison to the VMP (9 of 26) (Table 4.1). These transcripts were likely to be
specific to the epithelial or smooth muscle cells, present only in the VSU tissue.
'Control' genes, Notchl (Shou et al., 2001, Wang et al., 2004), Hepsin (Dhansekaran
et al., 2001, Ernst et al., 2002, Klezovitch et al., 2004) and FgfR2 (Igarashi et al.,
1998) were included in the analysis. They have each been previously localised to the
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epithelial cells of the developing and/or disease prostate. Additionally, Jagged2 was
included as a ligand of Notchl (Valsecchi et al., 1997). Verifying their predicted
gene expression as VSU-enriched helped to confirm the robustness of the
LightCycler screening process.











Hepsin 27 43 No 2.7
FGFR2 2 6 No 2.2
TGFp2 6 1 No 1.7
Notch 1 4 0 No 1.9
GDNFRal 3 4 No 1.9
BMP 7 3 0 No 4
Jagged 2 0 0 No 3
Hgf 0 0 No 1.6
Pdgf 0 0 No 2.5
4.2.2.3 LightCycler Analysis Identifies No Difference in Transcript
Expression
The remaining genes investigated (11 of 26) showed no difference in transcript
expression levels in the VSU and VMP (Table 4.2). Several of these genes had been
selected from the list of VMP-enriched genes identified by SAGE analysis
(P<0.05)(Appendix), and several of them had also been identified as cancer-
associated genes (Lapointe et al., 2004, Rhodes et al., 2002, Stuart et al., 2004). In
particular, MMP2 is highlighted within this group as a VMP -enriched gene
(P<0.05), identified by SAGE and is included in further analyses (Chapter 8).
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Table 4.2 : Genes that show no difference in expression between the VSU and
VMP by LightCycler analysis.
Gene VMP VSU VMP-enriched genes by Identified as a cancer-
tags tags SAGE tag counts associated by
(P<0.05) literature mining.
Decorin 384 270 Yes No
MMP2 69 33 Yes Yes
Fibronectin 21 10 No No
Basigin 18 6 Yes No
PMP 22 16 5 Yes Yes
Paralemmin 12 2 Yes Yes
Syntenin 11 2 Yes No
Midkine 10 11 No No
Lgl 5 2 No No
VAP 1 5 0 Yes Yes
BMP3 0 0 No No
4.2.2.4 Selection of Candidate Genes
Six genes were selected after LongSAGE and LightCycler analysis as "candidate
mesenchymal genes"; Dlkl, Ptn, Notch2, Nell2, MMP2 and MMP14. The associated
transcripts had each been identified by SAGE and/or LightCycler analysis as VMP-
enriched (Appendix and Graph 4.1). Additionally, in support of the choice of
candidate selection, the VSU and VMP libraries were interrogated for candidate -
associated genes (Table 4.3), to determine if other member of their developmental
and/or signalling pathways were present.
Characterisation of the candidates will be discussed in the following chapters of this
thesis. In particular, Dlkl (Chapter 5), Notch2 (Chapter 6) and Ptn (Chapter 7), were
studied in most detail.
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Table 4.3:
Candidate Gene Associated Genes in the VSU identified by SAGE analysis
and/ or RT-PCR
Notch 2 Notch 1, radical and lunatic fringe, Jagged 2, numb, nicastrin
Dlkl Notch associated genes?
Pleiotrophin midkine, syndecanl, 3 and 4, syntenin and nucleolin.
MMP2 and MMP14 MMP11, 16, 23, TIMP 1 and 2, ADAM 15 and 17,
ADAMTS-1 and 12.
Nell2 Unknown signalling pathway
4.2.3 Summary of Results
LightCycler analysis (qRT-PCR) was used as a screening process to verify the VMP
-enriched expression of 26 selected genes. Some genes were selected either by
bioinformatic analysis of the i.e VMP -enriched genes (P<0.05) (Appendix) (10), or
by intuitive selection, i.e those from established developmental pathways and/or
prostate cancer studies (16).
LightCycler identified six genes as confirmed as VMP-enriched (sl.5 fold) in
comparison to the VSU; Dlkl, Notch2, Ptn, Nell2, MMP14 and FgflO (a known
mesenchyme -specific factor). Dlkl, Notch2 and Nell2 had been selected by
bioinformatic analysis of the SAGE data, and had been identified as VMP-enriched
(P<0.05). However, these were only 3 out of 10 (30%) VMP-enriched genes
(P<0.05), determined by SAGE, to be confirmed as VMP-enriched (>1.5-fold) by
LightCycler analysis. The other 7 VMP-enriched genes (P<0.05) showed no
difference in expression between the VMP and VSU tissues, by LightCycler analysis
(Tables 4.1 and 4.2) although they did exhibit a trend towards VMP-enriched
expression according to their tag counts. This group included MMP2, a gene
commonly expressed with MMP14.
The intuitively selected genes, MMP14 and Ptn exhibited noticeable but not
statistically significant VMP-enriched expression by SAGE analysis, however,
subsequent LightCycler analysis confirmed that they demonstrated VMP-enriched
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expression (si.5-fold). Finally, 9 genes were confirmed as VSU-enriched (si.5
fold) by LightCycler analysis and were therefore, likely to contain factors from the
epithelium and smooth muscle. This group of genes included Notchl, Hepsin and
FgfR2, each previously identified in prostate epithelia.
Based on the SAGE and LightCycler data, six candidates were selected for further
characterisation studies: Dlkl, Notchl, Ptn, Nelll, MMP2 and MMP14. To support
the selected candidates the SAGE Libraries were interrogated for associated genes
and for other members of their developmental pathways.
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5. Delta-Like 1 homoiog
5.1 Introduction
The mammalian protein Delta-like 1 (Dlkl) is a member of the epidermal growth
factor (EGF)-like family of homeotic genes that includes Notch receptors and their
ligands (Laborda et al., 1993, Laborda, 2000). Notch ligands are transmembrane
proteins and belong to the DSL (Delta, Serrate, Lag-2) family of proteins. The ligands
are characterized by two conserved motifs: the DSL domain, important for Notch
binding and a series of EGF-like repeats. They are grouped into two subfamilies
based on the presence of a cysteine-rich region in the extracellular region: those with
the cysteine-rich region belong to the Serrate/Jagged family, whereas those without
belong to the Delta family. The delta-like 1 protein was so named because of its
similarity in structure and amino acid sequence in the EGF-like repeats to Delta
proteins (see Fig 5.1). Four Delta proteins (Deltal, Delta2, Delta 3, Delta4) have
been identified as Notch ligands in vertebrates, to date (Gray et al., 1999, Joutel and
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Fig 5.1: Structure of the Dlk1 and Delta Proteins
Comparison of the Dlk1 (Panel A) and Delta (Panel B) protein structures. Dlk1 lacks
the DSL (Delta, Serrate, Lag-2) domain. Signal peptide (SP), epidermal growth factor
repeats (EGF), protease target region (PRO) transmembrane domain (TM),
intracellular region (INT) (Baladron et al, 2005)
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The Dlkl protein comprises six EGF-like repeats, a signal sequence in the
extracellular domain, a unique transmembrane domain, and a short intracellular
region (Laborda et al., 1993). The EGF-like repeats, are 35- to 40-amino acid domains
with conserved spacing of six cysteine residues, first identified in epidermal growth
factor. However, there is one important difference between Notch ligands and dlk, in
the lack of a DSL domain at the dlk N-terminus. The cysteine-rich DSL motif is
thought to be important for binding to the Notch receptor in the extracellular region
(Artavanis-Tsakonas et al., 1995) therefore dlk has been reported to be an unlikely
ligand for Notch. However, a controversy still remains as to a possible interaction
between Dlk and Notch 1. Recently Baladron et al., 2005 reported that despite lacking
a DSL domain, dlk does interacts with Notch 1, competing with its ligands, and
inhibiting Notch 1 activation.
Dlkl (Pref-1) was first cloned in a cDNA library screen for differentially expressed
during adipocyte differentiation using the mouse preadipocyte cell line 3T3-Ll(Smas
and Sul, 1993). A clone for the rat homolog was more recently isolated (Carlsson et
al., 1997, Haider et al., 1998). Extensive sequence similarity has been reported
between reported between rat and mouse and rat and human FA1 (Carlsson et al.,
2000). Dlk orthologues have been identified in human, rat, bovine as well as mouse
independently and so many names have been given to the same molecule; pG2
(pheochromocytoma-specific protein)(a human adrenal specific mRNA), Pref-1
(Preadipocyte factor 1) (Fahrenkurg et al., 1999, Smas and Sul, 1993), SCP-1
(stromal cell-derived protein 1) (GenBank/D16847), ZOG, (zona glomerulosa specific
mRNA)(Halder et al., 1998) as well as FA1 (foetal antigen 1), (Jensen et al., 1994).
The Dlk protein, not only has several names, but different forms of the protein have
also identified. The Dlk mRNA undergoes differential splicing which encodes for
two main species of polymorphic proteins with or without, an extracellular amino acid
target sequence which is a target for an unknown protease capable of releasing the
EGF-like region to the external medium. The alternate mRNA splicing and protease
activity are thought to modulate the ratio of expression of the two variants; the soluble
and membrane-bound forms. Several spliced mRNA variants have been reported
(Lee et al., 1995, Smas et al., 1994, Smas et al. 1997). Four major forms of the
transcript, Pref-IA-D were identified during the initial study in the mouse 3T3-L1
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cells (Smas and Sul, 1993) and more recently in the mouse colon (Dong et al., 2004).
Of the four splicing products only the -1A and -IB forms, released from the
extracellular dlk region to the medium as soluble proteins, were found to be
biologically active (Mei et al., 2002). The soluble, Pref-IA was found to be the most
abundant form. Similar to the findings in the mouse, multiple cleaved soluble proteins
(48-60 kDa) have reported in the rat adrenal gland leaving a residual cell-associated
protein (25kDa), after cleavage of the extracellular domain (Haider et al., 1998, Smas
et al., 1997). The extracellular soluble part of the dlk protein often referred to as
foetal antigen 1(FA1), was originally isolated from second trimester normal human
amniotic fluid, and is highly expressed during pregnancy in maternal and foetal
circulation in the urine and amniotic fluid (Fay et al., 1988, Jensen et al., 1994).
The Dlk/FAl protein is widely expressed in embryonic tissues, including liver,
tongue, vertebrae, skeletal mytotubes, chodroblasts and pancreas (Floridon et al.,
2000, Smas and Sul, 1993, Tornehave et al., 1989, Tornehave et al., 1996), where its
role remains unknown. However, in the adult Dlk/FAl expression is confined to zona
glomerulosa of the adrenal gland (Haider et al., 1998, Jensen et al., 1994), the
somatotrophs in the pituitary gland (Larsen et al., 1996), the monoaminergic neurons
in the central nervous system (Jensen et al., 2001), the Leydig cells, and theca interna
and hilus cells of the testes and ovaries (Jensen et al., 1999), and the (5 cells in the
endocrine pancreas (Tornehave et al., 1996). Dlkl/FAl has also been demonstrated in
endocrine and neuroendocrine tumours (Jensen et al., 1994, Tornehave et al., 1996)
and increased serum concentrations have been demonstrated in patients with small
cell lung carcinoma (Jensen et al, 1999). Therefore, the distribution in embryonic and
adult tissues suggest that Dlkl/FAlmay be involved in the development and
maintenance of endocrine tissues.
More generally, Dlk is reported as a member of the EGF-like family of proteins that
mediate protein-protein interactions through their EGF-like repeats and mediate cell
fate and differentiation decisions during development in many organisms (Artavanis-
Tsakonas, et al., 1999, Artavanis-Tsakonas, et al., 1999, Laborda et al., 2000). Dlkl
is reported to be critical in modulating extracellular signals leading to either cell
differentiation or proliferation (Baladron et al., 2002,Garces et al., 1999, Ruiz-
Hidalgo, et al., 2002). Originally identified during a differential screening designed to
Chapter 5 Delta -Like 1 homolog 90
isolate genes that regulate adipogenesis (Smas et al., 1993), Dlkl/FAl is known to
participate in several differentiation processes, including adipogenesis (Smas et al.,
1997, Garces et al., 1999, Bauer et al., 1998, Boney et al., 1996), haematopoiesis
(Bauer et al., 1998, Kaneta et al., 2000), Miyazoto et al., 2001, Moore et al., 1997,
Ohno et al., 2001), and adrenal gland and neuroendocrine cell differentiation
(Laborda et al., 1993, Haider et al., 1998, Okamoto et al., 1998, Raza et al., 1998, Van
Limpt et al., 2003). Dlkl is also reported as involved in peripheral and central nervous
system differentiation (Costaglioli et al., 2001, Jensen et al., 2001), growth arrest and
increased malignance of undifferentiated tumours (Baladron et al., 2001, Laborda et
al., 1993, Van Limpt et al., 2000) and in wound repair (Samulewicz et al., 2002). In
addition mice lacking Dlk display pre- and postnatal growth retardation and
accelerated adiposity, whereas transgenic mice expressing the complete ectodomain
of Dlk show decreased adiposity and glucose tolerance. Dlkl null mice also displayed
eyelid and skeletal abnormalities smaller kidneys and lungs plus pulmonary defects,
and a dramatic increase in perinatal mortality. This study therefore concluded that
Dlkl was important for perinatal survival, normal growth and fat deposition. In
adulthood the deletion of Dlkl led to accelerated adiposity (Moon et al., 2002).
The role of Dlk remains elusive, but it is generally reported as a likely de-
differentiation factor, maintaining cells in an undifferentiated state and/or localised to
cells that are capable of regeneration. For example, in adipogenesis, on
differentiation of preadipocytes the expression of Dlk is downregulated, and cannot
by detected in mature adipocytes (Smas et al., 1993). Also, Dlk is expressed in foetal
liver stromal cells that are able to support haematopoiesis (Moore et al., 1997).
Further, Dlk modulates proliferation of thymocytes (Kaneta et al., 2000), foetal liver
haematopoietic cells (Ohno et al., 2001) and pre-B cells in the pancreas (Bauer et al.,
1998). It is not fully understood which forms of Dlk are regulating these processes,
however, it has been reported that only the secreted Dlk variants inhibit adipocyte
differentiation but membrane-bound variants do not; in fact they appear to play a
positive effect in differentiation (Garces et al., 1999, Mei et al., 2002). The
mechanism of Dlk regulation as a differentiation factor is unknown. There is an
hypothesis that up-regulation of Dlk may lead to suppression of certain differentiated
functions that may facilitate responsiveness to mitogenic stimuli in adjacent cells
thereby maintaining a population of stem cell/progenitor cells. Such a mechanism
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was suggested for haematopoietic stem cells, in which stromal cells expressing Dlk,
were found to support self-renewal of the stem cells (Moore et al., 1997).
91
Dlk gene expression and protein levels are subject to genomic imprinting, via a
differential methylation mechanism, and regulation of this process is important for
normal development. Dlkl is a paternally expressed imprinted gene on human
chromosome 14q32. Studies on the human chromsome 14 deletions and maternal
uniparental disomy (mUPD)14 have suggested that expression of unknown imprinted
genes on chromosome 14 cause congenital disorders. Further studies on dlkl null
mice, where Dlk is located on chromosome 12, found similar effects, and therefore it
was suggested that dlk may be responsible for most of the imprinting related
phenotypes of mUPD12 and syntenic human mUPD14 (Moon et al., 2002)
The signal transduction pathway mediated by Dlkl is not well understood. It has been
hypothesized that dlkl exerts its inhibitory effect on cell differentiation through an
unidentified receptor via its EGF-like domains, either through a paracrine or
juxtacrine mechanism. The presence of the full form Dlkl molecule, or the cleaved
smaller forms, would be as the result of alternate splicing, and this would determine
its mode of action (Laborda, 2000). However, there is evidence that Dlkl participates
in cell-to-cell interactions capable of modulating the ERK/MAPK pathway and Notch
1 has been proposed as a good candidate for a dlk receptor (Baladron et al., 2005,
Ruiz-Hidalgo et al., 2002). In addition, a potential cross-talking between the Ras-
ERK/MAPK signalling pathways has already been reported (Ruiz-Hidalgo et al.,
1999, Weijzen et al.2002) and that there is a functional relationship between Dlkl and
HES-1, a transcription factor whose expression is activated by Notch 1, although this
relationship is controversial (Baladron et al., 2005, Kaneta et al., 2000, Ohno et al.,
2001). Therefore, ifDlkl is a ligand for Notchl, it could be involved in Notch
signalling in many different systems, including, but not limited to adipogenesis,
haematopoiesis, nervous system differentiation and cancer. This is only a suggestion
at present, and I chose to study the Dlkl molecule independently of its possible
relationship with Notchl.
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5.2 Results
5.2.1 Delta-Like 1 Transcript Expression in the VMP and VSU
Bioinformatic analysis of the SAGE libraries (P<0.05) (Appendix) and LightCycler
analysis (Graph 4.1) identified Dlkl expression was VMP-enriched. Additionally,
Northern blot analysis was also used to measure the relative levels of Dlkl transcript
expression in the VMP and VSU (Fig 5.2). To verify the correct RNA loading, the
Northern blot was also hybridised with FgflO (Fig 8.3), a known VMP-specific gene
(Thomson and Cunha, 1999). The radioactively labelled probes were prepared using
primers in Table 2.4. A Northern blot comprising neonatal VP, VMP and VSU RNA
determined that Dlkl transcript abundance was ~2-fold higher in the VMP, in
comparison to the VSU, and also ~1.5-fold higher in the VMP than in the VP.








Fig 5.2 Dlkl mRNA expression in the male and female rat UGS.
Analysis of Dlkl transcript levels in P0 female and male prostate organ rudiments
(n=2). The VSU is the whole female prostate rudiment, the VMP is the
microdissected mesenchymal pad, and the VP is the microdissected male ventral
prostate lobe. Transcript levels were quantified using a phosphoimager and
normalised to GAPDH. The numbers below the figure represent the average
transcript abundance of Dlkl transcript relative to the VP.
5.2.2 Dlkl transcript levels in the prostate and selected organs
Further experiments were performed to investigate the expression of Dlkl transcript
during embryonic and postnatal prostate development and also expression in selected
neonatal organs (Fig 5.3). Dlkl transcript expression was found to be most abundant
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on the day of birth (PO) (100%), upregulated from embryonic life (el7.5) (23%) and
then downregulated after PO, most dramatically between P10 (61%) and P28 (3%),
and remaining low in adult life. Also, no difference in transcript abundance was
found between the male (E17.5m) and female embryonic UGS (E17.5f) (Fig 5.3,
Panel A). In the selection of PO organs, Dlkl expression was most abundant in the
VP (100%), liver (173%), ovary (147%) and testes (117%). Dlkl levels by
comparison were very low or negligible in the other organs tested (2-11%)(Fig 5.3,
Panel B).
5.2.3 Dlkl Protein Localisation in the UGS
Localisation of Dlkl protein in the neonatal rat male and female UGS was
investigated by immunocytochemistry. Two independent antibodies (see Table 2.1)
were used to verify the staining pattern found and P3 adrenal gland was included as
the control tissue. Dlkl was localised to the medulla and zona glomerulosa of the
adrenal gland, where downregulation of Dlkl expression is thought to be an important
step in adrenal zone differentiation (Hadler et al., 1998). In addition, Dlkl protein
expression was found in the kidney (PO), a branched organ, with similarities in its
developmental processes to the prostate, and Dlkl protein was localised to the renal
tubules (data not shown). This is consistent with a report of DLK1 expression in the
developing tubules of human foetal kidneys (8-21wks)(Fukuzawa et al., 2005).
The Dlkl antibody supplied by Santa Cruz gave the lowest background staining, and
was therefore used on the sections displayed in Figures 5.4-5.7. In the male and
female PO UGS, Dlkl protein expression was found in the mesenchyme of the VMP
and VP and also in the smooth muscle (SM) layer surrounding the urethra. The
urethral epithelium was mostly negative for Dlkl, and occasional weak staining was
attributed as background. Additionally, in the female UGS, it was noted that the Dlkl
staining in the SM layer was not uniform. Staining for Dlkl was weak or absent in
the SM layer that lies adjacent to the VMP, but positive in other areas of SM. This
was interesting as the SM layer is in general considered to be homogeneous, but here
displayed differential distribution of Dlkl, to a subset cells in the SM layer.
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Fig 5.3: Dlk1 mRNA expression during prostatic ontogeny and expression in
other organs (P0).
Analysis of Dlk1 transcript levels in the prostate; E17.5 until adulthood (Panel A), and
in branching and non-branching organs collected from P0 rats (Panel B) (n=2).
Ventral prostate (VP), bladder (Bid), brain (Brn), gut (Gt), heart (Ht), kidney (Kid),
liver (Lvr), ovary (Ov), testes (Test), lung (Lg). The transcript levels were quantified
using a phosphoimager and normalised to GAPDH. The numbers below the figure
represents the average Dlk1 transcript abundance relative to the P0 VP.
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To study this interesting pattern of Dlkl further, fluorescent immunocytochemistry
was used to co-localise Dlkl and smooth muscle a-actin, a marker of smooth muscle
cells in the male and female neonatal UGS. In the female UGS, Dlkl expression was
confirmed in the SM layer, except in the area adjacent to the VMP, where only
staining for SM a-actin was observed (Fig 5.5). Additionally, the Dlkl staining
where present in the SM layer, was most strongly expressed towards its outer edge.
The SM cells most adjacent to the UGM had low or absent Dlkl expression. Some
SM cells appeared to co-express Dlkl and SM a -actin, while some cells expressed
the proteins individually. In the male PO UGS, Dlkl protein expression was localised
to the mesenchymal cells of the VP and the smooth muscle layer (Fig 5.6). Similar to
staining in the SM layer of the female UGS, Dlkl expression was most evident in
cells towards the outside of the SM layer. A narrow band of the SM layer that lies
most adjacent to the UGM was absent of Dlkl staining.
Finally, in the sections of PO male UGS stained by fluorescent immunocytochemistry,
it was noted that strong staining for Dlkl protein was observed in the epithelial duct
cells of the VP. This was considered background staining due to the high
concentration of Dlkl antibody used, and no similar staining had been observed
previously in the male UGS by general immunocytochemistry (Fig 5.4).
5.2.4 The effect of testosterone on Dlkl distribution
Androgens may directly or indirectly induce the release of regulatory factors from the
mesenchyme during development. Consequently, it was investigated whether the
distribution ofDlkl, as a mesenchyme- expressed factor, in the VP, would be affected
by exposure to Testosterone. VP organ rudiments were cultured in the presence (+T)
or absence of testosterone (-T), and stained for Dlkl protein (Fig5.7). The VPs
cultured with testosterone were found to grow larger in size and show more epithelial
bud branching than VPs grown without. Dlkl protein was found similarly expressed
in the mesenchymal cells of the VPs under both culture conditions, and therefore
Dlkl distribution was not affected by testosterone treatment in vitro. Preliminary
studies were also performed to investigate changes in the Dlkl transcript levels in
treated and untreated organs by Northern blot analysis (data not shown, personal
communication, Dr. G. Vanpoucke), but no differences were found.
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Fig 5.4: Dlk 1 expression in Neonatal Female and Male Rat UGS
Immunohistochemistical localisation of the Dlk1 protein, in PO female (Panel A and B)
and male (Panels C-E) rat UGT. Ventral mesenchymal pad (VMP), smooth muscle
(SM), urethral epithelium (URE), mesenchyme (M), Epithelium (E). P3 Adrenal gland
(Panel F) is the positive control tissue. Zona glomerulosa (ZG), Medulla (Md). In
panel A arrows point to areas of high Dlk1 expression and * marks an area of
smooth muscle that has very low or absent Dlk1 expression. Preabsorbed primary
antibody were added to Panels B, E and F (insert). The scale bar in panel A
represents 200pm in B. C, E, and F, and 100 pm in panel D.












M * ♦ i





Fig 5.5 Dlk1 and smooth muscle alpha actin expression in the female UGS.
Immunohistochemistical co-localisation of Dlk1 and SM a-actin in PO female rat UGS
(Panels A-D) (n=3). Dlk1 is shown in red, SM a-actin in green, and nuclear staining in
blue. Co- expression of Dlk1 and SM a-actin is shown in yellow. The plane of tissue
section in Panel A does not include urogenital epithelium. Ventral mesenchymal pad
(VMP), smooth muscle (SM), urogenital mesenchyme (URM). Panel B is a higher
power magnification of the SM region marked * in Panel A, and Panel C is a higher
power magnification of the SM layer adjacent to the VMP. In Panel B, note that Dlk1
staining in the SM layer is not uniform, and is strongest towards the outer edge of the
tract. Panel C shows Dlk1 staining is absent in the SM layer adjacent to the VMP.
Primary antibodies were not added to Panel D. The scale bar in Panel A represents
100pm. The scale bar in panel B represents 50pm in panels C and D.
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Fig 5.6 Dlk1 and smooth muscle alpha actin expression in the male UGS.
Immunohistochemistical co-localisation of dlk1 and SM a-actin protein in PO male rat
UGS, including the VP lobe (Panels A-D) (n=3). dlk1 is shown in red, SM a-actin in
green, and nuclear staining in blue. Co- expression of Dlk1 and SM a-actin is shown
in yellow, mesenchyme (M), epithelium (E), smooth muscle (SM), urogenital
mesenchyme (UGM)). In panel A, * marks an area of the smooth muscle layer that
lacks Dlk1 staining. Also, note that strong Dlk1 staining in the epithelial cells of the
ducts is background, due to the high antibody concentration used. Primary antibodies
were not added to Panel D. The scale bar in Panel A represents 100pm and 50pm in
panel C. The scale bar in Panel B represents 100pm in Panels B and D.
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Fig 5.7 The effect of testosterone on Dlk 1 expression.
Immunohistochemical localisation Dlk-1 protein in PO VP lobes cultured for 6 days in
the in the presence (+T) (Panels C, D and F) or absence of testosterone (-T)(10"
8M)(Panels A, B and E). Preabsorbed primary antibody was added to Panels E and
F. Epithelium (E), mesenchyme (M) and urethral ends of ducts (U). The scale bars in
Panel A represent 200pm in Panels C. and in Panel B the scale bar represents
100pm in Panel D-F.
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5.2.5 Functional Studies on Dlk1
Dlkl transcript and protein expression in the mesenchyme of the male and female
UGS (P0) has been confirmed, in this thesis. Next, a possible functional role for Dlkl
as a mesenchymal regulator of prostate organogenesis was investigated.
VPs were cultured in the presence (+T) or absence of testosterone (-T) (10 8M), plus
recombinant human DLK1 protein 0.1-2.5pg/ml (Table 2.2). DLK1 treatment was
found to increase the size of VP organs and amount of epithelial budding and
branching observed, in a concentration-dependent manner (-T plus 0.1-0.75 pg/ml
DLK1) (Fig 5.8). No increase in the effect was observed when organs were treated
with the highest concentration of DLK1 (-T plus 2.5 pg/ml DLK1) (data not shown).
The greatest increase in VP growth and epithelial branching observed was induced by
+T treatment only. No incremental effect was observed when organs were treated +T
plus 0.1-0.75 pg/ml DLK1 (data not shown). Unfortunately, due to insufficient time,
it was not possible to make measurements of the effect of DLK1 treatment on VP
growth, and so the conclusions are based on observed changes in gross morphology of
the VPs and the evident increase in number of duct tips after DLK1 treatment,
indicating stimulation of branching morphogenesis.
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Fig 5.8: The effect of Dlk1 on VP growth.
VP's from P0 rats were grown for six days in the presence (+T) or absence of
testosterone (-T)(10"8M) and /or recombinant human DLK1 (0.1,0.25, and 0.75
pg/ml). The scale bar represents 500pm
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5.2.6 Summary of Results
Dlkl was identified as a VMP- enriched transcript by LongSAGE, LightCycler and
Northern blot analysis. During development and growth of the prostate Dlkl
transcript expression, was most abundant in the P0 VP and during the perinatal
period, when epithelial growth and branching occurs. In other selected neonatal
organs, Dlkl expression was most abundant in the liver, ovary, testes and VP. The
Dlkl protein was localised to the mesenchyme of the VMP and VP and also the
smooth muscle layer surrounding the UGS. Notably, Dlkl expression was not
uniform in the SM layer, and was most strongly expressed towards the outside of the
layer. Also, in the female UGS, Dlkl expression was low or absent in an area of SM
adjacent to the VMP. The SM layer was previously thought to be homogenous, but
here it exhibits differential protein distribution. Additionally, Dlkl was localised to
the mesenchyme of VP organs cultured in vitro in the presence or absence of
Testosterone, and the protein distribution was not affected by treatment with
Testosterone. Finally, VP organ cultures treated with recombinant DLK1 were found
to show an increase in overall size and epithelial branching. No additional effect was
found when Testosterone was also added.
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6. Notch 2
6.1 Introduction
Notch2 is a member of the evolutionary conserved Notch family of genes that help to
determine cell fate during development. Notch was originally reported in Drosophila,
which has only one copy of the Notch gene, while mammals possess at least four
such genes, Notchl, Notch2, Notch3, and Notch4 (Lardelli et al., 1994, Reaume et
al., 1992, Robbins et al., 1992, Weinmaster et al., 1992). Genes of the Notch family
encode large cell-surface receptors with several conserved domains, which interact
with membrane bound ligands encoded by the Delta, Serrate and Jagged family
genes. Six proteins have been recognized as Notch ligands in vertebrates (Deltal,
Delta2, Delta 3, Delta4, Jagged 1 and Jagged2), to date (Gray et al., 1999, Joutel and
Tournier-Lasserve, 1998, Lindsell et al., 1995, Shutter, et al., 2000, Valsecchi et al.,
1997). Proteins of the Notch family share several repeated peptide motifs, including
extracellular tandemly repeated copies of an epidermal growth factor (EGF-)-like
motif, involved in ligand binding, repeats of the Lin-12/Notch motif (LNR) with
unknown function in the extracellular domain and CDClO/ankyrin-like repeats in the
cytoplasmic domain (Hamada et al., 1999).
36 EGF-like repeats TM
N
LNR cdclO PEST
Fig 6.1: Schematic diagram of the Notch2 protein.
Epidermal growth factor (EGF-) like repeats (36), Lin-12/Notch repeats (LNR) (3),
transmembrane domain (TM), cdc10/ankyrin repeats (cdclO) (6), a region rich in
proline-glutamate-serine-threonine (PEST) (Hamada et al., 1999).
In vertebrates, Notch2 was originally cloned in the rat brain (Weinmaster et al.,
1992) and since then expression of Notch2 transcript and/ or protein has been
reported in diverse tissues particularly during development with more restricted
expression during adult life, and has also been associated with tumorigenesis.
Chapter 6 Notch2 104
Notch2 expression has been reported in the developing brain (Tanaka and
Marunouchi, 2003), eye and heart (McCright et al., 2001), liver (Tanimizu and
Miyajima, 2004) lung (Ito et al., 2000), kidney (Leimeister et al., 2003, McCright et
al., 2001), pancreas (Lammert et al., 2000, Norgaard et al., 2003), small intestine
(Schroder and Gossler, 2002) and tooth (Mitsiadis et al., 2003). Kitamoto et al.,
(2005) has reported a comprehensive study of Notchl, Notch2 and Notch3 transcript
expression in the foetal mouse. Reports of Notch expression in the developing
prostate have so far been confined to Notchl, which is expressed in the basal
epithelial cells of prostatic ducts (Wang et al., 2004). Whereas Notch2 expression
has been reported elsewhere in the male reproductive tract, in the developing rat
Wolffian duct (Bowman et al., 2005) and epididymis (Turner et al., 2003). In the
adult, Notchl expression is reported in developing follicles of the ovary (Johnson et
al., 2001), in the brain (Tanaka and Marunouchi 2003) and in adult wounded teeth
(Mitsiadis et al., 2003). Notchl is also reported to be involved in embryonal brain
tumour growth (Fan et al., 2004) and breast (Parr et al., 2004) and lung cancer
(Garnis et al., 2005)
As already mentioned, the only member of the Notch family studied in the prostate,
so far has been Notchl. Notchl expression was reported to be essential for prostatic
branching morphogensis, and also for re-growth of the prostate following castration
and androgen replacement. Notchl expression in the basal epithelial cells may
define the progenitor cells in the epithelial cell lineage, which are essential and
indispensable for prostate development and re-growth (Wang et al., 2004).
Additionally, Notchl was found upregulated in malignant prostatic epithelial cells of
TRAMP mice (transgenic adenocarcinoma of the mouse prostate) (Shou et al., 2001),
and dysregulation of Jagged 1, a Notch ligand has been associated with prostate
cancer progression and metastasis (Satagata et al., 2004). Therefore the Notch
signalling pathway is well -represented during normal and neoplastic prostate
growth
Notch2, on the other hand, has been reported in the developing epididymis (Turner et
al., 2003) and Wolffian duct (Bowman et al., 2005), where it is suggested to be
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involved in the mesenchymal-epithelial interactions that regulate development.
These studies also reported that Notch2 transcript expression levels in these tissues
were altered by anti-androgen treatment in utero, and that in the case of the
epididymis at least, this was not due to changes in the mesenchyme/epithelial cell
ratio. Therefore, Notch.2 may represent an androgen-regulated molecule.
In general, Notch genes have been reported as essential for embryonic development
and adult homeostasis. During development Notch signalling is thought to be
involved in regulation of tissue patterning and morphogenesis via direct cell-cell
interactions. Expression of mammalian Notch genes were reported to show
complementary and combinatorial patterns during development, suggesting distinct
functions for different members of the Notch family, with the possibility of some
functional redundancy (Kitamoto et al., 2005). For example, Notchl and -2 have
been reported as differentially regulated by modulated interaction with their ligands,
caused by signalling factors upstream in the Notch pathway. Therefore, the
differential expression pattern of Notch receptors in the embryo, combined with
- differential modulation of their ligands may act in concert to control tissue patterning
and morphogenesis during development (Hicks et al., 2000). Additionally, Notch
expression has been found throughout development in uncommitted proliferative
cells (Artavanis-Tsakonas et al., 1995, Lardelli et al, 1995, Reaume et al., 1992,
Williams et al., 1995), and later in development and in adult life, expression of Notch
continues in the proliferative layer of mature tissues (Kopan and Weintraub, 1993,
Milner et al., 1994, Zagouras et al., 1995). Therefore, these patterns of expression
might suggest that Notch proteins function in maintenance of the proliferative
capacity of immature cells.
Analysis of both inherited human diseases and mutant mice has shown that mutations
in Notch receptors result in developmental abnormalities and neoplasias (Gridley,
1997, Joutel and Tournier-Lasserve, 1998). Notch malfunction can disrupt aspects of
neurogenesis, somite formation, angiogenesis and kidney and lymphoid development
(Anderson et al., 2001, Conlon et al., 1995, de la Pompa et al., 1997, Lawson et al.,
2001, McCright et al., 2001). For example, studies of the Notch2 null mouse found
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that Notch.2 expression is necessary for perinatal mortality because of its role in the
developing kidney (Hamada et al., 1999, McCright et al., 2001). Also, in humans,
constitutively active aberrant forms of Notch have been associated with leukaemia
and solid tumours of the cervix, colon and pancreas (Allenspach et al., 2001,
Capobianco et al., 1997, Ellisen et al., 1991, Gray et al., 1999, Nickoloff et al., 2003,
Radtke and Raj, 2003, Zagouras et al., 1995). However, the role of Notch in cancer
is further complicated by reports that Notch 1 and 2 have opposing roles in
tumorigenesis, and this might parallel their functions in normal development (Fan et
al., 2004). In breast cancer for example Notch2 has been proposed to have a tumour-
suppressive role, whereas Notch 1 possesses tumour-promoting functions (Parr et al.,
2004).
Notch signalling is an evolutionary conserved mechanism that is known to be
involved in a variety of cellular processes, including the maintenance of stem cells,
specification of cell fate, differentiation, proliferation and apoptosis at all stages of
development, thus controlling organ formation and organogenesis (Artavanis-
Tsakonas et al., 1999, Frisen and Lendahl, 2001). As both Notch and its ligands are
transmembrane proteins, signalling only occurs between closely apposed cells.
Activation of Notch by ligand binding triggers cleavage of the receptor, releasing the
intracellular domain, which then translocates to the nucleus (Struhl and Adachi,
1998). In the nucleus, Notch forms transcriptional complexes with transcription
factors of the CSL family in mammals (Greenwald, 1998), and transactivates genes
targets such as those in the Hes and Hey families (Iso et al., 2003).
Additionally, in a study of Notch activity during development, it was proposed that
communication between the fibroblast growth factor receptor (FGFR) pathway and
Notch pathway might represent an important reciprocal autoregulatory mechanism
for the regulation of normal cell growth (Norgaard et al, 2003, Small et al., 2003). A
possible Notch/Fgf pathway interaction is interesting with relevance to the
developing prostate, as members of the FGF family are known to be important
regulatory factors in prostate growth and development (Thomson, 2001).
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In conclusion, the importance of the Notch pathway in development and cancer, and
in particular the proposed role of Notch 1 in the prostate made Notch2 an excellent
candidate gene to study in more detail during prostate development.
6.2 Results
6.2.1 Notch2Transcript Expression in the VSU and VMP
Bioinformatic analysis of the SAGE libraries (Appendix) and LightCycler analysis
(Graph 4.1) identified Notch2 expression was VMP-enriched. Additionally,
Northern blot analysis was used to measure the relative levels of Notch2 transcript
expression in the VMP and VSU (Fig 6.2). To verify the correct RNA loading, the
Northern blot was also hybridised with FgflO (Fig 8.3), a known VMP-specific gene
(Thomson and Cunha, 1999). The radioactively labelled probes were prepared using
primers in Table 2.4. A Northern blot comprising neonatal VP, VMP and VSU RNA
demonstrated that Notch2 transcript abundance was ~2-fold higher in the VMP, in
comparison to the VSU, and expression levels were similar in the VP. Therefore,
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Fig 6.2: Notch2 mRNA expression in the male and female UGS
Analysis of A/ofc/?,2 transcript levels in P0 male and female rat UGS (n=2). The VSU
is the whole female rudiment, the VMP is the microdissected mesenchymal pad, and
the VP is the microdissected male ventral prostate lobe. Transcript levels were
quantified using a phosphoimager and normalised to GAPDH. The numbers below
the figure represent the average Notch 2 transcript abundance relative to the VP.
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6.2.2 Notch2 transcript levels in the prostate and selected organs.
Further Northern blot analysis experiments were performed to study Notch2
transcript expression during embryonic and postnatal prostate development, and in
other selected neonatal organs (Fig 6.3). Notch2 transcript expression was found to
be most abundant in the prostate on the day of birth (P0) (100%), upregulated from
embryonic life (el7.5)(54%), and then downregulated towards adulthood, most
dramatically between P4 (81%) and P10 (39%)(Fig 6.3 Panel A). Also, it was noted
that Notch.2 expression in embryonic life was upregulated immediately prior to Dlkl
expression (Fig 5.3). Dlkl has been proposed as a possible Notch ligand (Baladron
et al., 2005). No difference in transcript abundance was found between the male
(E17.5m) and female embryonic UGS (E17.5f). However, it should be noted that
with the increasing age of VP organs, the increasing proportion of epithelial duct
tissue would act to dilute the expression of the Notch2 transcript in the mesenchyme,
and so the measurement of Notch2 represents a decreasing trend of mRNA
expression rather than definitive values.
In the other neonatal organs (Fig 6.3, Panel B), Notch2 was found expressed highly
selectively, and was most abundant only in the VP (100%) and brain (152%), with
much lower levels measured in the remaining tissues (1-5%).
6.2.3 Notch 2 Protein Localisation in the UGS.
Localisation of Notch2 protein in the neonatal rat male and female UGS was
investigated by immunocytochemistry (Fig 6.4). The antibody used, also localised
Notch2 to the granulosa cells of P21 ovary (control tissue) (Fig 6.4, Panel D), as
previously reported by Johnson et al., (2001). The Notch signalling pathway has
been implicated in regulation of mammalian folliculogenesis. In the UGS, Notch2
protein was localised to the mesenchymal cells of the VMP and VP and also the SM
layer (Fig 6.4). However, notably Notch2 expression was not uniform throughout the
SM layer. A thin ribbon of brown staining representing Notch 2 expression was
observed only in SM cells most proximal to the peri -urethral mesenchyme (Fig 6.4,
Panels A, C and D). This differential protein expression in the SM layer suggests it
is not a homogeneous tissue, as previously thought.
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Fig 6.3 Notch2 mRNA expression during prostatic ontogeny and expression in
other selected organs (P0).
Analysis of Notch2 transcript levels in the prostate; E17.5 until adulthood (Panel A),
and in branching and non-branching organs collected from P0 rats (Panel B) (n=2).
Ventral prostate (VP), bladder (Bid), brain (Brn), gut (Gt), heart (Ht), kidney (Kid),
liver (Lvr), ovary (Ov), testes (Test), lung (Lg). The transcript levels were quantified
using a phosphoimager and normalised to GAPDH. The numbers below the figure
represents the average transcript abundance of Notch2 transcript relative to the P0
VP.
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Furthermore, it was noted that the Notch2 expression in the SM layer was the
converse of Dlkl expression previously reported in this thesis (Fig 5.5; Panels A and
B and Fig5.6; Panel A). Comparison of Dlkl and Notch2 expression in the male
UGS found expression of both proteins in the mesenchyme of the VP, but expression
in the SM layer only in adjacent cells. Dlkl was found in cells at the outer edge of
the SM layer, while Notch2 as localised to cells most proximal to the peri -urethral
mesenchyme. As Dlkl has been reported as a possible Notch ligand (Baladron et al.,
2005), this distinctive protein expression pattern may provide supportive evidence of
a Notch2 -Dlkl ligand relationship. Unfortunately, due to insufficient time, co -
localisation of Dlkl, Notch2 and SM a-actin was not performed to confirm this
expression pattern.
6.2.4 The effect of Testosterone on Notch2 distribution.
Androgens may directly or indirectly induce the release of regulatory factors from
the mesenchyme during development. Consequently, it was investigated whether the
distribution of Notch2, as a mesenchyme- expressed factor, in the VP, would be
affected by exposure to Testosterone. VP organ rudiments were cultured in the
presence (+T) or absence of testosterone (-T), and the distribution of Notch2 was
localised by Immunocytochemistry (Fig 6.5). The VPs cultured with testosterone
were found to grow larger in size and show more epithelial bud branching than VPs
grown without. Notch2 protein expression was localised to the mesenchymal cells of
the VPs under both culture conditions, with no discernable differences, and was
therefore apparently unaffected by testosterone treatment.
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Fig 6.4 Notch 2 expression in Male and Female UGS and the Ovary
Immunolocalisation of Notch2 protein in the PO female (Panel A and B), male UGS
(Panels C -E), and P21 Ovary (Panel F) (n=4). Ventral mesenchymal pad (VMP),
smooth muscle (SM), urethral epithelium (URE), urogenital mesenchyme,(UGM),
epithelium (E), mesenchyme (M), follicle (F), granulosa cells (G). Arrows in Panels A
point to areas of high Notch2 expression. Arrows in Panels C and D, point in
particular to areas of Notch2 expression in a subset of cells in the SM layer,
adjacent to the peri -urethral mesenchyme. Preabsorbed primary antibody was
added to Panels B, E and F inset. The scale bar in Panel A represents 200pm in
Panels B, C and E, and 100pm in Panels D and F.
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Fig 6.5 The effect of testosterone on Notch2 expression.
Immunohistochemical localisation Notch2 protein in PO VP lobes cultured for 6 days
in the presence (Panels C, D and F) or absence (Panels A,B and E) of testosterone
(10"8M). Preabsorbed primary antibody was added to Panels E and F. Epithelium
(E), mesenchyme (M) and end of VP organ proximal to urethra (U). The scale bars
in Panel A represent 200pm in Panels C. and in Panel B the scale bar represents
100pm in Panel D-F.
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6.2.5 Summary of Notch2 Results
Notch2 was identified as a VMP- enriched transcript by LongSAGE, LightCycler
and Northern blot analysis. During development and growth of the prostate, Notch2
transcript expression, was most abundant during late embryogenesis and the perinatal
period, when bud induction, epithelial growth and branching occurs. In other selected
neonatal organs, Notch.2 expression was most abundant in the VP and brain. In the
PO UGS, Notch2 protein was localised to the mesenchyme of the VMP and VP and
the smooth muscle layer. Notch2 expression was not uniform in the SM layer, and
was most strongly expressed in a narrow ribbon of cells lying adjacent to the peri -
urethral mesenchyme. Comparison of Notch2 and Dlkl expression in the UGS,
supported a possible Notch2 -Dlkl ligand relationship, but this requires further
studies. Additionally, Notch2 was localised to mesenchyme of VP organ cultures,
and the protein distribution was unaltered by treatment with Testosterone. Finally,
due to insufficient time, this thesis lacks functional data on the activity of Notch2 in
the developing prostate, and this will be the subject of further studies.
Chapter 7 Pleiotrophin 114
7. Pleiotrophin
7.1 Introduction
Pleiotrophin (Ptn) belongs to a novel two-member family of heparin binding
molecules, with the structurally related (50%) protein midkine (Mk), also called
retinoic acid-induced heparin-binding factor (Kadomatsu et al., 1997). Besides amino
acid homology, Ptn and Mk also use the same receptors and share many biological
activities. Pleitotrophin (Li et al., 1990) is an 18kDa protein that has been
independently identified by different approaches leading to several names including
heparin affin regulatory peptide (HARP) (Courty et al., 1991) and heparin-binding
growth-associated molecule (HB-GAM)(Rauvala, 1989). The amino acid sequence
of pleiotrophin is highly conserved among human, rat, mouse and bovine species,
with 98% similarity (Li et al., 1990, Tezuka et al., 1990). Also, as its alternative
names suggest, Ptn protein interacts with heparin sulphate proteoglycans (HSPGs) at
the extracellular matrix (Vacherot et al., 1999b). Therefore, Ptn expression is most
often localised to the basement membrane at the surface of differentiating cells
(Mitsiadis et al., 1995).
The Ptn protein contains 24% of basic residues (18% of lysines), mainly arranged in
two clusters at the N- and C- terminal regions, and five intrachain disulfide bonds
(Kilpelainen et al., 2000). The molecule is organised in two |3-sheet domains linked
by a flexible linker, and each of these two domains includes one heparin -binding
site (as reviewed in Papdimitriou et al., 2004).
Pleiotrophin was first isolated from neonatal rat brain as a molecule that induced
neurite outgrowth of embryonic neurons (Rauvala, 1989), but further studies have
found that it is present in a variety of non-neuronal tissues including bone (Imai et
al., 1998), cartilage (Dreyfus et al., 1998), heart, (Chen et al., 2004), liver (Asahina et
al., 2002) limb bud (Szabat and Rauvala, 1996), uterus (Milhiet et al., 1998) and
testes (Zhang et al., 1999). In general however, the most frequent reports of Ptn
expression are in tissues derived from mesoderm (Li et al., 1992) and in organs in
which mesenchymal-epithelial interactions are thought to play an important role,
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such as the salivary gland, lung, pancreas, kidney and mammary gland (LeDoux et
al., 1997, Mitsiadis et al., 1995, Vanderwinden et al., 1992).
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Ptn expression has been reported as a highly regulated temporal and cell-type
specific process. Ptn expression is usually only present in tissues during late
embryogenesis and perinatal growth, and expression usually fades around the time of
birth (Li et al., 1990, Rauvala, 1989 Rauvala et al., 1994). In the adult, Ptn is
expressed only at minimal levels in a very few tissues. The highest levels of Ptn
expression reported in the adult are in the brain (Vanderwinden et al., 1992), but Ptn
has also been found in the adult pancreas (Klomp et al., 2002), uterus (Milhiet et al.,
1998), testes (Zhang et al., 1999) and mammary gland (Bernard-Pierrot et al., 2004).
Additionally, Ptn expression has been associated with prostate (Vacherot et al.,
1999), ovarian (Nakanishi et al., 1997), testicular (Aigner et al., 2003), pancreatic
(Klomp et al., 2002) and breast cancer (Zhang et al., 1997), solid gliomas (Mentlein
and Held-Feindt, 2002), neuroblastomas (Nakagawara, et al., 1995), melanomas
(Souttou et al., 1998), and in several malignant cell lines of different origin (as
reviewed in Papadimitriou et al., 2004).
Ptn and the closely related Mk have both been implicated as important proteins
during development. Furthermore, Ptn and Mk share a similar pattern of expression
during a period of foetal development. However, Mk expression peaks around mid-
gestation, whereas Ptn expression peaks around the day of birth. In the mouse
urogenital tract, for example, Ptn and Mk was localised to the surface of the
epithelial cells and mesenchyme of the genital tubercle during early embryonic
development, but only Ptn expression persisted at 16.5 dpc (Mitsiadis et al., 1995).
It has been proposed therefore, that development involving these factors may be
regulated by the difference in their temporal expression (Mitsiadis et al., 1995).
Additionally, it has been reported that Pm-deficient mice (Arnet et al., 2000) and
Mk-deficient mice (Nakamura et al., 1998)) have no gross anatomical abnormalities.
This does not necessarily indicate that Ptn or Mk is not required for normal
development. Instead it has been proposed, that because they are closely related and
found co-expressed during development, it is likely that Ptn might compensate for
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Mk and vice versa, when there is an overlap in temporal expression (Mitsiadis et al.,
1995).
Pleiotrophin is generally described as a secreted growth factor that plays a key role in
cellular growth and differentiation. Ptn has also been demonstrated as involved in
angiogenesis and tumour growth (as reviewed in Papadimitriou et al., 2004). The
angiogenic properties of Ptn have been associated with inflammatory diseases such
as endometriosis (Chug et al., 2002), rheumatoid (Pufe et al., 2003) oestoarthritis
(Pufe et al., 1993) and renal fibrosis (Henger et al., 2004), and in tumour growth and
progression, Ptn may act to recruit stromal tissue and blood to expanding tumours
(Czubayko, et al., 1996, Choudhuri et al., 1997, Jager et al., 1997, Sugino et al.,
2002). Ptn has also been linked to cancer because of its activity in vitro, stimulating
the proliferation of a wide range of cells including epithelial, endothelial and
fibroblastic cells (Fang et al, 1992), and preventing apoptosis. The highly restricted
expression of Ptn protein in the adult, unlike the many other growth factors
implicated in cancer, make it a possible target for tumour therapy. Additionally,
elevated serum levels of Ptn have been measured in patients with pancreatic (Klomp
et al., 2002) or testicular cancer (Aigner et al., 2003), and so monitoring Ptn serum
levels has been suggested as possible diagnostic marker of these diseases
(Papadimitriou et al., 2004).
The most compelling evidence for the mechanism of Ptn activity has been provided
by the expression pattern of Ptn mRNA and its protein. Ptn mRNA is mainly found
in the neuroectoderm and mesoderm of the rat and mouse foetus, whereas its protein
is found in endoderm and nerve tissues (Vanderwinden et al., 1992, Mitsiadis et al.,
1995). Therefore, this suggests that Ptn act as a mesenchymal factor on epithelial
tissues during development. With relevance to branching organs like the prostate,
Ptn mRNA and protein expression patterns have implicated Ptn in regulating
development of the kidney (Sakurai et al., 2001) and mammary gland (Bernard-
Pierrot, et al., 2004, LeDoux et al., 1997).
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In the mammary gland, for example, Ptn mRNA and protein were found expressed in
adjacent myoepithelial and glandular epithelial cells, during development, pregnancy
and lactation. This expression pattern was reported to suggest that Ptn is acting in a
paracrine and autocrine growth factor in the regulation of mammary gland
development and its homeostatic regulation during pregnancy and lactation
(Bernard-Pierrot, et al., 2004, LeDoux et al., 1997).
Additionally, Ptn mRNA is expressed in the metanephric mesenchyme at the onset
of kidney development (Vanderwinden et al., 1992), and has been reported as
regulating branching morphogenesis of the uteric bud. Ptn protein isolated from the
conditioned medium of metanephric mesenchyme cells was found to induce
morphogenetic changes in the uteric bud in a concentration-dependent manner. Ptn
was proposed to be acting like a classic "morphogen", inducing phenotypic changes
in tissues according to its concentration (Sakurai et al., 2001).
Studies of Ptn in branched organs have not included reports of Ptn expression during
prostate organogenesis, however Ptn activity has been associated with prostate
cancer. Vacherot et al., (1999) reported Ptn mRNA was expressed in the stromal
cells of normal adult prostate, prostate cancer and benign prostatic hyperplasia
(BPH). The Ptn protein was similarly expressed in the stromal cells, but in addition,
Ptn protein was also found in the epithelial cells of prostate cancer tissue, but not in
the normal prostate or BPH tissues. They suggested that Ptn was therefore, acting in
a paracrine manner from mesenchymal to epithelial cells, involved in tumour growth
(Vacherot et al., 1999).
Finally, although there is considerable evidence for the paracrine manner of Ptn
activity, the signal transduction pathways used by Ptn are not clearly established. The
biological actions of Ptn are reported to be mediated by three different receptors;
syndecan-3 (N-syndecan)(Raulo et al., 1994, Kinnunen et al, 1998), receptor protein
tyrosine phosphatase, RPTBt; (Maeda et al., 1996) and anaplastic lymphoma kinase
(ALK) (Stoica et al., 2001). Interaction of Ptn with syndecan-1 has also been
proposed (Mitsiadis et al., 1995). Studies of Ptn signalling however have so far only
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been able to conclude that a signal transduction pathway induced by Ptn includes
phosphatidylinositol 3-kinase (PI3K) and mitogen activated protein kinase (MAPK),
with MAPK downstream of PI3K (Qi et al., 2001, Stoica et al., 2001, Souttou, et al.,
1997, Souttou et al., 2001).
7.2 Results
7.2.1 Ptn Transcript Expression in the VSU and VMP
Bioinformatic analysis of the LongSAGE libraries did not identify Ptn transcript
expression as VMP-enriched (P<0.05), but did show a trend toward VMP-enriched
expression (Graph 4.1). Ptn was selected for LightCycler analysis after mining the
published research literature on Ptn activity. Ptn has been proposed to have a role in
growth and development of other branching organs, like the kidney (Sakurai et al.,
2001) and mammary gland (Bernard-Pierrot, et al., 2004, LeDoux et al., 1997), and
Ptn expression has also been associated with prostate cancer (Vacherot et al., 1999).
Subsequent LightCycler analysis identified Ptn as VMP-enriched by (Graph 4.1).
Additionally, Northern blot analysis was used to compare the relative levels of Ptn
transcript expression in the VMP and VSU (Fig 7.1). To verify correct RNA loading,
the Northern blot was also hybridised with FgflO (Fig 8.3), a known VMP-specific
gene (Thomson and Cunha, 1999). The radioactively labelled probes were prepared
using primers in Table 2.4. A Northern blot comprising neonatal VP, VMP and VSU
RNA demonstrated that Ptn transcript levels were ~ 2.6-fold higher in the VMP, in
comparison to the VSU, and ~1.5 fold higher than in the VP. Therefore, two
independent techniques identified Ptn as a VMP-enriched transcript.
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Fig 7.1 Ptn mRNA expression in the male and female UGS
Analysis of Ptn transcript levels in PO male and female rat UGS (n=2). The VSU is
the whole female prostate rudiment, the VMP is the microdissected mesenchymal
pad, and the VP is the microdissected male ventral prostate lobe. Transcript levels
were quantified using a phosphoimager and normalised to GAPDH. The numbers
below the figure represent the average transcript abundance of Ptn transcript
relative to the VP
7.2.2 Ptn transcript levels in the prostate and selected organs.
Further experiments were performed by Northern blot analysis, to study Ptn
transcript expression during embryonic and postnatal prostate development and also
expression in selected tissues (PO) (Fig 7.2). Ptn transcript expression was most
abundant in the prostate on the day of birth (P0)(100%), upregulated from embryonic
life (E17.5) (59%), and downregulated after PO, most dramatically between P10
(49%)and P28 (8%), and of low abundance in adult life (3%)(Fig 7.2, Panel A).
Also, no difference in transcript abundance was found between the male (E17.5m)
and female embryonic UGS (E17.5f).
In the selected neonatal organs Ptn expression was most abundant was in the VP
(100%) and ovary (94%). Similar Ptn expression levels were found in the brain
(50%), liver (36%) and testes (39%), and low levels of Ptn expression were
measured in the remaining tissues (3-22%) (Fig7.2, Panel B).
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Fig 7.2: Ptn mRNA expression during prostatic ontogeny and expression in
other organs (P0).
Analysis of Ptn transcript levels in the prostate; E17.5 until adulthood (Panel A), and
in branching and non-branching organs collected from P0 rats (Panel B) (n=2).
Ventral prostate (VP), bladder (Bid), brain (Brn), gut (Gt), heart (Ht), kidney (Kid),
liver (Lvr), ovary (Ov), testes (Test), lung (Lg). The transcript levels were quantified
using a phosphoimager and normalised to GAPDH. The numbers below the figure
represents the average transcript abundance of ptn transcript relative to the P0 VP.
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7.2.3 Pleiotrophin Protein Localisation in the UGS
Localisation of Ptn protein expression was investigated in the male and female
neonatal rat UGS by immunocytochemistry. Two antibodies against Ptn (Table 2.1)
were used to localise Ptn and generated the same results (data not shown), therefore
there was confidence in the staining pattern. Ptn protein expression was also
immunolocalised in the neonatal kidney, (data not shown), where expression was
most evident in the renal tubules. This result is consistent with previous reports of
Ptn in the early kidney and a role for Ptn in renal branching morphogenesis (Sakurai
et al., 2001,Vanderwinden et al., 1992). The Ptn antibody supplied by RnD Systems
was used on the sections displayed in Figures 7.3-7.6.
In the neonatal female UGS, Ptn was localised to the VMP and UGM, and weak
staining for Ptn was also present in the smooth muscle layer (Fig 7.3, Panel A). In
the neonatal male UGS (Fig 7.3, Panels C and D), Ptn was expressed in the
mesenchymal cells of the VP, plus there was strong staining for Ptn associated with
the epithelial cells of the VP, and weak Ptn staining present at the basement
membrane of the URE, and in the SM layer. Furthermore, the Ptn associated with
the epithelial cells in the VP displayed a gradient of expression, with the strongest
staining at the tips of the ducts, and decreasing towards the urethra. At this stage, it
was unclear if the Ptn protein was expressed within the cytoplasm or at the surface of
the epithelial cells. It was speculated that the Ptn expressed by the mesenchyme,
might diffuse into the epithelial cells, to give this staining pattern. This was
investigated further.
To study the precise location of Ptn expression in the epithelial duct cells, fluorescent
probes were used to co-localise Ptn with |3-catenin, a cell-surface protein marker
(Fig7.4). Ptn expression was as previously reported (Fig 7.3). The strongest Ptn
staining in the mesenchyme was in the peripheral VP, and in the mesenchyme cells
juxtaposed to the epithelial cells. Plus, Ptn was found co-expressed with P-catenin,
and therefore located at the surface, of the epithelial duct cells.
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Fig 7.3: Pleiotrophin expression in Female and Male UGS
Immunohistochemistical localisation of the Ptn protein in female (Panel A and B)
and male rat UGS (PO) (Panel C-E) (n=5). Panels B and E are the negative control
sections, ventral mesenchymal pad (VMP), smooth muscle (SM), urogenital
mesenchyme (UGM), urethral epithelium (URE), BM (basement membrane), ventral
prostate (VP), anterior prostate (AP). Black arrows in Panels A and D point to areas
of high Ptn expression. Panel D shows the concentration of Ptn at the epithelial duct
tips. The scale bar in Panel A represents 200pm in Panels B, C, E and 50pm in
Panel D.
Chapter 7 Pleiotrophin 123
Also confirmed was the gradient of Ptn expression, with the strongest Ptn staining
associated with the epithelial cells most distal from the urethra (the epithelial duct
tips). From previous studies on Ptn expression, it is known that Ptn protein interacts
with heparin sulphate proteoglycans (HSPGs) at the extracellular matrix (Vacherot et
al., 1999b), and its expression is most often localised to the basement membranes on
the surface of differentiating cells (Mitsiadis et al., 1995). Therefore, the findings of
this thesis correlate well with the literature reports.
The epithelial cells at the tips of the branching ducts in the prostatic lobes are
characterized as undifferentiated and undergoing rapid proliferation (Marker et al.,
2003). In this thesis, it was hypothesized that the association of strong Ptn staining
with the epithelial tip cells might implicate Ptn as having a role in the differentiation
process that occurs in these cells during development. To investigate this theory, Ptn
was co-localised with p63, (a differentiation marker protein) in the neonatal male
UGS (Fig 7.5). The expression of p63 becomes restricted to basal epithelial cells of
the developing prostate, during the perinatal period. These basal cells are
undifferentiated and still have the ability to proliferate (Marker et al., 2003). In the
male P0 UGS, (Fig 7.5) p63 expression was localised to the undifferentiated basal
cells of the VP ducts, and Ptn expression was localised, as described previously. Ptn
and p63 expression showed some similarity in distribution i.e. at the epithelial duct
tips and Ptn associated with the basement membrane of the VP ducts correlated with
some p63 expression in the basal epithelial cells. However, replication of the co -
localisation on different sections, determined no clear relationship between Ptn and
p63 (undifferentiated cells) expression, and therefore the results are inconclusive, so
far.
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Fig 7.4: Pleiotrophin and p-catenin expression in Male UGS
Analysis of the co-localisation of Ptn and p-catenin protein in PO male rat UGS by
fluorescent immunocytochemistry. (n=4) The Ptn protein is shown in green, the p-
catenin protein is shown in red and nuclear staining is shown in blue. Co-
expression of Ptn and p-catenin is shown in yellow. Primary antibody was not
added in Panel H. Mesenchyme (M), epithelium (E), urethra (UR), basement
membrane (BM). The scale bar in Panel A represents 100pm. The scale bars in
Panels B and C represent 50pm. Panel E is the same magnification as Panel C.
The scale bar in Panel D represents 20pm.
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Fig 7.5: Ptn and p63 expression in the Male UGS
Analysis of Ptn and p63 protein co-localisation in PO male rat UGS by fluorescent
immunocytochemistry (n=5). Ptn is shown in green, p63 is shown in red and the
nuclear staining is shown in blue. No primary antibodies were added to Panel B.
epithelial cells (E), mesenchyme (M), basement membrane (BM), basal cells (B),
luminal cells (L). The scale bar in Panel A represents 50|am in both panels.
7.2.4 Effect of Testosterone on Ptn distribution
Androgens may directly or indirectly induce the release of regulatory factors from
the mesenchyme during development. Consequently, it was investigated whether the
distribution of Ptn, as a mesenchyme- expressed factor in the VP, would be affected
by exposure to Testosterone. VP organ rudiments were cultured in the presence (+T)
or absence (-T) of Testosterone, and Ptn expression was investigated by
immunocytochemistry (Fig 7.6). The VPs cultured with testosterone were found to
grow larger in size and show more epithelial bud branching than VP grown without.
Ptn protein was found associated with the basement membrane and cell-surface of
the epithelial duct cells, in a similar pattern to that reported previously in vivo (Fig
7.3-7.5). Additionally, it was noted Ptn expression was not uniform in all epithelial
ducts within an organ. The ducts most proximal to the urethra had Ptn expression
associated only with the basement membrane, while in more distally located ducts (at
the edge of the organ), Ptn expression was also associated with the cell -surface of
epithelial cells within the ducts. Overall however, there was no noticeable difference
in Ptn expression between the treated and untreated organs, and Ptn distribution was
not affected by Testosterone treatment.
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Fig 7.6: The effect of testosterone on Ptn localisation
Immunohistochemistical localisation of the Ptn protein in PO VP organs cultured for
6 days in the presence in the presence (+T) (Panels E-H) or absence (Panels A-D)
of testosterone (-T)(10'8M). Panels D and H are the negative control sections.
Epithelial cells (E), mesenchyme (M), basement membrane (BM), end of organ
proximal to urethra (U). Peripheral ducts are marked * and ducts proximal to the
urethra are marked with a black dot. The scale bars in Panel A and E represent
200pm. The scale bar in Panel B represents 100pm in Panels F and G, and
200pm(Panels A-D) in Panels C and G.
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7.2.5 Functional Studies on Ptn
Ptn transcript and protein expression in the mesenchyme of the male and female
UGS (PO) has been confirmed, in this thesis. Next, a possible functional role for Ptn
as a mesenchymal regulator of prostate organogenesis was investigated. VP organs
were cultured in the presence or absence Testosterone plus recombinant human PTN
(RnD Systems) (0.25 -2.5 pg/ml) (Table 2.2). Treatment with Testosterone induced
an increase in VP growth and branching morphogenesis, but treatment with PTN
only, had no effect on organ growth (data not shown).
7.2.6 Summary of Pleiotrophin Results
Ptn was intuitively selected from the LongSAGE libraries as a candidate gene, and
also showed a trend towards VMP- enriched expression by tag counts. LightCycler
analysis and Northern blot analysis confirmed Ptn was VMP -enriched. During
development and growth of the prostate, Ptn transcript expression, was most
abundant in the PO VP and late embryogenesis and the perinatal period, when bud
induction, epithelial growth and branching occurs. In other selected neonatal organs,
Ptn transcript expression was most abundant in the VP and ovary.
Ptn protein was localised to the mesenchyme of the VMP and VP and weakly in the
SM layer in the UGS (PO). Additionally, in the male UGS, Ptn protein was
associated with the basement membrane and surface of the epithelial duct cells, and
also exhibited a gradient of expression, where with most abundant expression was
associated with the undifferentiated tip cells. This was thought to suggest a role for
Ptn in regulating differentiation of these epithelial duct cells. However, co -
localisation of Ptn and p63 (differentiation marker) showed no clear relationship
between Ptn expression and p63 (undifferentaited cells), and at present the results
remain inconclusive. Additionally, Ptn was localised to mesenchyme of VP organ
cultures, and the protein distribution was not affected by treatment of the growing
organs with Testosterone. Finally, due to insufficient time, this thesis lacks data on
the function of Ptn in the developing prostate, and will be the subject of further
studies.
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8. Other Candidate Genes; Nell2, MMP2and MMP14
8.1 Introduction
The three remaining candidate genes Nell2, MMP2 and MMP14 were selected for
further studies after LightCycler analysis (Chapter 4). Unfortunately, there was
insufficient time to characterise their expression fully.
8.1.1 Nell2
Neural epidermal growth factor -like like 2, (Nell2), is a member of the mammalian
Nell gene family, which has only two members (Nell 1 and Nell2). The nel (neural
epidermal growth factor) gene was originally identified as a gene encoding a protein
containing six epidermal growth factor (EGF-) like domains from a chick-embryo
cDNA library (Masuhashi et al., 1995). NELL1 and NELL2 were first isolated from a
human foetal brain cDNA library as part of the Human Genome Project (Watanabe et
al., 1996), and then from a rat brain cDNA library (Kuroda et al., 1999). The NELL2
gene is more closely related to the nel gene than NELL1 (Masuhashi et al., 1995).
Chicken NEL is approximately 40-50% homologous to mammalian NELL1 and
approximately 80-90% homologous to mammalian NELL2. The NELL genes code
for large peptides of approximately 90kDa.and are heavily glycosylated with an
additional approximately 50kDa of N-linked carbohydrate moieties for total
monomeric size of approximately 140kDa. The secreted forms of the NELL peptides
are processed to approximately 130 kDa. monomers and form approximately 400
kDa. trimers in solution (Kuroda et al., 1999).
NELL2 is a secreted glycoprotein, and belongs to a class of proteins that contain
epidermal growth factor domains. This group includes amongst others, Notch and its
ligands (Delta/Serrate/Lag (DSL), the Neuregulin (NRG) family of ligands and the
SLIT family of ligands (Kuroda et al., 1999, Kuroda and Tanizawa, 1999, Oyasu et
al., 2000). The EGF-like domains are likely to serve as potential binding sites for
novel protein interactions. NELL2 also belongs to the laminin G/N-terminal
thromobospondin-1 (N-TSPl)/Pentraxin supergene family, a large class of multi-
domain adhesive proteins in the extracellular matrix that act as molecular bridges
between cells and the matrix, and participate in cell-cell communication and contact
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(Beckmann et al., 1998).
family.
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Lastly, NELL2 also belongs to the chordin-like domain
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NELL2 contains a cleavable signal peptide and N-TSP1 domain, six EGF-like and
five cysteine-rich chordin-like/von Willebrand Factor C (C/vWc) domains.
Also, NELL2 has also been identified as a protein that interacts with protein kinase C
(PKC), by which it is phosphorylated, and as a member of the EGF-like family it has
been shown to have three Ca2+ binding sites in its EGF-like repeat domains and
suggested to play a role in the regulation of cellular events related to Ca2+ (Kuroda et
al., 1999).
TSP-1 EGF-like
>> C/vWc r A s, C/vWc
Fig 8.1: Schematic of NELL2 protein
N-terminal thrombospondin 1 motif (TSP-1) with N-terminal heparin-binding domain
(HB) and coiled-coiled (cc) domain; chordin-like/von Willebrand factor c motif
(C/vWc); epidermal growth factor-like motif (EGF-like) (Nelson et al., 2004).
NELL1 and NELL2 expression is tightly regulated in several vertebrate tissues both
during development and in the adult (Kim et al., 2002, Kuroda et al., 1999, Luce and
Burrows, 1999, Matsuhashi et al., 1995, Nelson et al., 2002, Oyasu et al, 2000,
Watanabe et al., 1996). During development, NELL2 expression is temporally and
spatially restricted to a period of differentiation in discrete regions of the nervous
system, the pharyngeal arches, and the forelimb and trunk skeletal muscle (Nelson et
al., 2002). NELL2 expression has also been reported in the early kidney and heart
(Mutsahashi et al., 1995, Watanabe et al., 1996). In the adult human, NELL2 is
reported to show brain specific expression (Oyasu et al., 2002, Watanabe et al., 1996).
However, NELL2 expression has also been found in the adult prostate, where an over-
expression of NELL2, localised to the basal epithelial cells was associated with benign
prostatic hyperplasia (DiLella et al., 2001). Additionally, NELL2 and NELL1 have
been detected in several transformed cell lines, hyperplasias and malignancies
(DiLella et al., 2001, Kuroda et al., 1999, Luce and Burrows, 1999, Maeda et al.,
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2001). The expression of NELL2 has been well documented but the role of NELL2
in vivo has not been fully studied.
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The focus of Nell2 studies have been on its expression in the developing and adult
nervous system, where it is thought to play an important role during neuronal
development (Nelson et al., 2004). The likely role of Nell2 in other developing
tissues has not been studied. However, based on homologies to the Notch/DSL,
NRG, SLIT and TSP-1 proteins, Nell2 has been proposed as a signalling ligand in
similar key developmental events. A summary of Notch function during development
is included in Chapter 4. Also, the ligand Slit and its receptor ROBO are known to
acts as target-derived factors that attract or repel extending neurites during neuronal
development (reviewed in Nguyen-Ba-Charvet and Chedotal, 2002). Finally, TSP-1
is known to regulate cell proliferation, migration and apoptosis in a variety of
physiological and pathological conditions such as wound healing, inflammation,
angiogenesis and neoplasia (Chen et al., 2000). The association of NELL with some
hyperplasias and malignancies indicates that mis -regulation of NELL genes is
correlated with oncogenic potential in certain cancerous pathologies (DiLella et al.,
2001, Kuroda et al., 1999, Luce and Burrows, 1999, Maeda et al., 2001).
The mechanism of Nell2 activity has not been elucidated, as yet, but it has been
suggested that NELL2 activity is reminiscent of the classical lateral inhibition
mediated by Notch and Delta (Morrison et al, 2000, Wakamatsu et al., 2000).
Recently, NELL2 was shown to demonstrate dual cell autonomous and paracrine
functions, in the brain. NELL2 promoted differentiation of neuronal progenitor cells
that express NELL2 while simultaneously stimulating neighbouring cells to
proliferate (Nelson et al., 2004). How NELL2, a secreted glycoprotein could
simultaneously exert both cell autonomous and paracrine activities are not yet
understood. Possible direct or indirect interactions with the Notch pathway and
Wnt/p-catenin signalling pathway have been suggested (Hari et al., 2002, Nelson et
al., 2004). Also, interactions with cell surface receptors such heparin sulfate
proteoglycans or FGF receptor-heparin complexes or indirectly with the heparin
sufate -rich extracellular matrix (HS-ECM) (Kuroda et al., 1999). Finally, NELL2
could also bind other secreted factors since it contains cysteine-rich chordin-like/von
Willebrand factor-C and N-TSP1 motifs, which can interact with TGF|3/ BMP family
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members and a myriad of cell-surface and ECM molecules, respectively (as reviewed
in Adams and Tucker, 2000, Bornstein and Sage, 2002, Garcia Abreu et al., 2002).
8.1.2 MMP2 and MMP14
Matrix metalloproteinases (MMPs) are a large family of Zn2+ and Ca2+ dependent
enzymes with different substrate specificities MMPs share many structural and
functional properties and are known to take part in extracellular matrix (ECM)
remodelling. MMPs are divided into groups according to their substrate specificities
and exist as both secreted and membrane bound forms. MMPs are often secreted as
inactive pro-forms and their activity is carefully regulated by an activation process
(Docherty et al., 1992, Sommerville et al., 2003, Werb, 1997). At the level of the
gene, different signalling pathways will activate different MMPs in response to
cytokines, hormones or growth factors such as IL-1|3, IL-6, TNFa, Platelet derived
growth factor (PDGF) and basic fibroblast growth factor (Jones et al., 2003). Also,
following activation, the MMPs can be inhibited by tissue inhibitors of
metalloproteases (TIMP's) (Brew et al., 1999).
Structurally, nearly all MMPs have a basic minimal structure consisting of a terminal
peptide signal sequence (enables their secretion), a propeptide domain (removed
during activation) and a catalytic domain. MMP2 and MMP14 have an additional
hemopexin like domain (involved in substrate recognition and the binding of
endogeneous inhibitors-TIMPS). MMP2 also contains fibronectin like domains (that
bind gelatin), and MMP14 contains a recognition motif for furin-like serine proteases
(Fig 8.2) (Nuttal et al., 2004).
MMP14 (MT1-MMP) is the first member of a more recently established group of
MMPs containing a membrane-spanning sequence, and is the most extensively
studied of the cell-surface MMPs. MMP14 can degrade molecules such as collagen I,
laminin, fibrin and fibronectin (Hotary et al., 2002, Ohuchi e t al., 1997), but it is
better known as the cell-surface activator of pro-MMP2 (Sato et al., 1994).











Fig 8.2: Schematic of MMP2 and MMP14 Proteins
Signal peptide (SP), pro-domain (PRO), catalytic domain (C), Zinc binding site
(Zn2+), Hinge region (H), membrane-type loop (MT-loop), transmembrane
domain(TM) (modified from Apte et al., 1997).
MMP14 also activates MMP13 (Knauper et al., 2002). MMP14 is subject to a high
degree of transcriptional regulation during development. The pro-domain of MMP14
is constitutively removed by a proprotein convertase (furin) in the secretory pathway,
resulting in delivery of catalytically active enzyme at the cell-surface (Sato et al.,
1996).
MMP2, also called gelatinase A. is a member of the gelatinase subgroup of MMPs,
with the capacity to degrade basement membrane Type IV collagen (Massova and
Kotra, 1998). MMP2 is synthesised and released in the inactive form (pro-MMP2)
(72kDa). It requires extracellular activation for biological function and the activation
process is mediated in part by MMP14. Activation of pro-MMP2 occurs most
efficiently at the cell surface and requires the formation of a trimolecular process in
which TIMP2 links MMP14 to MMP2. The active form ofMMP2 is 62kDa (Sato et
al., 1994, Strongin et al., 1995)
The ability of MMPs to remodel the ECM has implicated their involvement in
embryonic development and morphogenesis, as well as in the invasion and metastasis
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postnatal life in mice, MMP2 is most highly expressed in the kidney, spleen, lung,
skeletal muscle and heart, which partially mirrors the reported most abundant
expression of MMP14 in placenta, kidney, heart and lung tissue (Nuttal et al., 2004).
The destructive nature of these enzymes means that in normal tissue they tend to be
expressed at low levels. High expression occurs as part of inflammation tissue
remodelling (wound healing in adults) in response to growth factors, cytokines and
interactions between cells and components of the ECM (Dyer and Hupe, 1998). The
actions of MMP2 and MMP14 are too extensive to report fully, therefore only those
relevant to prostate development and prostate cancer will be discussed here.
MMPs are often investigated for their involvement in development of branched
organs, such as the kidney and lung and submandibular and mammary gland, where
the key to successful branching morphogenesis is controlled turnover of the ECM and
thus a balance between the activities of MMPs and TIMPs. The process of branching
involves the thinning of the basement membrane of epithelial cells followed by
metalloproteinase -mediated penetration into the mesenchyme. MMPs are described
as mesenchymal factors that are ideally positioned to regulate such stromal-epithelial
interaction (Sternlicht and Werb, 2001), although their expression is not always
restricted to the mesenchyme. MMP2 expression has been localized to the
mesenchyme of branching organs like the lung (Reponen et al., 1992), kidney (Stuart
et al., 2003), and mammary gland (Wiseman et al., 2003) while MMP14 expression is
often reported in the mesenchyme and epithelium (Kheradmand et al., 2002, Wiseman
et al., 2003).
In the embryonic kidney, both MMP2 and MMP14 have both been reported to show
increased expression at the uteric bud tips (Kanwar et al., 1999) and MMP14 is
associated with the branching uteric bud tip in vitro (Meyer et al., 2004). Also,
MMP14 is reported to be essential for tubular formation in vitro (Kadono et al., 1998,
Miyamori et al., 2000), but blocking MMP2 activity has no effect on kidney
morphogenesis in vitro (Lelongt et al., 1997). The roles ofMMP2 and -14 in the
developing kidney are not fully understood. Additionally, MMP14 null mice have
been reported to have defects in the lung and submandibular gland. Lack of MMP14
substantially affected branching morphogenesis in the submandibular gland, and
impaired angiogenesis in the lung affecting postnatal development. Also, it was
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proposed that the fact that MMP2 null mice did not have comparable anomalies
suggests that MMP14 acted in this context via mechanism(s) independent of pro-
MMP2 activation (Oblander et al., 2005). However, it should be noted that a previous
study had reported that lung branching and morphogenesis were severely affected by
inactive MMP2 caused by low levels of MMP14 (Kheradmand et al., 2002). Finally,
in development of the mammary gland MMP2 has been shown to regulate ductal
invasion and repress lateral budding (Wiseman et al., 2003), while overexpression of
MMP14 in mammary epithelium leads to development of roughly twice the number
of branch sites (Ha et al., 2001).
Therefore, MMP2 and MMP14 are both important during development, but MMP14
null mice have been reported to have the most distinctive phenoytpe of all the null
MMP alleles. MMP14 null mice usually die within 3 weeks of age, with postnatal
dwarfism and musculoskeletal defects (Holmbeck et al., 1999, Zhou et al., 2000).
Whereas, MMP2 mull mice do not have major developmental anomalies, but have
been found to show defective angiogenesis (Itoh et al., 1997, Itoh et al., 1998) and
impaired postpubertal mammary gland duct development (Wiseman et al., 2003).
Also, mutations in human MMP2 cause a multicentric osteolysis and arthritis
syndrome (Martigentti et al., 2001).
MMP2 and MMP 14 are also in involved pathological processes including cancer.
MMP2, as a gelatinase, has the ability to degrade basement membrane Type IV
collagen a major structural barrier for malignant tumor cells. Therefore, gelatinase
expression in tumors has been associated with tumor invasion and metastasis. MMP
2 overexpression has been reported in many neoplasms (Nelson et al., 2000) including
ovarian (Davidson et al, 1999, Sakata et al, 2000), urothelial (Davies et al., 1993,
Gohiji et al., 1996, Kanaymama et al, 1998), cutaneous (Dumas et al., 1999 Ikebe et
al., 1999), gastric (Mori et al., 1997), breast (Pacheco et al., 1998, Talvensaari-Mattila
et al. 2001), cervical (Nuovo et al., 1995) and prostate cancers (Kuniyasu et al, 2000,
Riddick et al, 2005, Ross et al, 2003, Still et al, 2000, Stearns and Stearns, 1996,
Trudel et al, 2003). Additionally, in prostate cancer, reports of inconsistent results of
MMP2 expression suggest a discrepancy exists between MMP2 mRNA and protein
expression levels. Riddick et al (2005) and Lightingaghen et al (2002) reported a
decrease in MMP2 mRNA in prostate tumours, which differs from the increase in
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MMP2 protein observed by Brehmer et al., (2003). Also, in contrast, a study
identified an increase in MMP2 RNA in the highest grades of cancer (Still et al, 2000)
and high expression of MMP2 has been associated with aggressive behaviour and
metastasis (Wood et al., 1996). Finally, MMP2 and MMP14 co-localisation has been
reported in the epithelial compartments of benign prostate epithelium, high-grade
prostatic intraepithelial neoplasia and prostate cancer (Upadhyay et al., 1999).
MMP14 expression has also been reported to correlate with the malignancy of
different tumour types such as the lung (Kettunen et al., 2004, Nawrocki et al., 1995,
Sato et al., 1994, Tokuraki et al., 1995), gastric (El-Rifai, et al., 2001, Martinez et al,
2005, Nomura, et al., 1995, Mori et al., 1997), colon (Okada et al., 1995, Ohtani et al.,
1996), breast (Okada et al., 1995, Polette et al., 1996, Ueno et al., 1997), cervical
(Gilles et al., 1996), prostate carcinomas (Cao et al., 2005, Upadhyay et al., 1999),
gliomas (Belien et al., 1999) and melanomas (Hofman et al., 2000). Cao et al., (2005)
recently reported that MMP14 promotes human prostate cancer invasion and
metastasis, and suggest MMP14 as a suitable target to prevent cancer metastasis.
Finally, one of the key roles that MMP2 and MMP14 play in promoting tumor growth
is their function with TIMP-2 to promote tumoral angiogenesis (Sounni et al., 2002).
8.2 Results
8.2.1 Nell2, MMP2 and MMP14 Transcript Expression in the VSU and
VMP
Nell2 was identified by bioinformatic analysis of the SAGE libraries
(P<0.05)(Appendix) and LightCycler analysis (Graph 4.1) as VMP-enriched. MMP2
was identified by SAGE analysis as VMP-enriched, and although this was not
confirmed by LightCycler analysis, it did show a trend towards VMP-enriched
expression (1.2 fold). MMP14 was not identified as VMP-enriched by SAGE
analysis but was included in LightCycler analysis after finding reports of MMP14
activity in other branching organs, the lung and submandibular gland (Oblander et al.,
2005) plus, MMP14 has an important role as a pro-MMP2 activator (Sato et al.,
1994).
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Additionally, Nell2, MMP2 and MMP14 transcript expression was investigated in the
male and female UGS (PO) by Northern blot analysis (Fig 8.3). The radioactively
labelled probes were prepared using primers in Table 2.4. To verify the correct RNA
loading, the Northern blot was also hybridised with FgflO, a known VMP-specific
gene (Thomson and Cunha, 1999). In a Northern blot containing PO VP, VSU and
VMP, FgflO transcript abundance was shown to be ~4-fold higher in the VMP than
the VSU, and ~2-fold higher than the VP. The high expression of FgflO in the VMP
in comparison to the VSU, confirmed that the blot had been correctly loaded. Nell2
transcript expression was ~ 3-fold more abundant in the VMP than the VSU, and ~
1.9 fold more abundant than in the VP. MMP2 transcript expression was ~1.4 fold
more abundant in the VMP than in the VSU, and was expressed at a similar level in
the VP. The MMP14 transcript expression was ~3-fold more abundant in the VMP
than the VSU, and ~ 1.9 fold higher than the VP. Therefore, Nell2, MMP2, MMP14
and FgflO all showed VMP-enriched expression, to varying degrees and they were
also expressed in the VP. Unfortunately, due to insufficient time and lack of working
antibodies, no analysis of the their associated protein distribution was performed.
8.2.2 Nell2Transcript Levels in the Prostate and Selected Organs.
Further experiments were performed to investigate the expression ofNell2 transcript
during embryonic and postnatal prostate development and also expression in other
selected neonatal organs. Nell2 transcript expression (Fig 8.4, Panel A) was most
abundant on the day of birth (PO), upregulated from embryonic life (31%) and
downregulated dramatically by P4 (40%), with subsequent reduced expression levels
until adult life (11%). Also, no difference in transcript abundance was found between
Nell2 expression in the male (E17.5m) and female embryonic UGT (E17.5f). The
peak of Nell2 expression coincided with an important period of prostate development,
epithelial growth and branching morphogenesis.
In other selected neonatal tissues (Fig 8.4, Panel B), levels of Nell2 expression were
most abundant in the brain (152%) and VP (100%), and were measured at much lower
levels (1-15%) in the remaining tissues.
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Nell2 •►•ir 2.6 kb
MMP2 VmW 3.2 kb
MMP14 2.4 kb
Fgf10 » 2.8 kb
GAPDH 1.5 kb
100 187 61 Av. % Nell2 transcript level
100 96 69 Av. % MMP2 transcript level
100 189 64 Av. % MMP14 transcript level
100 195 50 Av. % Fgf10 transcript level
Fig 8.3: Nell 2, MMP2, MMP14 and Fgf10 mRNA expression in the male and
female UGS.
Analysis of the transcript levels for the named genes in P0 male and female UGS.
The VSU is the whole female rudiment, the VMP is the microdissected ventral
mesenchymal pad, and the VP is the microdissected male ventral prostate.
Transcript levels were quantified using a phosphoimager and normalised to GAPDH.
The numbers below the figure represent the average transcript abundance of each
transcript relative to the VP.
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8.2.3 MMP2Transcript Levels in the Prostate and Selected Organs.
MMP2 transcript expression was investigated during embryonic and postnatal
development of the prostate (Fig 8.5, Panel A). MMP2 expression in the prostate was
most abundant on the day of birth (PO) (100%, and downregulated dramatically by
P10 (44%), and subsequently until adulthood (4%). Also, no difference in transcript
abundance was found between the male (E17.5m) and female embryonic UGS
(E17.5f). The most abundant levels of MMP2 expression coincide with the period of
bud induction and epithelial growth and branching in prostate organogenesis. In the
selected PO organs (Fig8.5, Panel B), MMP2 transcript expression was most abundant
in the VP (100%) and ovary (85%), also with significant levels in the liver (58%),
testes (42%) and bladder (29%). Low levels of MMP2 were measured in the
remaining tissues (1-12%).
8.2.4 MMP14Transcript Levels in the Prostate and Selected Organs.
MMP14 transcript expression was also investigated during prostatic ontogeny (Fig
8.6, Panel A). MMP14 expression was most abundant on the day of birth (PO)
(100%), and downregulated dramatically by P10 (53%), and subsequently until
adulthood (5%). Also, no difference in transcript abundance was found between the
male (E17.5m) and female embryonic UGT (E17.5f). The most abundant levels of
MMP14 expression coincide with the period of bud induction and epithelial growth
and branching in prostate organogenesis In the selected P0 organs (Fig 8.6, Panel B)
MMP14 transcript expression was most abundant in the VP (100%), and similar levels
were found in the ovary (87%), liver (78%) and testes (70%). Lower levels of
MMP14 were measured in the remaining tissues (6-40%).
Also, it was noted that MMP2 and MMP14 expression levels were similar at each
stage of prostate development, and both were most abundantly expressed in the same
P0 organs.
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transcript level
Fig. 8.4: Nell2 mRNA expression during prostatic ontogeny and expression in
other organs (P0). Analysis of Nell2 transcript levels in the prostate; embryonic
(E17.5) until adult life (Panel A), and in branching and non-branching organs
collected from P0 rats (Panel B) (n=2). Ventral prostate (VP), bladder (Bid), brain
(Brn), gut (Gt), heart (Ht), kidney (Kid), liver (Lvr), ovary (Ov), testes (Test), lung (Lg).
The transcript levels were quantified using a phosphoimager and normalised to
GAPDH. The numbers below the figure represents the average Nell2 transcript
abundance relative to the P0 VP.
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transcript level
Fig. 8.5: MMP2 mRNA expression during prostatic ontogeny and expression in
other organs (P0). Analysis of MMP2 transcript levels in the prostate; E17.5 until
adulthood (Panel A), and in branching and non-branching organs collected from P0
rats (Panel B) (n=2). Ventral prostate (VP), bladder (Bid), brain (Brn), gut (Gt), heart
(Ht), kidney (Kid), liver (Lvr), ovary (Ov), testes (Test), lung (Lg). The transcript
levels were quantified using a phosphoimager and normalised to GAPDH. The
numbers below the figure represents the average MMP2 transcript abundance
relative to the P0 VP.
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Fig. 8.6: MMP14 mRNA expression during prostatic ontogeny and expression
in other organs (P0).
Analysis of MMP14 transcript levels in the prostate; E17.5 until adulthood (Panel A),
and in branching and non-branching organs collected from P0 rats (Panel B) (n=2).
Ventral prostate (VP), bladder (Bid), brain (Brn), gut (Gt), heart (Ht), kidney (Kid),
liver (Lvr), ovary (Ov), testes (Test), lung (Lg). The transcript levels were quantified
using a phosphoimager and normalised to GAPDH. The numbers below the figure
represents the average MMP14 transcript abundance relative to the P0 VP.
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8.2.5 Summary of Results
Nell2, MMP2 and MMP14 were identified as VMP-enriched genes by bioinformatic
anlaysis of the LongSAGE libraries and/or LightCycler analysis. They were each
further verified as VMP -enriched by Northern blot analysis. During prostatic
prostate developement, Nell2, MMP2 and MMP14 were all highly expressed around
the day of birth (PO) and during the perinatal period, but with low expression in adult
life. Nell2 was expressed highly selectively in the panel of neonatal organs, with
significant transcript levels present in only the brain and VP. MMP2 and MMP14
expression was most abundant in the VP, and with lower but significant expression in
the liver, ovary and testes. Also, it was noted that MMP2 and MMP14 showed
synchronicity in their levels of expression during prostate development and in other
PO organs.
These candidates support the use of the experimental approach used in this thesis to
identify VMP-enriched genes. Unfortunately, due to insufficient time it was not
possible to characterise their protein distribution and function.
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9. Candidate Expression in Prostate Cancer Stroma
9.1 Introduction
Developmental mechanisms involved in prostate organogenesis may have relevance
to the genesis and biology of prostate cancer. Prostate carcinogenesis is associated
with perturbation of the reciprocal homeostatic mesenchymal-epithelial interactions
that in the normal prostate maintains epithelial and stromal differentiation and growth
quiescence. Changes in the stromal microenvironment, have been linked to
disturbance of these homeostatic stromal-epithelial interactions, which promotes
tumorigenesis (Grossfeld et al., 1998, Hayward etal., 1996, 1997, 1998). A process
possibly mediated by developmental factors.
The role of stroma in the initiation and promotion of carcinogenesis has been
considered for many years and is based upon the observation that "tumour stroma"
frequently exhibits a variety of phenotypic differences relative to normal stroma
(Bosman et al., 1993, Selijelid et al., 1999). Tumour stromal cells have been shown
to exhibit abnormal migratory behaviour in vitro (Schor et al., 1988), alterations in
cell-surface molecules (Choudhuri et al., 1975, Oishi, et al., 1981), altered expression
of growth factors (Ellis, et al., 1994, Frazier and Grotendorst, 1997, Nakamura et al.,
1997, Ponten et al., 1994, Yan et al., 1993, Yee et al., 1989), expression of
prostaglandin synthase enzymes (Shattuck-Brandt et al., 1999, 2000) and alterations
in the ECM (Pupa et al., 2002, Werb et al., 1996). They also show increased
expression of MMPs, which may affect tumour initiation, growth, migration,
angiogenesis, apoptosis, invasion and metastasis (Lynch and Matrisian, 2002).
The mechanisms by which stromal cells influence tumorigenesis are poorly
understood, although it is suggested that it involves the differential expression of
factors by cancer-associated fibroblasts (CAFs) versus normal prostate fibroblasts
(NPFs), which act to modulate the local micro-environment. Studies have reported
that CAFs have the ability to promote carcinogenesis in initiated, but non-tumorigenic
human prostate epithelial cells, also increasing angiogenesis (Tuxhorn et al., 2002),
while NPFs, restrain epithelial proliferation (Fig 9.1) (Grossfeld et al., 1998, Olumi et
al., 1999).
















Fig 9.1 Summary of tissue recombination experiments in which normal human
prostatic fibroblasts (NAF) or carcinoma-associated fibroblasts (CAF) were
grown in vivo in association with either normal human prostatic epithelial cells
or initiated human prostatic epithelial cells (BPH-1).
As indicated in the four-way grid, tumors only develop when initiated human prostatic
epithelial cells (BPH-1) are grown in association with CAF. The bottom depicts the
gross size differences between CAF + BPH-1 recombinants, which form tumors,
versus NAF + BPH-1 recombinants, which do not. (modified from Olumi et al., 1999,
in Cunha et al., 2004)
Therefore, cancer associated stroma and the molecules they express are proposed to
be involved in regulating prostatic carcinogenesis (as reviewed in Cunha et al., 2002,
2004). In this thesis, it was hypothesized that mesenchyme-expressed molecules,
abundantly expressed during prostate organogenesis, may be re-expressed in prostate
cancer stroma cells (CAFs) to regulate neoplastic growth.
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9.2.1 Transcript Expression in the Human Prostate
Samples of human CAFs and NPFs were tested for the expression of the human
orthologues of the developmental candidate genes; DLK1, PTN, NELL2, NOTCH2,
MMP2 and MMP14. Initial studies were performed by general RT-PCR (Fig 9.1),
using the relevant primers in Table 2.5. CAFs and NPFs were supplied as a gift from
Dr. Simon Hayward, University of Vanderbilt, USA. The CAF and NPF samples
were supplied as matched pairs, derived from the same patient. The CAFs and NPFs
had been tested for their ability and inability, respectively, to stimulate tumorigenesis.
PTN, NOTCH2, MMP2 and MMP14 expression was found in both CAFs and NPFs,
but DLK1 and NELL2 expression was absent. Immunocytochemistry of tissue arrays
with normal adult prostate and prostate cancer also verified DLK1 protein was not
expressed (data not shown, personal communication, Mr. O. C. Grace).
PTN and NOTCH2 expression levels were then measured by LightCycler analysis in
CAFs and NPFs, using the relevant primers in Table 2.5. The results were normalised
by GAPDH. PTN and NOTCH2 were both found to show a downregulation of
transcript expression in the CAFs in comparison to their matched NPFs (Graph 9.2).
PTN mRNA expression was downregulated by 1.7 and 1.4-fold, and NOTCH2 mRNA
expression was downregulated by 1.7 and 2.6-fold in CAF1 and CAF2, respectively.
PTN and NOTCH2 transcript expression in the CAF and NPF samples was then
investigated by Northern blotting analysis. Radioactively labelled probes were
prepared using the primers in Table 2.5. The results were normalised by GAPDH.
Similar to the LightCycler results, PTN and NOTCH2 transcript expression was found
to be downregulated in the CAFs in comparison to their matched NPFs, in both
patients (see Fig 9.3). PTN mRNA was ~1.6-fold and downregulated ~2-fold, and
NOTCH2 mRNA was downregulated ~1.4-fold and ~1.5-fold in CAF1 and CAF2,
respectively.
However, these results are based CAF and NPF cells from only two patients, and
therefore are not conclusive. It will be necessary to repeat these experiments on
further CAF and NPF samples, to make robust conclusions.
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Fig 9.2: Gene Expression in Human Foetal Tissues and Cells
PCR analysis of DLK1 (429bp), PTN (346bp), NELL2 (377bp), NOTCH2 (692bp),
MMP2(294bp), and MMP14 (354bp) expression in cancer associated fibroblasts
(CAF) and normal prostate fibroblasts (NPF) of human origin. Foetal liver (Lvr) and
brain (Brn) were included as positive controls, and a cDNA template made with no








Graph 9.1: PTN and NOTCH2mRNA Expression in CAFs and NPFs.
LightCycler analysis of transcript expression in cancer-associated fibroblasts (CAFs)
and normal prostate fibroblasts (NPFs) (n=2). Transcript expression was normalised
to TBP. The samples were analysed as matched pairs; NPF1, CAF1 and NPF2,
CAF2, where the paired samples were derived from the same patient. The graph
displays the downregulation of PTN and NOTCH2 transcript expression in each CAF
sample in comparison to its matched NPF.
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Fig 9.3: PTN and NOTCH2mRNA Expression in CAFs and NPFs.
Analysis of P77V and NOTCH2 transcript levels in cancer associated fibroblasts
(CAF) and normal prostate fibroblasts (NPF). Foetal prostate (Prost), liver (Lvr) and
brain (Brn) were included as positive control tissues (n=1). The samples were
analysed as matched pairs (CAF1, NPF1 and CAF2, NPF2), where each pair was
derived from the same patient. The transcript levels were quantified using a
phosphoimager and normalised to GAPDH. The numbers below the figure
represents the average transcript abundance relative to the NPF within each sample
group.
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9.2.2 Pleiotrophin Protein Localisation in the Human Prostate
The distribution of PTN protein in the human foetal (15wk) prostate (Fig 9.3) was
investigated by immunocytochemistry using a Ptn primary antibody supplied by RnD
Systems (Table 2.1). PTN protein was localised to the epithelial cells of the prostate
ducts and more diffusely in the surrounding mesenchyme. The precise localisation of
the PTN with relation to the epithelial cells was not clear. A further co-localisation
experiment would be required to verify if PTN was associated with the cell-surface
and basement membrane of the human epithelial cells, as was found in the neonatal
male rat UGS (Fig 7.4). Due to insufficient time, localisation of the other candidate
proteins was not performed in the human foetal prostate.
Fig 9.4: Pleiotrophin protein expression in the human prostate
Immunohistochemical localistion of PTN protein expression in human foetal (wk15)
prostate (n=3). Epithelium (E), mesenchyme (M), wolffian ducts (WD). No primary
antibody was added to Panel D. The scale bar represents 200pm in Panels A and D,
40pm in Panel B and 20pm in Panel C.
Chapter 9 Candidate Expression in Prostate Cancer Stroma 149
9.2.3 Summary of Results
Human cancer associated fibroblast cells (CAFs) and normal prostate fibroblast cells
(NPFs) were tested for expression of candidate mesenchyme genes: DLK1, NOTCH2,
PTN, NELL2, MMP2 and MMP14. The CAF and NPF cells expressed PTN,
NOTCH2, MMP2 and MMP14 transcripts but DLK1 and NELL2 expression was
absent. Further analysis of PTN and NOTCH2 expression, by LightCycler and
Northern blot analysis, determined transcript levels were downregulated in the CAFs
in comparison to their matched NPFs. However, these results are based on cells
isolated from only two patients and are therefore are not considered as conclusive.
Finally, PTN protein expression was immunolocalised in the human foetal prostate.
Strong staining for PTN was associated with the epithelial duct cells and weak PTN
associated staining was present in the surrounding mesenchyme.
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10. Discussion
10.1 LongSAGE
The LongSAGE technique was used to investigate the gene expression profile of the
prostate rudiment, and in particular, genes that are expressed in the
mesenchyme/stromal cells. The LongSAGE method was updated from the published
SAGE protocol (Invitrogen), and used to generate Libraries of the VSU and VMP
from the neonatal female UGS. The tissue quality was recognised as being essential
to the validity of the Libraries they would generate. Also, the number of PCR cycles
in the cDNA amplification step was minimised, to reduce the possibility of creating a
transcript bias in the gene expression profiles.
The Libraries generated were analysed and presented by the software according to
the tag sequences and the associated tag abundance. A 'back-comparison' between
the VMP and the VSU Libraries, and statistical analysis identified 218 VMP-
enriched tags (P<0.05), where the minimum tag count in the VMP Library was 5
tags. The Libraries of tags were annotated to their associated genes using the rat
LongSAGEmap, although this was not a comprehensive procedure. BLAST was able
to increase the number of genes named, using the more fully characterised rat
genomic data. BLAST was used to verify the accuracy of the gene assignments for
the VMP-enriched transcripts (P<0.05), and further genes were intuitively selected
from the Libraries. Genes expressed in the VSU and/or VMP Libraries were found to
include those from known prostate development signalling pathways, such as the low
abundance gene, FgflO, and also genes known to be upregulated in prostate cancer
e.g. hepsin. Therefore, there was confidence in the validity of the Library data, and
in the sensitivity of the technique to identify transcripts with low levels of
expression. A more detailed discussion of the preparation and analysis of the
Libraries have been included in Section 3.3.
After completion of the Libraries, the aim of the project was to characterise the
expression and function of a few of the candidate mesenchymal genes in more detail.
It was hoped that the results of this study would help to validate the data in the
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Libraries and support the main hypothesis of the project, that mesenchymal/stromal
factors play a role in prostate development and cancer.
10.2 Experimental Validation of the LongSAGE Libraries
Completion of the LongSAGE Libraries had taken ~18months, but ultimately
planned to characterise some of the VMP-enriched genes identified. In the time
remaining, only a few selected genes could be studied in any depth. QRT-PCR was
used as the initial screening process to confirm the VMP-enriched expression of
candidate mesenchymal transcripts, by an independent quantitative technique.
LightCycler analysis was able to confirm the preferential VMP expression (^1.5
fold) of the majority of genes (18 out of 26) that had been identified by SAGE as
VMP-enriched (P<0.05) or had demonstrated a trend towards VMP-enriched
expression. The LightCycler analysis process was further validated by confirmation
of expression of the 'control' genes. FgflO was confirmed as a VMP-enriched gene
(Thomson and Cunha), while FgfR2 (Giri et al, 1999, Igarashi et al, 1998, Leung et
al, 1997), Notchl (Shou et al., 2001, Wang et al., 2004) and Hepsin (Dhanasekaran et
al., 2001, Ernst et al., 2002, Klezovitch et al., 2004) each of which has been localised
to the epithelial cells of the developing prostate and/or prostate cancer, were
confirmed as VSU-enriched. Also, it was noted that on no occasion did the SAGE
data and LightCycler data directly contradict each other i.e a VMP-enriched tag
(P<0.05) identified by the SAGE data was never identified as VSU-enriched (>1.5
fold) by qRT-PCR or vice versa.
However, only 3 of the 10 genes (30%) identified as VMP-enriched (P<0.05) by
SAGE were confirmed by qRT-PCR (^1.5 fold). It is proposed that this is not a
direct measurement of the accuracy of the SAGE method, as the trends in gene
expression in the VSU/VMP were generally upheld by qRT-PCR. It is suggested that
any problems with the SAGE and/ or the LightCycler analysis would contribute to
poor rates of verified gene expression levels. For example, in the SAGE analysis,
the cDNA amplification step and/or the depth of sampling in the Libraries, could
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have introduced inaccuracies in the transcript quantification. While, on the other
hand, LightCycler analysis was found to produce variable results in transcript
quantification, particularly with the low abundance transcripts. Also, as both the
SAGE and LightCycler analysis contain cDNA amplification steps, it was concluded
that any variability between starting material used would result in different relative
transcript expression levels being measured by each technique. It was hoped to
minimise these differences during the LightCycler analysis by taking an average of
the results from at least two individually prepared batches of VSU and VMP RNA.
However, it was ultimately concluded that the LongSAGE or LightCycler analysis
could not be wholly relied on to identify VMP-enriched tags, and Northern blotting
analysis was used as a final confirmation.
Additionally, it was noted that the bioinformatic analysis of the SAGE data was more
effective at identifying VMP-enriched genes than intuitive selection. Only 2 out of
the 13 (~15%) intuitively selected possible VMP-enriched genes (i.e not including
the VSU 'control' genes) were confirmed by LightCycler analysis. Therefore,
SAGE analysis was twice as effective as intuitive selection in identifying VMP-
enriched genes i.e 30% vs. 15%.
Further studies were only performed on transcripts that had demonstrated VMP-
enriched expression, either in this project and/or in the Literature. Other
considerations for the choice of transcripts to be studied in more depth, included the
availability of relevant commercial antibodies and recombinant proteins that would
be needed for a full characterisation of protein localisation and protein function. In
the time remaining it would not have been possible to produce the relevant factors,
by other means.
The six final candidates, Dlkl, Notch2, Ptn, Nell2, MMP2 and MMP14, were
selected based on the results of the SAGE, qRT-PCR data, and/or previously
reported studies. Specifically, four of the candidates {Dlkl, Notch2, Nell2 and
MMP2) had been initially identified as VMP-enriched (P<0.05) by SAGE, whereas
Ptn and MMP14 showed a trend towards VMP-enriched expression by SAGE, with
Chapter 10 Discussion 153
both factors also previously reported in association with roles in branching
morphogenesis in other developing organs. Additionally, Midkine (Mk), a molecule
closely related to Ptn, which also play an important role during early development,
was identified in the LongSAGE libraries but was not included in the experimental
analysis, as both the SAGE and qRT-PCR data did not suggest VMP-enriched
expression.
The following Sections will discuss the results of more detailed experimental
analysis of the six candidates, their transcript expression, and protein distribution in
the developing rat prostate, and also in human cancer stroma.
10.3 Delta-Like 1 (Homolog)
10.3.1 Dlk1 Transcript Expression
Dlkl was identified as a VMP-enriched gene, and its expression was also confirmed
in the male UGS during prostatic development. Dlkl expression was found to be
most abundant during the processes of ductal branching morphogenesis, epithelial
and mesenchymal/stromal cytodifferentiation (reviewed in Marker et al., 2003),
which would suggest Dlkl has a role in one or more of these processes.
Dlkl has previously been reported as being highly expressed during embryonic life,
and its expression becomes more restricted in adulthood, and the levels of Dlkl
expression are proposed to be critical to modulate the extracellular signals leading to
either cell differentiation or proliferation (Baladron et al., 2002, Garces et al, 1999,
Ruiz-Hidalgo, et al., 2002). As both of these processes are occurring during prostate
development, it is speculated that the Dlkl expression is carefully regulated during
the perinatal period to regulate normal organogenesis. Also, based on preliminary
data, it is suggested that Dlkl mRNA is not an androgen-regulated molecule, as no
difference was found between expression in the embryonic male and female UGS
(E17.5), when levels of Testosterone would be high in the males in comparison to the
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female. Dlkl expression is sufficiently high at E17.5 that a relatively small
difference in expression between the sexes would have been noticeable.
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Dlkl mRNA levels were found to be most abundant in the neonatal VP, liver, ovary
and testes. High levels of Dlkl expression have been reported previously in each of
these tissues, except the prostate (Floridon et al., 2000, Jensen et al., 1999, Ohno et
al., 2001, Rockett et al., 2004, Tanimizu et al., 2003). Unfortunately, they provide
no additional evidence of a likely role for Dlkl in the prostate, as there are no
obvious similarities between the morphology of their development.
Furthermore, it was noted that it would have been possible to test for molecules
common to the branching process if actively branching embryonic lung and kidney
RNA had been included in the tissue samples tested for candidate transcript
expression. Low levels of transcript expression were measured in the neonatal lung
and kidney for each of the candidate genes tested in this project. However, as the
embryonic kidney and lung are more actively branching than their functioning
neonatal tissues, this does not preclude the genes studied from a role in branching.
Conversely, it is proposed that if high levels of a candidate gene transcript were
found expressed in branching organs, other than the developing prostate, then this
would suggest the candidate plays a common role in regulating branching
morphogenesis.
It has been reported that Dlkl is expressed in branching tissues and may have a role
in branching morphogenesis. Studies ofDlkl null mice have reported smaller lungs
and kidneys than wild-type mice at birth, and that they did not catch up in size, such
that the null mice had resulting pulmonary defects (Moon et al., 2002). However, a
possible role for Dlkl in branching in the developing prostate has not been studied.
10.3.2 Dlkl Protein Expression in the Neonatal UGS
Dlkl protein was localised to the mesenchymal cells of the VMP and VP, and also in
the smooth muscle layer surrounding the urethra in the neonatal male and female rat
UGS. The pattern of protein expression is supported by the transcript data presented
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and by in situ hybridisation (data not shown, G. Vanpoucke, personal
communication).
The distribution of the Dlklprotein suggests it may be acting in a paracrine and/or
autocrine manner, or a combination of both in the developing prostate. Here it is
suggested that the Dlkl protein expressed in the mesenchyme of the ventral prostate,
could act in a paracrine manner on adjacent epithelial cells, either as the full
transmembrane protein or as a secreted soluble factor, regulating epithelial
proliferation/differentiation, and/or acting in an autocrine manner on the
mesenchyme.
However, the story is further complicated by reports that the secreted and membrane-
bound variants of Dlkl may have opposite effects on differentiation (Garces et ah,
1999, Mei et ah, 2002). In this thesis, Dlkl immunolocalisation has recognised both
the soluble and membrane-bound forms, and without knowledge of definite Dlkl
receptor and its localisation, it is difficult to suggest a likely signalling pathway.
A possible role for Dlkl is as a member of the Notch signalling pathway. Notch 1 is
expressed in the epithelial duct cells, and is reported to be essential for normal
prostatic branching morphognesis (Wang et ah, 2004). Dlkl is proposed to be able to
bind to the Notch 1 receptor (Baladron, et al, 2005, Laborada, 2000), even though it
lacks the CSL domain reported to be important for Notch binding (Artavanis-
Tsakonas et ah, 1995), and could therefore act as a Notch ligand. Additionally, in
this thesis it has been speculated that Dlkl could also act as a ligand for Notch2.
The expression of Dlkl in the smooth muscle layer was of interest because it
contrasts with a report that Dlkl was found absent in embryonic and foetal human
smooth muscle (Floridon et ah, 2000). Also, because Dlkl demonstrated differential
expression in subset of cells in the SM layer, a tissue generally thought of as
homogeneous. Dlkl was found co-localised with some of the SM a- actin
expressing cells, particularly in the female UGS, but the exact nature of the Dlkl
only, expressing cells has not been confirmed. Additionally, in the female UGS (P0),
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Dlkl expression was notably absent from the section of the SM layer that lies
adjacent to the VMP.
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As a known differentiation/de-differentiation factor, it is speculated that Dlkl may be
active in the differentiating SM cells, as they form from the mesenchyme. The
differential distribution of Dlkl in the SM layer could implicate it in a role in SM
differentiation. The direct/indirect control of SM distribution in the male and female
UGS has been proposed as one hypothesis for the regulation of prostate
organogenesis (Thomson et al., 2002) and if Dlklwas involved in this process, would
make it an interesting avenue for further studies. More specifically, it is speculated
there may be some relationship between the absence of Dlkl expression in the SM
cells adjacent to the VMP, and the maintenance of these SM cells during
development of the female UGS, while this area of SM layer thins and disappears in
the male UGS.
10.3.3 The Effect of Testosterone on Dlkl Protein Distribution.
Normal development of the prostate is dependent on androgen action, and may
directly/ indirectly act to regulate the release of growth factors from the mesenchyme
that are also necessary for prostate organogenesis. It was hypothesised that the
Testosterone could be acting indirectly through its control of Dlkl distribution to
regulate the differentiated or de-differentiated state of the epithelial cells and to
control normal growth. According to this proposal, the Dlkl expression would
become restricted in its distribution either to the mesenchyme most proximal to the
urethra i.e. adjacent to epithelial ducts (differentiating) or to the mesenchyme cells at
the edge of the VP organ i.e. adjacent to the proliferating epithelial tip cells
(undifferentiated). However, cultures of VP organs treated with Testosterone
demonstrated the Dlkl protein was immunolocalised to the mesenchymal cells of
both the treated and untreated organs, and no obvious difference was noted in the
distribution of the Dlkl protein. Unfortunately, it was not possible to use Western
blotting analysis to measure changes to protein levels, as the Dlkl antibody was not
compatible with this technique.
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Therefore, the data presented here has not fully investigated the question of
androgen-regulation of Dlkl, and so it is interesting that two previous studies have
reported Dlkl expression modified by Testosterone levels. Rats treated in utero with
anti-androgens Linuron or DBP were found to show significantly altered Dlkl
expression in the foetal (GD21) epididymis (Turner et al. 2003) and Wolffian duct
(Bowman et al., 2005), respectively. Dlkl was significantly upregulated in the
epididymis and slightly upregulated in the Wolffian duct. This was confirmed to not
be the result of changes to the mesenchyme-epithelial cell ratio in the epididymis
only (Turner et al. 2003). However, here it is speculated that the observed changes to
Dlkl expression may not be the result of androgen-regulation but are an indirect
result of the differentiation process occurring in these developing tissues. At present
androgen-regulation of Dlkl remains inconclusive and further studies are required.
10.3.4 Dlkl Functional Studies
The functional role of Dlkl in normal prostate growth was studied using a VP assay
system. Addition of DLK1 to VP organs cultured in the absence of Testosterone was
found to induce an increase in their growth and the amount of epithelial branching
observed, apparent by increased number of duct tips. This effect was found to be
concentration-dependent (0.1 -0.75pg/ml), although no increase in the effect was
found at the highest dose of 2.5mg/ul. On the other hand, VPs cultured in the
presence of Testosterone showed an increase in organ size and amount of epithelial
branching, but no additional effect was found with increasing DLK1 treatment. It is
suggested that the Testosterone in this system was driving the growth process
maximally, and overwhelming any effect of DLK1 treatment.
Additionally, it is noted that as Dlkl is already expressed the VP organ culture
system, addition of excess DLK1 creates an artificial overloading of the growth
system. Therefore, an interesting and necessary further experiment could be the
addition of Dlkl antibodies to block the effect of Dlkl activity on VP growth. If the
converse results were observed in the VPs, with an inhibition of growth and
branching, this would verify the positive effects recorded with DLK1 treatment.
Based on the findings in vitro it is speculated that Dlkl may have a similar role in
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vivo, and may be involved in regulation of VP growth and branching morphogenesis,
although whether this is via a paracrine and/or autocrine mechanism not known.
In conclusion, Dlkl was identified as a mesenchyme-enriched gene. As yet its role
remains unknown although it increases growth and branching in a VP organ culture
system, and may have a similar effect in vivo. Also, it is speculated that the
differential distribution of Dlkl in the SM layer of the male and female UGS may
play a role in the earliest stages of prostate induction, although it remains unknown if
Dlkl expression may be affected directly/indirectly by Testosterone. Finally, it is
difficult to speculate on the mechanism of Dlkl activity without knowledge of a
definite receptor and its localisation, therefore further studies are required to
understand the role of Dlkl in the developing prostate.
10.4 Notch2
10.4.1 Notch2Transcript Expression
Notch2 was identified as a VMP-enriched gene, and its expression was also
confirmed in the male UGS (P0). Therefore, as a member of the Notch family of
receptors with important roles during organ development, Notch2 was selected as an
interesting candidate mesenchymal gene. Notch2 transcript and/or protein expression
has been previously reported in other organs where development is regulated by
epithelial-mesenchymal interactions, such as the lung (Ito et al., 2000, Weinmaster et
al., 1992), kidney (Liemaster et al., 2003, McCright et al., 2001,Weinmaster et al,
1992), teeth (Mitsiadis et al., 1995) and breast (Parr et al., 2004) but not the prostate.
Other members of the Notch signalling family, Notchl and Jagged2 (a Notch ligand)
were also found expressed in the female UGS (P0), and identified as VSU-enriched
genes, thereby localising their expression to the epithelial or SM cells. Jagged2
expression has not previously been localised in the prostate but Notchl expression
has been reported in the epithelial cells of the prostatic ducts (Wang et al., 2004).
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Confirmation of Notchl expression as a VSU-enriched gene supports the validity of
the LightCycler data.
The differential distribution of Notchl and Notch2 in epithelial and mesenchymal
cells, respectively, is not unusual as their individual expression in different cell types
has been reported in other developing organs (Johnson et al., 2001, Leimeister et al.,
2003, Schroder and Gossler, 2002, Tanaka and Marunouchi, 2003, Tanimizu and
Miyahjima, 2004, Weinmaster et al, 1992), and with different members of the Notch
family having distinct functions (Kitamoto et al., 2005).
The most abundant Notch2 expression in the developing prostate was found to
coincide with the processes of prostatic bud induction (E18.5), ductal branching
morphogenesis, epithelial and mesenchymal/stromal cytodifferentiation (reviewed in
Marker et al., 2003), and suggested Notch2 has a role in one or more of these
processes. Also, the Notch2 levels in the embryonic UGS were shown to be
upregulated immediately prior to the upregulation of Dlkl expression, and it was
speculated that this is further evidence of a link between Notch2 and Dlkl activity.
The Notch family of receptors are generally known for their role in tissue patterning,
during embryonic development, but the specific role of Notch2 has not been
elucidated. Among the selected neonatal organs, expression of Notchl was most
abundant in the VP ovary, liver and testes. Notch2 expression has been previously
reported in each of these tissues (as reviewed in Kitamoto et al., 2005), except the
prostate. Additionally, it is suggested that the high levels of Dlkl found in these
tissues, would support the presence of a Notch2-Dlkl relationship. Unfortunately,
the abundant Notch2 expression in this selection of developing tissues does not
provide additional evidence of a likely role for Notch2 activity in the prostate.
10.4.2 Notch2 Protein Expression
Notch2 was found strongly expressed in the mesenchymal cells of the VMP and VP,
and was also present in the peri-urethral mesenchyme and smooth muscle layer in
the male and female UGS (P0). The protein expression in the mesenchyme was
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supported by the transcript expression data. The Notch2 expression in the SM was
of particular interest because the SM layer is generally considered to be
homogenous, but here demonstrated differential protein distribution. Also, the
Notch2 localisation in the SM was noted to be the converse of the Dlkl localisation,
where the two factors were apparently expressed in adjacent SM cells. The
significance of this distribution is not understood. Unfortunately, due to insufficient
time, this complementary expression pattern of Dlkl/Notch2 has not been verified by
co-localisation of Dlkl, Notch2, and SM a-actin. If confirmed this would support a
hypothesis that Notch2 and Dlkl are may represent a ligand-receptor relationship,
acting in a paracrine manner between adjacent SM cells, while the expression of both
molecules in the VP mesenchyme would act via an autocrine mechanism.
10.4.2.1 The Effect of Testosterone on Notch2 Protein Distribution
The Notch2 protein was localised to the mesenchyme of cultured VP organs, treated
+/- Testosterone, but no difference was observed in the distribution of protein
between the treatment groups. This experiment was not considered to be a full
investigation of whether Notch2 expression was modulated by Testosterone and
unfortunately the Notch2 the antibody tested was not compatible with Western
blotting analysis to measure protein levels. However, this experiment did confirm
that Notch2 was expressed in an in vitro VP, and could therefore, be used as a model
system for studying Notch2 function. Also, it was suggested that in the absence of a
working antibody, the levels of Notch2 transcript expression could be compared
between treated and untreated organs, but unfortunately there was insufficient time to
complete this.
Two previous studies, have proposed that Notch2 expression may modulated by
androgens. These studies have also been referred to in this thesis with relation to
Dlkl. Rats treated in utero with anti-androgens Linuron or DBP showed altered
Notch2 expression levels in the foetal (GD21) epididymis (Turner et al. 2003) and
Wolffian duct respectively (Bowman et al., 2005). Notch2 was significantly
downregulated in the epididymis, and significantly upregulated in the Wolffian duct.
As with Dlkl, these modified transcript levels were confirmed in the epididymis to
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not be the result of changes in the mesenchyme/ epithelial cell ratio, a possibility that
was ignored in the Wolffian duct. It is speculated that the altered Notch2 expression
may not be an example of androgen-regulation, but may be the indirect result of
differentiation taking place in these in the developing tissues, or due to altered
expression of its ligand. As yet, there are no conclusive studies as to the possible
effect of Testosterone on Notch2 expression.
10.4.3 Notch2 Function in the Developing Prostate
As member of the family of Notch receptors, Notch2 could have a wide variety of
roles, including determination of cell fate and tissue patterning (Kitamoto et al.,
2005). Unfortunately, due to insufficient time, the role of Notch2 during prostate
development was not studied in this thesis. The effect of a loss of Notch2 activity on
VP growth and branching morphogenesis, could have been studied using an in vitro
culture system. By adding recombinant Notch2 protein to VP cultures, this would
have acted as a ligand trap, binding the endogenous Notch2 ligands, and inhibiting
normal Notch2 activity. Alternatively, it was proposed to add an inhibitor of a
member of the Notch signalling pathway, such as Presenilin, (reported to cleave the
transmembrane Notch receptor prior to translocation to the nucleus) (as reviewed by
Baron, 2003), to cultured VPs, and thus block Notch activity. Although in this case,
the activity of all the Notchl-4 receptors could be affected, and the specific role of
Notch2 would not be characterised.
Notch 1, the only member of the Notch family previously studied in the prostate, has
been reported as essential for normal prostatic branching morphogenesis (Wang et
al., 2004) and, it is tempting to speculate that Notch2 may be of similar importance.
For example, high expression of Notch2 has been reported in the branching
embryonic lung (Ito et al., 2000) and kidney. More specifically, a study on Notch2
null mice reported perinatal mortality as a result of kidney malformation, specifically
defects in glomerular development (McCright et al., 2001). As Notch.2 expression is
found during development of branching organs, and plays a critical role in the
developing kidney, it is suggested this could be indicative of a role for Notch2 in the
developing prostate.
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Also, whileNotchl has been localised to the epithelial duct cells of the VP (Wang et
al., 2004), Notch2 expression has been demonstrated in the mesenchyme, and
therefore it is likely that each receptor has distinct roles. Also, studies have reported
that Notchl and Notch2 may have opposing effects. For example, in the mammary
gland NOTCH2 is proposed to have a tumour-suppressive role while NOTCH1 has a
tumour-promoting role (Parr et al., 2004). Consequently, it is speculated that this
may be suggest opposing roles for the receptors during development? Further work
is required to investigate Notch2 function in the prostate.
In conclusion, the Notch2 transcript was identified as a mesenchyme-enriched gene
and from its expression pattern is speculated to be involved in prostatic bud
induction and/or epithelial branching, although no functional studies were
performed. The Notch2 protein localisation confirmed the transcript data, and also
highlighted a possible receptor-ligand relationship between Notch2 and Dlkl. The
possible modulation of Notch2 expression by Testosterone remains unknown.
Further work is required to determine the role of Notch2 in prostate organogenesis,
and whether Dlkl could be acting as a receptor.
10.5 Pleiotrophin
Ptn has been associated with development of organs that are regulated by epithelial-
mesenchymal interactions. Ptn expression has been reported in the developing
kidney (Sakurai et al, 2001) and lung (Lu et al., 2003) and in the adult mammary
gland (Bernard-Pierrot et al., 2004), the adult prostate, and prostate cancer (Vacherot
et al., 1999), but has not previously been studied in the developing prostate.
10.5.1 Pleiotrophin Transcript Expression
Ptn was identified as a VMP-enriched molecule, and its expression was also
confirmed in the VP of the male UGS (P0). During development, Ptn was most
abundant in the VP during the processes of prostatic bud induction, ductal branching
morphogenesis, epithelial and mesenchymal/stromal cytodifferentiation (reviewed in
Marker et al., 2003), suggesting it has a role in one or more of these processes.
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Among selected neonatal organs, Ptn expression most abundant in the VP and ovary,
with lower levels measured in the brain, liver and testes. In support of these findings
Ptn expression has been reported previously in each of these tissues during
development (Asahina et al., 2002, Rauvala, 1989, Vanderwinden et al., 1992, Zhang
et al., 1999), and has also been implicated as a growth factor in neuroblastomas
(Nakagawara et al., 1995), testicular (Aigner et al., 2003), ovarian (Nakanishi et al,
1997) and prostate cancer (Vacherot et al., 1999). Confirmation of a growth factor
expressed during development and in cancer is further evidence in support of the
hypothesis that mis-expression of developmental factors may regulate neoplastic
growth. However, unfortunately, the organs that demonstrated high Ptn expression
also provided no clues of a likely common role in organogenesis.
10.5.2 Pleiotrophin Protein Expression
Ptn protein was immunolocalised to the mesenchymal cells of the VMP and VP, and
also to the UGM with weak expression in the smooth muscle layer. The pattern of
protein expression supports the transcript data already discussed, and also in situ
hybridsation data (not shown, G. Vanpoucke, personal communication). Of
particular interest, were the association of Ptn with the epithelial duct cells and its
gradient of expression, with the most abundant expression at the ductal tips. Co-
localisation of Ptn with P-catenin, (a cell-surface marker) confirmed that Ptn was
associated with the cell-surface, and was not expressed in the cytoplasm of the
epithelial cells. The distribution of Ptn found here is supported by previous studies
which have reported that Ptn protein interacts with heparin sulphate proteoglycans
(HSPGs) at the extracellular matrix (Vacherot et al., 1999b), and therefore, that Ptn
is often found localised at the cell-surface and basement membrane of cells
(Mitsidias et al., 1995).
Additionally, the gradient of Ptn expression exhibited in the ductal tips is reminiscent
of a study in the developing kidney. Sakurai et al., (2001), demonstrated that Ptn was
expressed in the metanephric mesenchyme of the developing mouse kidney (E13) in
vitro and was also localised to the basement membrane of the branching uteric bud,
where a concentration gradient of protein exhibited the most abundant expression at
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the uteric bud tip. Furthermore, they treated kidney cultures with recombinant Ptn
and caused an increase in the branching morphogenesis observed. Therefore, here it
is highlighted that there are similarities between the distribution of Ptn in the
developing kidney and prostate, with protein expression in the mesenchyme and also
at the sites of proliferation and growth, the uteric bud and ductal tips, respectively.
It is speculated that as Ptn has been reported to increase branching morphogenesis in
the kidney it may have a similar role in the prostate. This will be discussed in more
detail later.
The epithelial ducts tips that exhibited the most abundant Ptn expression in the
developing prostate contain undifferentiated cells, and consequently it was proposed
that Ptn might be involved in epithelial cell differentiation. Co-localisation of Ptn
with p63 (a differentiation marker) (Wang et al., 2001) in the male UGS (P0)
demonstrated no consistently positive correlation between the distributions of each
protein. At present the results are inconclusive and further work is required to
establish if Ptn plays a role in differentiation.
10.5.2.1 Effect of Testosterone on Pleiotrophin Protein Distribution
VPs cultured +/- Testosterone demonstrated that the distribution of the Ptn protein
was not affect by exposure to androgens. Unfortunately, as the Ptn antibody was not
compatible with Western blotting analysis, it was not possible to confirm if the levels
of protein expression were affected. The localisation of Ptn to the mesenchymal
cells and also to the cell-surface and basement membrane and of the epithelial cells
was similar to that that observed in vivo. Additionally, it was suggested that the
concentration of Ptn in the ducts located most distally from the urethera, was the
result of the high Ptn concentration found at these growing tips. Also, it may be
indicative of an association between Ptn and the undifferentiated cells at the ductal
tips, as opposed to the more differentiated cells proximal to the urethra. Further work
is required to study this conclusively.
Chapter 10 Discussion 165
10.5.3 Pleiotrophin Functional Studies
Ptn is a secreted factor that has been proposed to play a role in branching
morphogenesis, including the developing kidney (Sakurai et al., 2001) and mammary
gland (Bernard-Pierrot, et al., 2004, LeDoux et al., 1997). This was of particular
interest because the developing prostate is a branching organ. As already mentioned,
Sakurai et al., (2001), was able to induce an increase in branching morphogenesis, in
a concentration-dependent manner, in kidney cultures by adding conditioned medium
isolated from metanephric mesenchymal cells (containing secreted Ptn)
This thesis has highlighted the parallels between Ptn in the developing kidney and
the prostate, however, when recombinant PTN (RnD Systems) was added to VP
organ cultures, it was found to have no effect on growth or branching
morphogenesis. As a similar result had been found in the kidney with this particular
source of PTN protein (Sakurai et al., 2001) it was speculated that the recombinant
protein was inactive, as opposed to concluding that Ptn does not play a role in
prostate growth. No alternative source of PTN protein was available at the time.
Other sources of recombinant PTN, such as conditioned medium isolated from
prostate mesenchyme cells or metanephric mesenchymal cells may be more
effective, but unfortunately, due to insufficient time, these experiments were not
undertaken.
A model has been reported of the possible mechanism of Ptn activity in the
developing kidney, and here it is speculated that it may also describe a likely model
for Ptn activity in the developing prostate. Sakurai et al., (2001) proposed that
during early kidney development, the high concentration of Ptn associated with the
uteric bud tip may act as a protein "reservoir", and from here the Ptn could act in a
paracrine manner to regulate branching morphogenesis. The concentration gradient
of Ptn expression observed along the elongating uteric stalk could be generated by
matrix degrading proteases. The most abundant Ptn is found at the proliferating tips
with decreasing amounts along the length of the stalk, which may induce elongation
of the forming tubule. Also, the concentration gradient of Ptn would provide a basis
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for modulating the shape and directionality of the developing uteric bud, and help to
regulate branching morphogenesis.
Consequently, it was proposed that Ptn in the developing prostate is secreted by the
mesenchyme of the VP and becomes associated with the epithelial cells in the ducts.
Here it is bound to HSPGs and its release and activity could then be regulated by
MMPs. Several members of the MMP family have been identified in the LongSAGE
VSU library, e.g. MMP-2, -11, -14, -16 and -23, TIMP 1 and -2, and therefore could
play a role in this mechanism. Then the direction and shape of the growing epithelial
ducts would be modulated by the concentration gradient of the Ptn, with a high
protein concentration at the duct tips, and decreasing amounts along the epithelial
duct, a pattern that has already been confirmed. However, further studies are
required to investigate this hypothesis more fully. Additionally, if the mechanism of
Ptn activity is similar in two branching organs, this may be also related to other
organs with branching epithelia.
In conclusion, Ptn was identified as a mesenchyme-enriched molecule that is
abundantly expressed during prostate development. A possible association between
Ptn and regulation of differentiation remains inconclusive but it has been suggested
that similarities between the Ptn expression in the developing kidney and prostate are
indicative of a role for Ptn in regulation of branching morphogenesis during prostate
organogenesis.
10.6 Nell2
Nell2 was identified as a VMP- enriched gene and was also found in the VP of the
male UGS (P0), with the most abundant expression on the day of birth. Nell2 was
unique amongst the mesenchymal candidates, in having a very brief "window" of
expression, but the significance of this is not yet understood. Therefore, it was
concluded that Nell2 activity is most active during epithelial growth and branching
morphogenesis taking place in the VP at this time. There have been no previous
reports of Nell2 expression in the developing prostate, although Nell2 has been found
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upregulated in BPH (DiLella et al., 2001), but its role is unknown. Additionally, as
no commercial Nell2 antibody was available, it was not been possible to confirm the
distribution of the Nell2 protein.
Most research on Nell2 has concentrated on its role in neuronal development (Aihra
et al., 2003, Kuroda et al., 1999, Matsuhashi et al., 1995, Nelson et al., 2004).
Therefore, it was not surprising that among the selected neonatal organs, Nell2
expression was most abundant in the VP and brain, where its highly selective
expression suggested that there could be similarities in Nell2 activity in both tissues.
Unfortunately, little is known in general about the activity of Nell2.
Previous studies have suggested that because of its homology to the Notch/DSL,
NRG, SLIT and TSP-1 proteins, Nell2 may be acting as a signal ligand in similar key
developmental events, including; cell proliferation, apoptosis and /or as a possible
trophic factor (Aihra et al., 2003, Garcia Abreu et al., 2002, Kuroda et al., 1999,
Matsuhashi et al., 1995, Nelson et al., 2004, Watanabe et al., 1996). During neuronal
development NELL2 is proposed to act autonomously on progenitor cells and
promotes differentiation into neuronal cells, and also acts in a paracrine manner to
stimulate mitogenesis in adjacent cells (Nelson et al., 2004). Consequently, it was
speculated that Nell2 could regulate proliferation /differentiation in the prostate
mesenchyme and/or epithelial cells via an autocrine and/or paracrine mechanism.
Additionally, as a factor with a possible role in branching morphogenesis in the
developing prostate, it is interesting that Watanabe et al., (1996) has reported NELL2
expression in the early, developing kidney, although they made no suggestion of its
likely roles.
Finally, a report of NELL2 over-expression in BPH (DiLella et al., 2001) supports
the speculation that Nell2 is involved in prostate organogenesis, and more
specifically can regulate epithelial growth. Also, it supports the hypothesis of
developmental "awakening" proposed by McNeal, (1969).
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In conclusion, Neltt may be acting as proliferation and/or differentiation factor
during prostate organogenesis with a role in epithelial growth and/or branching. The
mechanism of Nell2 activity may be similar to that reported during neuronal
development.
10.7 MMP2 and MMP14
MMP2 and MMP14 were identified as VMP-enriched genes that were also expressed
in the male VP (P0). There are no previous reports of MMP2 and MMP14 transcript
or protein expression in the developing prostate, although both have been associated
with BPH and prostate cancer (Cao et al., 2005, Kuniyasu et al, 2000, Riddick et al,
2005, Ross et al, 2003, Still et al, 2000, Stearns and Stearns, 1996, Trudel et al, 2003,
Upadhyay et al., 1999). The most abundant MMP2 and-14expression was measured
in the developing VP during late embryogenesis and the perinatal period, suggesting
that both genes could be involved in prostatic bud induction and/or epithelial growth
and/or branching. Furthermore, it was demonstrated that both MMPs were expressed
at similar levels in the developing prostate at each time-point measured, a finding
which is supported by reports of the co-expression of MMP2 and MMP14 (Nuttal et
al., 2004), in a variety of tissues and the role ofMMP14 as a pro-MMP2 activator
(Sato et al., 1994).
Unfortunately, in the absence of working antibodies it was not possible to confirm
the distribution of the MMP2 and MMP14 proteins in the UGS (P0) although Karl
Sternad (MSc. student), in collaboration with this project, used zymography to
confirm the expression of pro- and active MMP2 in the male and female UGS
(P0)(personal communication, data not shown).
The discovery of MMP2 and MMP14 expression in the developing prostate was not
surprising as MMPs in general, are described as mesenchymal factors that are ideally
positioned to regulate stromal-epithelial interactions (Sternlicht and Werb, 2001).
Also, MMP2 and MMP14 have both been associated with branching morphogenesis
in other organs, such as the kidney (Kadono et al., 1998, Kanwar et al., 1999, Meyer
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et al., 2004 Miyamori et al., 2000), lung, submandibular gland (Kheradmand et al.,
2002, Oblander et al., 2005) and the mammary gland (Ha et al., 2001, Wiseman et
al., 2003). Their exact roles remain controversial, and whether they act
independently or in concert. MMPs act with TIMPS in the controlled turnover of the
ECM and thinning of the basement membrane of epithelial cells to facilitate
penetration into the mesenchyme (as reviewed in Nuttal et al., 2004). Consequently,
it was speculated that MMP2 and MMP14 may be either acting in concert or
independently, in the developing prostate to regulate branching morphogenesis, and
may also play additional roles.
Additionally, among the other selected neonatal organs tested, MMP2 and MMP14
expression was similar in each tissue, which is further support for their co-expression
with the most abundant expression measured in the VP, ovary, liver and testes. A
high expression of MMP2 and MMP14 has been previously reported in all of these
tissues (Mazaud et al, .2005, Robinson et al., 2001, Zhou et al., 2004) except the
developing prostate. Also, expression of MMP2 and MMP14 in the developing
prostate, BPH and prostate cancer may be further support for the developmental
'awakening' hypothesis proposed by McNeal, (1969).
In conclusion, MMP2 and MMP14 were identified as mesenchyme-enriched
molecules and may be involved in the processes of prostatic bud induction, epithelial
growth and branching. The strongest case is for their involvement in branching
morphogenesis, either acting in concert or independently. However further
characterisation of the distribution and function of the MMP2 and MMP14 proteins
in the developing male UGS is required.
10.8 Candidate Expression in Prostate Cancer Stroma
The mesenchyme is important not only during development, and recently, a role for
mesenchyme/stroma in cancer has been established where developmental factors
may be involved in mediating the effects of the stroma. Studies have demonstrated
that cancer associated fibroblast cells (CAF) cells have the ability to promote
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tumorigenesis in initiated, but non-tumorigenic human prostate epithelial cells,
whereas normal prostate fibroblast cells (NPFs) restrain epithelial proliferation
(Cunha et al., 2002, 2004, Grossfeld et al., 1998, Olumi et al., 1999). Therefore,
CAF cells and the molecules they express have the ability to regulate neoplastic
development (Barclay, et al., 2005, Cunha et al., 2002, 2004, Orimo et al., 2005).
Research has suggested that there is a relationship between development and
carcinogenesis, based on the observations that virtually all properties of neoplasms
have a normal counterpart in embryonic development (as reviewed by Cunha et al.,
2004). In this thesis, it was hypothesized that developmentally expressed
mesenchymal factors may be mis-expressed in prostate cancer stroma, and regulate
neoplastic epithelial development. This theory was supported by the identification of
NOTCH2, PTN, MMP2 and MMP14 expression in CAF and NPF cells, although
DLK1 and NELL2 expression were absent. PTN, MMP2 and MMP14 expression
have previously been reported in association with prostate cancer (Cao et al., 2005,
Kuniyasu et al, 2000, Riddick et al, 2005, Ross et al, 2003, Still et al, 2000, Stearns
and Stearns, 1996, Trudel et al, 2003, Upadhyay et al., 1999, Vacherot et al., 1999),
but NOTCH2 has not, although the Notch signalling pathway is known to be active
(Shou et al., 2001, Satagata et al., 2004).
Preliminary data indicated that NOTCH2 and PTN expression was modestly
downregulated in CAFs in comparison to their matched NPFs, but these results
remain inconclusive as the cells were derived from only two patients. However, it is
noted that this data supports a report by Parr et al (2004) that proposed NOTCH2
plays a tumour-suppressive role in breast cancer differentiation in contrast to a
tumour-promoting role of NOTCH1. Consequently, as Notchl upregulation is
associated with prostate cancer, and is proposed to have a tumour -promoting role in
TRAMP (transgenic adenocarcinoma of the mouse prostate) mice (Shou et al., 2001),
it is suggested Notch2 could have a tumour suppressive role in prostate cancer,
where downregulation in expression would be expected in the CAFs in comparison
to their NPFs.
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Conversely, Ptn has been reported as a playing a significant role in promoting
tumour growth and angiogenesis (as reviewed in Papadimitriou et al., 2004), and can
stimulate the proliferation of a wide range of cells including epithelial, endothelial
and fibroblastic cells, but also prevents apoptosis in vitro (Fang et al, 1992). In a
study on prostate cancer, Vacherot et al., (1999), reported that PTN mRNA and
protein was expressed in the stroma, of normal prostate, BPH and prostate cancer,
but additional PTN protein expression was also found only in the epithelial cells of
the prostate cancer. They proposed PTN was acting in a paracrine manner, secreted
by the stroma, and promoting neoplastic epithelial cell growth. Although this data
would at first appear to contradict the downregulation of PTN observed in the CAF
cells, it is suggested that as Vacherot et al., (1999) did not measure PTN levels, their
findings cannot be directly compared with the data reported here. Also, it is
suggested that the modest PTN downregulation observed might not be significant,
and levels of other transcript expression (data not shown) were found to vary
considerably between samples. Additionally, it is speculated that PTN expression
may have been altered when CAF and NPF cells were isolated from their associated
epithelial cells and cultured in vitro. The presence of PTN binding receptors on
epithelial cells undergoing neoplasia, but which are absent from normal epithelial
cells and BPH (Vacherot et al., 1999), may affect PTN expression in prostate cancer.
Therefore, levels of PTN expression in the isolated CAFs tested may have been
affected by the absence of epithelial cells and their associated PTN receptors.
Alternatively, another proposal for PTN activity in the adult prostate is in the
maintenance of homeostasis. This proposal is supported by two main facts; 1) PTN
has been associated with the regulation of homeostasis in the glandular epithelial and
myoepithelial cells of the mammary gland, during pregnancy and lactation (Bernard-
Pierrot et al., 2004, LeDoux et al., 1997), and 2) PTN expression in the adult is
normally highly restricted but is expressed in the normal adult prostate (Vacherot et
al., 1999). Therefore, perhaps the downregulation of PTN observed in the CAF cells
may be indicative of a loss of PTN activity and homeostatic regulation which
precedes neoplastic growth.
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Finally, PTN protein distribution in the human foetal prostate (15wks) was localised
to the epithelial cells and weakly in the surrounding stroma, a pattern which was
moderately similar to that observed in the neonatal male rat prostate, although Ptn
was more evident in the mesenchyme of the rat. However, further work is required
to determine if PTN is localised to the cytoplasm or the cell-surface of the epithelial
ducts, and if there is a gradient of PTN expression, as identified in the rat epithelial
ducts.
In conclusion, verification of the expression of four developmental genes; NOTCH2,
PTN, MMP2 and MMP14, in CAF and NPF cells, supports the proposal that the mis-
expression of developmental genes can result in neoplastic growth in adult tissues
McNeal (1969). Further studies are needed to confirm the modified transcript
expression measured in the CAF in comparison to the NPFs. These studies could
include the addition of recombinant PTN or NOTCH2 proteins to CAF cells
recombined with 'initiated' BPH cells in vitro.
10.9 Project Conclusions
10.9.1 A Novel Approach to Studying Prostate Development
Prostate development is a complex process involving androgen-regulation and
mesenchymal-epithelial interactions. Most studies of gene expression in prostate
development have focused on individual signalling pathways, or use techniques such
as micro-arrays that preclude the possibility of identifying novel genes. However, as
it is likely that a group of different factors regulates prostate development,
LongSAGE was considered the most comprehensive approach to studying prostate
organogenesis, providing a 'snap-shot' of the gene expression and signalling
pathways.
This project focused on the importance of mesenchyme/stroma in prostate
development and cancer. The mesenchyme/stroma produces molecules that can
regulate prostate organogenesis, and may also play a role in prostate cancer. To date,
only a few developmental mesenchymal factors had been identified and studied in
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any detail e.g Fgf7, FgflO and BMP4 (Lamm et al., 2001, Sugimura et al., 1986,
Thomson and Cunha, 1999). At the time of preparing the VSU and VMP
LongSAGE Libraries, no other rodent libraries of the developing prostate had been
published. Recently, Zhang et al., (2006) has published SAGE Libraries of
embryonic, (including UGM) neonatal, and P12 mouse prostate.
Also, the majority of research on gene expression in the prostate has concentrated on
the study of prostate cancer because of its increasing prevalence and the associated
healthcare costs. The importance of the stroma in regulation of neoplastic growth
was first highlighted over a decade ago, but the mechanisms are poorly understood
(Cunha et al., 1996, Cunha et al., 2002, Cunha et al., 2003). Prostate cancer is a
heterogeneous tissue, making it difficult to study at the cellular level. The VMP
provided a homogenous source of mesenchyme/stroma tissue, which is technically
difficult to isolate in prostate cancer. Also, identifying VMP-enriched factors in the
SAGE libraries highlighted developmental mesenchymal factors that might be active
in prostate cancer stroma.
10.9.2 How successful was the use of LongSAGE analysis?
The LongSAGE approach was found to be moderately successful in the
identification of mesenchyme-enriched specific transcripts. The VSU and VMP
Libraries were found to contain signalling pathways known to be active during
prostate development and factors upregulated during prostate cancer. Also,
LongSAGE and the subsequent bioinfomatic analysis of the data, was confirmed by
qRT-PCR analysis, to be twice as successful as 'intuitive' selection in identifying
VMP-enriched genes.
Also, it is proposed that SAGE analysis was successful in highlighting genes that
have not previously been studied in prostate development and prostate cancer. Six
candidate genes, previously not reported in prostate organogenesis, have been
confirmed as demonstrating VMP-enriched and VP expression, and one gene (Dlkl)
demonstrated a functional role in prostate development in vitro. Additional VMP-
enriched/specific genes are currently under investigation by other members of Dr.
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Thomson's research group, and their mesenchymal expression has also been
confirmed.
Furthermore, one of the major benefits of using the LongSAGE technique was the
potential identification of novel genes. The VSU and VMP Libraries, and more
specifically the list of VMP-enriched (P<0.05) tags were found to contain many
'unknown' and novel tags. It is proposed that some of these previously unrecognised
tags may represent important developmental regulatory factors that may have not
have been highlighted if SAGE had not been used. It is hoped that improvements in
characterisation of the rat genome will increase the number of genes able to be
identified.
10.9.3 How could the LongSAGE data be further mined?
The LongSAGE libraries were interrogated for candidate genes by bioinformatic
analysis and by intuitive selection. Two possible further avenues of investigation are;
1) the very low abundance transcripts (tag counts <A) and 2) using other
developmental SAGE data sets.
Statistical analysis of the SAGE Library comparison excluded genes with tag counts
<4. It was noted that this group of low abundance transcripts contained mesenchyme-
expressed genes that are known to be important during prostatic development,
including BMP4, Fgf7 and FgflO. Therefore, it is proposed that this group of low
abundance genes has not been adequately investigated and may also contain other
important regulators of prostate organogenesis.
Additionally, comparison of the VSU and VMP Libraries with other SAGE libraries,
such as those of the developing rat and human kidney (Dekel et al., 2002, Stuart et
al., 2001) may highlight genes that are commonly expressed in branching organs. It
is proposed that similarities in gene expression between developing organs may
indicate similar regulatory mechanisms. These mechanisms have been studied more
comprehensively in organs such as the kidney (as reviewed by Davies, 2002). Also,
comparison of the rat VSU/VMP Libraries with the SAGE Libraries of the
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developing mouse prostate (Zhang et al., 2006) may provide mutually supportive
evidence of the genes and signalling pathways identified.
10.9.4 is LongSAGE analysis a robust, reliable and interesting
approach to gene expression profiling?
The LongSAGE method was shown to be robust but not infallible. The contents of
the Libraries were verified based on expected gene expression and the data was
further verified using independent quantitative techniques. The 'control' transcripts
identified supported the validity of the Library data. However, preparation of the
Libraries was too expensive in terms of tissue, time and cost to repeat, and so the
reproducibility of the Libraries has not been tested. The results of the LightCycler
analysis screening suggest that quantification of the transcripts by LongSAGE was
not always accurate, although it was noted that the trends in expression were upheld
by qRT-PCR and Northern blotting analysis. It is recommended that in the future, a
more cost-efficient method than LightCycler analysis be used to screen the candidate
genes, in a high throughput manner. This would help to characterise the Library data
more fully, ensuring that quantification of the transcripts were verified. Also, if gene
expression levels were estimated by an independent technique, this could help to
indicate when a SAGE library has been adequately sampled.
As an open-ended technique, the LongSAGE approach could be considered of high
risk. In particular, the wealth of data generated has been cited as a possible
weakness when searching for candidate genes. This was overcome by comparison of
the VSU and VMP libraries and statistical analysis, which highlighted a manageable
number of VMP-enriched candidate genes (P<0.05) (218). A similar process is
commonly used to identify disease-related genes by comparison of normal and
cancer cell/tissue SAGE profiles. The additional intuitive selection process in this
project is similar to the candidate-based approach that has been used with success by
multiple research groups.
It was concluded that any problems associated with the LongSAGE technique are
outweighed by the enormous potential that an open-ended approach provides.
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Furthermore, undertaking this project has been extremely interesting and
informative, and the limited success presented in this thesis, has not fully explored
the several avenues of possible further research that the VSU/VMP SAGE libraries
represent.
10.10.5 What does the LongSAGE data tell us about prostate
development and prostate cancer?
The mesenchyme/stroma is known to produce factors that regulate prostate
development and neoplastic growth, but the mechanisms of action are not fully
understood. The VSU/VMP Libraries were shown to contain developmental
mesenchymal factors that are expressed in both the male and the female UGS (P0).
It is proposed that this data is supportive of the hypothesis that constitutive
expression of molecules in the VMP, are capable of regulating prostate development
(as reviewed by Thomson et al., 2001). However, it also raises the question of how
these factors are differentially regulated during development so that prostate growth
is induced in the male and not the female. One mechanism proposed is the
direct/indirect regulation of mesenchymal factors by androgens, but this project did
not identify any factors as androgen-regulated. Consequently, it is suggested that the
findings of the SAGE data may be supportive of an alternative mechanism proposed
for regulating prostate induction, via sexually dimorphic smooth muscle expression
(Thomson et al., 2002). In the absence of androgen-regulation, perhaps the physical
barrier of the smooth muscle layer in the female UGS is responsible for preventing
inductive factors signalling from the VMP to the epithelium. Furthermore, it is
suggested that the possible importance of the smooth muscle layer during prostate
development may be supported by the unusual distribution of Dlkl and Notch2 in the
SM, reported in this thesis.
The LongSAGE data has also provided evidence that the developing prostate
expresses signalling pathways that are active in other branched organs i.e Fgfs, Tgf(3,
MMPs, BMPs (as reviewed by Davies, 2002). Branching epithelia in different organs
share a number of anatomical features, matrix requirements and signalling pathways,
but they are by no means identical. A 'consensus model' of mammalian branching
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epithelium has been reported by Davies, (2002), but not all branching systems make
used of all the pathways in the 'consensus set'. Epithelial branching in organs such
as the kidney and lung are essential for viability, and attract greater research interest,
while the factors and mechanisms that regulate branching morphogenesis in the
prostate are poorly understood. The VSU and VMP libraries could be a valuable
data source to investigate the factors that control branching in the prostate.
However, it is also recognised that as a result of using VSU and VMP tissues to
make the SAGE Libraries, it is speculated that the genes identified in this project
may only represent factors expressed during prostate induction, and that any changes
to gene expression that take place epithelial branching could have been missed. A
common mechanism for controlling branching epithelia has been proposed for the
developing kidney and lung (as reviewed by Davies, 2002), where the tips of a
branching tubule renders the mesenchyme incapable of supporting further branching
after it has passed through it. Therefore, it is possible that the prostate mesenchyme
may only act to regulate epithelial branching once the epithelium has invaded the
virgin mesenchyme, and the epithelia may induce changes in the local mesenchyme
as it passes through it. These local changes in gene expression in the mesenchyme
would be absent from the SAGE libraries prepared.
Finally, the LongSAGE libraries and the subsequent characterisation of genes
expressed in the developing rat prostate and the human CAF cells has supported the
use of a developmental model when looking at neoplastic growth in the prostate, and
the theory of developmental 'awakening' proposed by McNeal (1969). The
LongSAGE libraries provided a useful source of data for comparison with prostate
cancer, with the ability to highlight the mesenchymal/stromal compartment.
Identifying the genes that are mis-expressed during prostate cancer, and
understanding the factors that regulate their expression, could represent useful
therapeutic targets.
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10.10 Final Summary
The aim of this thesis was to identify mesenchyme specific/enriched genes that
regulate normal and neoplastic growth. The LongSAGE technique was used to
generate comprehensive transcriptome profiles of the VSU and VMP tissues micro-
dissected from the female rat UGS (P0). The expression of 'control' genes within the
Libraries confirmed the validity of the data. Candidate gene transcripts were selected
from the Libraries for further studies either by bioinformatic analysis or intuitive
selection. The genes selected had not previously been reported in association with
the developing prostate.
Six candidate transcripts; Dlkl, Notch2, Ptn, Nell2, MMP2 and MMP14 were
confirmed as showing VMP-enriched transcript expression in the female UGS (P0).
Candidate transcript expression was also identified in the VP of the male UGS (P0),
and the levels of expression were studied from embryonic to adult life. Each
candidate demonstrated the most abundant expression during late embryogenesis and
the perinatal period. Investigation of the candidate protein distribution confirmed the
localisation of Dlkl, Notch2 and Ptn to the mesenchymal cells of the VMP and VP.
Each protein also exhibited an individual distribution pattern in the UGM and SM
layer of the UGS. An unusual and complementary pattern of Dlkl and Notch2
expression in the smooth muscle layer, apparently in adjacent cells, suggested they
represented a possible receptor-ligand relationship in the Notch signalling pathway.
The significance of this is not yet understood. Ptn, on the other hand, demonstrated a
strong association with the cell-surface of the epithelial cells in the VP, and a
gradient of expression, which has been likened to a model of Ptn activity in the
developing kidney. Consequently, it was speculated that the prostate and kidney
might share similar regulatory mechanisms involving Ptn, during branching
morphogenesis. Furthermore, the function of one of the candidates was successfully
tested in on VP cultures in vitro. Addition of rhDLKl to the cultures caused an
increase in the size of the organ and the amount of epithelial branching in the VP. It
is proposed that Dlkl may also play a similar role in vivo. Finally, the possibility
that developmental mesenchymal factors may be active during neoplastic
development was studied using isolated human CAF and NPF cells. Four of the six
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candidates were expressed in both cell types, but levels of NOTCH2 and PTN were
found moderately downregulated in CAFs in comparison to their matched NPFs.
PTN protein expression was also confirmed in the human foetal prostate.
In conclusion, this project has been successful in generating two LongSAGE
Libraries, which were used for the identification of six mesenchymal genes, at least
one of which has demonstrated the ability to regulate prostate growth in vitro.
Furthermore, some of the developmental mesenchymal factors were also found
expressed in prostate cancer stroma cells, and therefore may represent therapeutic
targets, although this remains to be investigated in the long-term.
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APPENDIX
VMP-enriched genes (P<0.05) identified by LongSAGE analysis
Genes selected for LightCycler analysis
'Candidate genes selected after LiqhtCycler analysis
Tag VMP vsu fold P-value Unigene Description genomic BLAST
ATAACACAT
AAAAAAAA
492 363 1.4 4.38E-02 11317 protein tyrosine phosphatase, non¬
receptor type 1
no hits, not 3' tag
GACTTTGGA
AAACATTT
370 139 2.7 4.67E-05 2953 collagen, type 1, alpha 1 unique hit
GGCTATGTA
AAATTTTC
362 258 1.4 3.25E-02 106103 decorin unique hit
TTTGGTTTTC
CAAAAAG
252 142 1.8 9.76E-05 107239 procollagen, type I, alpha 2 unique hit
CGAACTCTC
ACAGTGAT
236 142 1.7 1.16E-03 98989 secreted acidic cysteine rich
glycoprotein
unique hit, also called osteonectin
TGTTCCTCTT
GCTTTAA
158 83 1.9 3.67E-04 3247 collagen, type III, alpha 1 unique hit
TGCTACCCT
TCTAAAAA






151 91 1.7 9.69E-03 98160 smooth muscle alpha-actin multiple hits
CATTTTCTG
GCAAAATC
124 34 3.6 2.35E-05 964 insulin-like growth factor 2 unique hit
TGGAAATGA
AAAAAAAA
108 51 2.1 4.85E-04 2953 collagen, type 1, alpha 1 multiple genomic hits
TGGAAATGA
CCCAAAAA
105 52 2.0 1.34E-03 2953 collagen, type 1, alpha 1 multiple genomic hits
GATCACCTG
TTTTATAC
99 39 2.5 5.41E-05 17012 Rattus norvegicus similar to
microfibril-associated glycoprotein
1 (LOC313662), mRNA
similar to microfibril-associated glycoprotein 1
Tag VMP vsu fold P-value Unigene Description genomic BLAST
TAGAATTCA
GATTCCCC
97 57 1.7 2.71 E-02 1046 transforming growth factor, beta
induced, 68 kDa
unique hit, close to novel transcript with homology
to TGFbeta induced 68kDa (betaIG-H3)
AGAGAGGCA
GCAGAGAA
92 55 1.7 3.93E-02 12328 Rattus norvegicus similar to
RIKENcDNA 1110007F23
(LOC287382), mRNA
unique hit close to novel transcript with similarity
to mRIKEN cDNA 1110007F23 (= MFAP4:
microfibrillar associated protein 4
TGGAAATGA
CCCAACGC
88 40 2.2 8.99E-04 2953 collagen, type 1, alpha 1 unique hit -collagen, type 1 , alpha 1
CCCAATGGC
CCAATAAA
85 44 1.9 7.27E-03 11889 Rattus norvegicus similar to





84 43 2.0 6.52E-03 8527 Rattus norvegicus transcribed
sequence with strong similarity to
protein pir:S55054 (H.sapiens)






78 34 2.3 9.81E-04 94978 actin, beta multiple genomic hits
CCCTGAGTC
CACACCGG
78 34 2.3 9.81E-04 115044 Rattus norvegicus transcribed
sequence with moderate similarity
to protein pir:S50866 (H.sapiens)
S50866 translation initiation factor
4E-binding protein 1
unique hit no assigned rat locus within 5kb
ACAAATAAA
CCAACTTT
77 39 2.0 8.03E-03 47029 SEC61, alpha subunit (S.
cerevisiae) unique hit-Sec61 alpha- 1
GGAAATGGC
AAAAAGTA





61 33 1.8 3.60E-02 multiple random hits
TCTCACCAA
CCCCACCT
55 24 2.3 5.68E-03 54384 elastin hit - elastin
Tag VMP vsu fold P-value Unigene Description genomic BLAST
TCTCACCAA
CCCCACCT
55 24 2.3 5.68E-03 11372 lysyl oxidase
ATGTAGTAG
TGTCTTAC
54 20 2.7 1.14E-03 33807 Rattus norvegicus similar to CCT
(chaperonin containing TCP-1) zeta
subunit (LOC288620), mRNA




54 20 2.7 1.14E-03 94022 RNA binding protein p45AUFl
CTAATAAAT
GTTTTTGG
53 26 2.0 2.07E-02 102247 Rattus norvegicus similar to DREV
protein (LOC300672), mRNA
similar to DREV protein
CTAATAAAT
GTTTTTGG
53 26 2.0 2.07E-02 109804 Rattus norvegicus transcribed
sequences
unique hit, part of mDREV protein
TGTATAAAA
ATAAAAAA
51 19 2.7 1.66E-03 101146 Rattus norvegicus similar to
Endoplasmin precursor
(Endoplasmic reticulum protein 99)
(94 kDa glucose-regulated protein)
(GRP94) (ERP99) (Polymorphic
tumor rejection antigen 1) (Tumor
rejection antigen gp96)
(LOC362862), mRNA
unique hit- wrong direction- close to named gene
CCTAGCCCC
TCCCACCA
49 15 3.3 3.22E-04 7961 Rattus norvegicus similar to latent
transforming growth factor-beta
binding protein 4S (LOC292734),
mRNA
unique hit, close to novel transcript with homology
to mLTbp4 short splice variant
TTTGGTTTTC
CAAAAAA




38 13 2.9 3.47E-03 14547 delta-like 1 homolog (Drosophila) unique hit
TTCAATTAA
AATCAGTT
37 14 2.6 8.25E-03 19642 Rattus norvegicus similar to Ik
protein (LOC291659), mRNA
unique hit, close to novel transcript with homology
to Ik protein (RER)
CACTCATTT
AAAAATAA
34 13 2.6 1.22E-02 2862 calpain 6 unique hit
TATTTCAGT
GAAATATT
33 13 2.5 1.65E-02 3313 adenylyl cyclase 6 unique hit
Tag VMP vsu fold P-value Unigene Description genomic BLAST
AAATAAAGT
CTGAAAAC
29 10 2.9 1.12E-02 2163 agrin unique hit
TGGAAAACA
CCAAATAA
28 7 4 2.12E-03 22352 Rattus norvegicus similar to
gamma-filamin (LOC362332),
mRNA
unique hit- similar to gamma-filamin
TTTTAAAAT
AAACAATT
27 7 3.9 3.08E-03 37666 Rattus norvegicus similar to tweety
homolog 2 (LOC304315), mRNA ,
RIKENcDNA 2900029G13













23 6 3.8 6.48E-03 No exact hit in rat genome
TAACAGAAG
TCCAGAAG
23 6 3.8 6.48E-03 2875 collagen, type V, alpha 2 unique hit- wrong direction - close to collagen, type
V, alpha 2 (Col5a2), mRNA
TATAACGAG
CCAATATC
22 8 2.8 3.47E-02 54261 four and a half LIM domains 1 multiple genomic hits
TGAAAGCCC
CACTGAAC
22 8 2.8 3.47E-02 9073 Rattus norvegicus transcribed
sequence with moderate similarity
to protein pdb:lLBG (E. coli) B
Chain B, Lactose Operon Repressor
Bound To 21-Base Pair Symmetric
Operator Dna, Alpha Carbons Only
unique hit, close to novel transcript with wimilarity















Tag VMP vsu fold P-value Unigene Description genomic BLAST
AATAAATGA
CCCTATCT
21 7 3 2.66E-02 8685 Rattus norvegicus transcribed
sequence with moderate similarity
to protein ref:NP_001488.2
(H.sapiens) UDP-Gal:betaGlcNAc








20 6 3.3 1.96E-02 3437 small nuclear ribonucleoprotein
polypeptides B and B1
Small nuclear ribonucleoprotein associated protein




19 6 3.2 2.81E-02 106103 decorin unique hit
AGATGTACT
GTACCTTT
18 3 6 3.67E-03 7055 Rattus norvegicus similar to VE-
cadherin (LOC307618), mRNA
unique hit- no assigned gene locus within 5kb
CTCTGACTTT
ACCCTGT
18 5 3.6 2.01E-02 2269 basigin unique hit
GCTTAGCCA
TTTCCTGT
18 5 3.6 2.01E-02 91417 Rattus norvegicus similar to
microtubule-associated protein 4
(LOC367171), mRNA




18 6 3 4.01E-02 2517 Rattus norvegicus similar to LIM
domain only 4; LIM only 4; ethanol




17 3 5.7 5.58E-03 774 laminin, beta 2 unique hit
GGCCTGGGT
TACTTTAC
16 3 5.3 8.48E-03 102346 Rattus norvegicus similar to
hypothetical protein 5730443G10
(LOC303260), mRNA
unique hit, close to novel transcript with homology
to sperm associated antigen
CTGGGGCAT
CCGTAGAT
16 5 3.2 4.24E-02 no hit in rat genome, mitochondrial sequence
TTTTTACTGA
TGTTCGT
16 5 3.2 4.24E-02 8450 Rattus norvegicus similar to
integral membrane protein 2C
(LOC301575), mRNA
unique hit, close to novel transcript with similarity
to Mus musculus integral membrane protein 2C
(Itm2c)
Tag VMP vsu fold P-value Unigene Description genomic BLAST
ATGACTGAG
CCCCTAAT
15 2 7.5 4.76E-03 2595 Rattus norvegicus similar to
divalent cation tolerant protein
CUTA (LOC294288), mRNA unique hit- in wrong direction
CACTTCCTC
CTGGGTTT











15 3 5 1.29E-02 8538 splicing factor, arginine/serine-rich
(transformer 2 Drosophila
homolog) 10
unique hit- no loci within 5kb
GCCCGTGCC
ACCCTTGC
15 3 5 1.29E-02 1226 Rattus norvegicus similar to
GAMM1 protein (LOC300258),
mRNA




15 3 5 1.29E-02 7967 Rattus norvegicus similar to SON
protein (LOC304092), mRNA
Unique hit, close to novel transcriipt belonging to
the SON protein family
TGTTAGAGT
CTAATCTG
15 3 5 1.29E-02 16968 Rattus norvegicus transcribed
sequences
uniqueht hit, 1.5kb from retinol dehydrogenase 10
TAAATATCT
GTGTCCCC
15 4 3.75 2.98E-02 29232 step II splicing factor SLU7 no exact hit in rat genome
GGGATTTGT
GGGGGCAG
14 3 4.67 1.95E-02 2458 tubulin, beta 5 unique hit
GATAAAGCA
AGATTTCC
14 4 3.5 4.40E-02 120904 Rattus norvegicus transcribed








14 4 3.5 4.40E-02 3552 Rattus norvegicus similar to
CG14967-PA (LOC303280),
mRNA
unique hti, close to novel transcript with homology




14 4 3.5 4.40E-02 10600 transcription factor 8 unique hit
Tag VMP vsu fold P-value Unigene Description genomic BLAST
GTTTGTACA
ATAAATAC
14 4 3.5 4.40E-02 37338 latent transforming growth factor









13 1 13 3.63E-03 23810 casein kinase 1, alpha 1 unique hit
TATTTTCAG
CATTTTTG
13 2 6.5 1.14E-02 2744 Rattus norvegicus transcribed
sequences
No exact hit in rat genome
TACACTCCC
CCCTACTC
13 3 4.33 2.94E-02 8628 protocadherin gamma subfamily C,
3
only 1 EST seq to confirm => more likely to be
gluco reg kinase tag
TACACTCCC
CCCTACTC





12 2 6 1.77E-02 fibronectin unique hit, 2kb from mRIKEN cDNA1200009022,
fibronectin like containing structures
TTCTTGACTT
TCCCAGA
12 2 6 1.77E-02 18947 paralemmin unique hit
TAAACGTTT
TCAGGGAA
12 3 4 4.42E-02 69085 Rattus norvegicus transcribed
sequence with moderate similarity
to protein pir:I39175 (H.sapiens)
139175 SH2-domain protein Grb-IR
unique hit, 2.5kb from mGrblO locus (growth
factor receptor binding protein)
TGACAGTGT
TCATTAAC
12 3 4 4.42E-02 3882 Rattus norvegicus similar to
cleavage and polyadenylation
specific factor 5; cleavage and
polyadenylation specific factor 5,
25 kD subunit (LOC291877),
mRNA




12 3 4 4.42E-02 3622 hypothetical protein CDA08 unique hit -close to T-cell immunomodulatory
protein (TIP protein) (CDA08-like protein)
TTAATGTAT
CGTCTTAA
12 3 4 4.42E-02 115615 Rattus norvegicus transcribed
sequence
unique hit, part of RIKEN cDNA 2310047C21 (=
CDA08 protein, TIP protein, predicted membrane
protein)
Tag VMP vsu fold P-value Unigene Description genomic BLAST
AAGCTAAAC
GCTGGTAT
11 1 11 9.05E-03 106046 Rattus norvegicus similar to
RIKEN cDNA 2310047013
(LOC291320), mRNA
unique hit, close to novel transcript with homology




11 1 11 9.05E-03 79423 Rattus norvegicus similar to
Wbscrl (LOC288599), mRNA




11 1 11 9.05E-03 8257 Rattus norvegicus transcribed
sequences




11 1 11 9.05E-03 No exact hit in rat genome
GGTAAACAC
AAATGAAT
11 2 5.5 2.73E-02 96446 Rattus norvegicus similar to
RIKEN cDNA 5330414D10
(LOC311726), mRNA
unique hit, lkb from novel transcript
TAAAAGTTG
TTATACTA
11 2 5.5 2.73E-02 4309 syntenin Syntenin 1 (Syndecan binding protein 1)
TAACAGTTG
CGTCTTAA




11 2 5.5 2.73E-02 19707 Rattus norvegicus similar to
importin 9 (LOC304817), mRNA
unique hit- wrong direction - similar to importin 9
TGTTAAGAT
GTATGTGA
11 2 5.5 2.73E-02 29900 Rattus norvegicus transcribed
sequences




11 2 5.5 2.73E-02 16536 Rattus norvegicus transcribed
sequence with strong similarity to
protein pdb: 1LBG (E. coli) B Chain
B, Lactose Operon Repressor
Bound To 21-Base Pair Symmetric
Operator Dna, Alpha Carbons Only
unique hit, no assigned loci within 5kb
TGTTTTGGA
ACATTTAT
10 0 0 3.60E-03 101054 Rattus norvegicus similar to RAN




Tag VMP vsu fold P-value Unigene Description genomic BLAST
TGTTTTGGA
ACATTTAT
10 0 0 3.60E-03 110951 Rattus norvegicus transcribed
sequence with moderate similarity






10 1 10 1.43E-02 22555 Rattus norvegicus similar to
KIAA0368 (LOC313196), mRNA
unique hit, close to novel transcript with homology
to m AI314180 expressed sequence
TAAGAGCTC
TTTCCATC
10 1 10 1.43E-02 8672 Rattus norvegicus similar to
hypothetical protein, estradiol-
induced (LOC308843), mRNA
unique hit, close to novel transcript, with similarity
to h estradiol-induced (E2IG4) - NM_015516
TAGACTGCC
TCACAATA






10 1 10 1.43E-02 55771 Rattus norvegicus transcribed
sequence with moderate similarity
to protein pir:I60307 (E. coli)
160307 beta-galactosidase, alpha
peptide
unique hit, novel transcript in neighourhood but not
clear if tag is part of it...
AGTTAAGCA
TACTTGTT





10 2 5 4.22E-02 101845 Rattus norvegicus similar to
enthoprotin; epsin 4; clathrin
interacting protein localized in the
trans-Golgi region (LOC317516),
mRNA
unique hit- no assigned gene locus within 5kb
GTGTGTGGT
GCCCCCAG
10 2 5 4.22E-02 3222 Rattus norvegicus transcribed




unique hit close to novel transcript with similarity
to prion protein interacting protein 1
TACATAGGA
TTGTTTGC
10 2 5 4.22E-02 1476 peripheral myelin protein 22 unique hit
Tag VMP vsu fold P-value Unigene Description genomic BLAST
TCAGAATTT
AGCCATAT
10 2 5 4.22E-02 94979 Rattus norvegicus similar to
Hypothetical protein FLJ25422
(LOC294789), mRNA
unique hit, close to novel transcript with similarity
to human hyp prot FLJ25422
TCTGGCAGT
CTCCTTCA
10 2 5 4.22E-02 79893 Rattus norvegicus similar to
karyopherin beta 3; Ran_GTP
binding protein 5; importin beta-3
subunit (LOC306182), mRNA
unique hit- close to named transcript
TCTGGCTCC
TTTACAAA
10 2 5 4.22E-02 17033 Rattus norvegicus similar to RNA
binding motif protein 5
(LOC300996), mRNA
unique hit- wrong direction -similar to RNA
binding motif protein 5
TGGGCATAG
CTGAGGTG
10 2 5 4.22E-02 41133 Rattus norvegicus transcribed
sequences
unique hit, 2kb from novel transcript with similarity




10 2 5 4.22E-02 106222 Rattus norvegicus similar to Murine
homolog of human ftp-3
(LOC308650), mRNA
unique hit, close to novel transcript with homology




9 0 5.74E-03 12759 fibrillin-1 no hit, no poly A
ACGCTGTAC
AGAATTTT
9 1 9 2.28E-02 20981 phosphodiesterase 9A unique hit
ACTGTGTTG
TAATATAG
9 1 9 2.28E-02 101908 Rattus norvegicus similar to
hypothetical protein DJ667H12.2
(LOC360899), mRNA
unique hit, close to novel transcript with similarity
to hyp protein DJ667H12.2
ATGTGTATG
TTTTAACT





9 1 9 2.28E-02 2560 Rattus norvegicus transcribed
sequences
2 genomic hits, no transcripts in neighbourhood
CAGTTGGTT
GTAAATTC
9 1 9 2.28E-02 95170 Rattus norvegicus similar to EIB-
55kDa associated protein 5
(LOC361522), mRNA
unique hit, lcose to novel transcript with homology
to ElB-55KDA-associate proteub 5 isoform A
GGAGCTGGC
TGCTGAGG
9 1 9 2.28E-02 41227 Rattus norvegicus transcribed
sequences
unique hit, close to novel transcript with homology
to ADAMTS-1 precursor
Tag VMP vsu fold P-value Unigene Description genomic BLAST
GTCAAAGTT
CTGTGTCT
9 1 9 2.28E-02 9517 nucleolar phosphoprotein pl30 unique hit
TACATACGT
ACATAAAT
9 1 9 2.28E-02 70655 Rattus norvegicus similar to
Probable ATP-dependent RNA
helicase DDX27 (DEAD-box
protein 27) (LOC362274), mRNA
unique hit, close to DDX27
TATTAACTC
TCCTCGGA
9 1 9 2.28E-02 22808 Rattus norvegicus transcribed
sequences




9 1 9 2.28E-02 28161 fatty acid desaturase 1 unique hit
TGACTGCTG
CTTCAATA
9 1 9 2.28E-02 unique hit, no assigned locus in same direction
TTTAGTGAC
GTTTACAT
9 1 9 2.28E-02 94887 Rattus norvegicus transcribed
sequences




8 0 9.21E-03 119131 Rattus norvegicus transcribed
sequence with strong similarity to
protein sp:P00722 (E. coli)
BGAL_ECOLI Beta-galactosidase
(Lactase)
unique hit, no assigned locus in neigbourhood
GTGTGGTTC
CCAGGCAT
8 0 9.21E-03 6171 H19 fetal liver mRNA unique hit
AATAAACTT
TGCTTTCC
8 1 8 3.63E-02 28050 Rattus norvegicus similar to pre B-
cell leukemia transcription factor 3
(LOC311876), mRNA
unique hit, close to Pbxl (or 3?)
CACACACAA
ACACACAC
8 1 8 3.63E-02 24541 Rattus norvegicus similar to old
astrocyte specifically induced
substance (LOC362165), mRNA
100s of genomic hits
CATACGCTC
ACAAAAGA
8 1 8 3.63E-02 unique hit, novel transcript at 5kb, based on mouse
data, tag comes from ribophorinl
CCTTAGGTC
GTCTGTGA
8 1 8 3.63E-02 30223 Rattus norvegicus similar to
RIKEN cDNA 0610027018
(LOC363171), mRNA
Unique hit close to rat transcript -XP_343511.1
Tag VMP vsu fold P-value Unigene Description genomic BLAST
CTGCAGCAA
AAGTTTAC
8 1 8 3.63E-02 10293 low density lipoprotein receptor-




8 1 8 3.63E-02 1878 Rattus norvegicus transcribed
sequences
unique hit, no assigned locus within 5kb
GCAATCATT
TCATACTT
8 1 8 3.63E-02 1712 Rattus norvegicus transcribed
sequence with moderate similarity
to protein prf:2018199A (E. coli)
2018199A beta lactamase IRT-4
[Escherichia coli]




8 1 8 3.63E-02 9547 Rattus norvegicus transcribed
sequences
unique hit, 5kb from novel transcript with similarity




8 1 8 3.63E-02 22787 Rattus norvegicus similar to sprouty
1 (LOC294981), mRNA









8 1 8 3.63E-02 101799 Rattus norvegicus Ab2-450 mRNA,
complete cds
unique hit, close to MAN2B2 locus (Mannosidase
alpha class 2B member 2
TTAATTTCTC
ATAAAAG
8 1 8 3.63E-02 1100 Rattus norvegicus similar to Pon2
protein (LOC296851), mRNA
unique hit, close to novel transcript with similarity
to Pon2 9 (serum paraxonase/arylesterase 2)
ATTGTATTCT
TTCTGCC






7 0 1.48E-02 36822 Rattus norvegicus transcribed
sequences
unique hit, no assigned locus in neigbourhood
CAGCATAAA
TTAATTGT
7 0 1.48E-02 7015 Rattus norvegicus similar to DIP13
beta (LOC362860), mRNA
unique hit, overlaps with mouse dip3 locus, dip 13)
CCCCCAATT
CTGTGGCG
7 0 1.48E-02 12939 vesicle-associated membrane
protein 2
unique hit
Tag VMP VSU fold P-value Unigene Description genomic BLAST
CCCCCAATT
CTGTGGCG
7 0 1.48E-02 114545 Rattus norvegicus transcribed
sequence with moderate similarity
to protein pdb:lLBG (E. coli) B
Chain B, Lactose Operon
Repressor Bound To 21-Base Pair
Symmetric Operator Dna, Alpha
Carbons Only




7 0 1.48E-02 84878 Rattus norvegicus similar to




7 0 1.48E-02 23175 Rattus norvegicus transcribed
sequence with moderate similarity
to protein pir:RGECDW (E. coli)
RGECDW transcription activator
of D-serine dehydratase
unique hit, close to novel transcript with homology to
vascular endothelial zinc finger 1 (= ZnF 161)
CTGAGGTAT
TCTTGCAA
7 0 1.48E-02 3507 Rattus norvegicus similar to ATP
sulfurylase/APS kinase
(LOC295443), mRNA




7 0 1.48E-02 no unique hit
GGAAGAGGC
AGGACCAC
7 0 1.48E-02 2924 Rattus norvegicus transcribed
sequence with weak similarity to
protein prf:2018199A (E. coli)
2018199A beta lactamase IRT-4
[Escherichia coli]









7 0 1.48E-02 3247 collagen, type III, alpha 1 unique hit
Tag VMP vsu fold P-value Unigene Description genomic BLAST
TTTTCTAGTG
AATAAAT
7 0 1.48E-02 7870 Rattus norvegicus transcribed




associated protein 1; chromosome
condensation-related SMC-
associated protein 1; KLAA0159
gene product
unique hit, close to novel transcript with homology to
chromosome condensation-related SMC-associated
protein 1 (structural maintainance of chromosomes)
AAAAAATAA
ATATATTT
6 0 2.41 E-02 40381 Rattus norvegicus transcribed
sequences
unique hit, no assigned locus within 5kb
AAATAAAAC
AGGCAACT
6 0 2.41 E-02 22244 Rattus norvegicus transcribed
sequences
unique hit, > 5kb from closest assigned transcript
AATGCGAAC
ACCATCAC
6 0 2.41 E-02 25144 squamous cell carcinoma antigen
recognized by T-cells 1
no hits in same direction
ATACTGACA
CTTNGTAG
6 0 2.41E-02 No exact hit in rat genome
CACGCACAG
TCAGCCGA
6 0 2.41E-02 11305 dentatorubral pallidoluysian
atrophy (=atrophin 1)
unique hit, part of DRPL gene, atrophin 1
CACTGTGCC
TTCAAGAT
6 0 2.41E-02 35353 Rattus norvegicus transcribed
sequences
unique hit, 3.5kb from carboxypeptidaseD locus
CAGTTTGTA
CATTTACT
6 0 2.41 E-02 32253 Rattus norvegicus transcribed







6 0 2.41E-02 101891 zinc finger protein Y1 (RLZF-Y) multiple genomic hits
CCGCTTGAG
ACTCCTTC
6 0 2.41 E-02 25124 Rat insulin-like growth factor I
mRNA, 3' end of mRNA
chr7,3.5kb from Igfl locus
CCTCACTTA
ACTCTTAA
6 0 2.41E-02 12859 Rattus norvegicus transcribed
sequences
multiple genomic hits
Tag VMP vsu fold P-value Unigene Description genomic BLAST
CCTCTGTTTG
GTGGTAA
6 0 2.41 E-02 100120 cysteine string protein (chaperone) unique hit no assigned rat locus within 5kb
CCTTTATCCC
AATTCCT
6 0 2.41E-02 No exact hit in rat genome
CTAGCTCAC
TAAGGGCA
6 0 2.41E-02 37737 iGb3 synthase unique hit
CTCCAATAA
TTGATATT
6 0 2.41E-02 94808 protein kinase inhibitor, alpha unique hit
CTGGCCTCT
GAGGCTGG
6 0 2.41 E-02 20730 Rattus norvegicus transcribed
sequence with weak similarity to
protein pir:S10889 (H.sapiens)
S10889 proline-rich protein
unique hit, close to vnovel transcript with
homology to hKLAA0720 protein
CTTGCATAA
AATTTAAG
6 0 2.41 E-02 16704 Rattus norvegicus transcribed
sequence with weak similarity to
protein pir:S15433 (Mmusculus)
S15433 hypothetical protein
unique hit, chrX, no assigned transcript within 5kb
GAGACGGAG
TCCAAAGG
6 0 2.41 E-02 63247 Rattus norvegicus similar to
chromodomain helicase DNA
binding protein 4; Mi-2b
(LOC312712), mRNA
hit close to named transcript
GCAGATGTT
ATGAATTG
6 0 2.41 E-02 13832 Rattus norvegicus transcribed
sequences




6 0 2.41 E-02 40510 Rattus norvegicus transcribed
sequences
2kb from Wnt4 locus??
GGTAGGAGC
ACCGCACT
6 0 2.41 E-02 72442 Rattus norvegicus similar to TBC1
domain family, member 8; BUB2-
like protein 1; vascular Rab-
GAP/TBC-containing
(LOC360520), mRNA
unique hit, close to novel transcript with homology
to KIAA clone of the TBC1 domain family
GTGAAAGAA
TAAATGCA
6 0 2.41 E-02 98686 Rattus norvegicus similar to KDEL
containing protein 1; endoplasmic
reticulum-resident KDEL protein
(LOC315664), mRNA
< 5kb -similar to KDEL containing protein 1;
endoplasmic reticulum-resident KDEL protein [
Tag VMP vsu fold P-value Unigene Description genomic BLAST
GTGAAAGAA
TAAATGCA
6 0 2.41 E-02 14013 Rattus norvegicus transcribed
sequences
uniquehit, 2kb from mRIKEN cDNA 2010004J24
GTGTACATT
GTTCTTAT
6 0 2.41E-02 34113 Rattus norvegicus similar to
hypothetical protein MGC10067
(LOC360514), mRNA




6 0 2.41E-02 24229 Rattus norvegicus transcribed
sequences
unique hit, lkb from mBTB and Kelch domain
protein2 = Kelch-like 13 (Klhll3)
TAAATAACT
TTTCTCCA
6 0 2.41E-02 8311 Rattus norvegicus transcribed
sequence with weak similarity to
protein sp:Q64707 (M.musculus)
U2R1_M0USE U2 small nuclear
ribonucleoprotein auxiliary factor
35 kDa subunit related-protein 1
(SP2)
unique hit- wrong direction
TAAATATAA
TTTATTGT
6 0 2.41 E-02 3989 Rattus norvegicus transcribed
sequences
unique hit, lkb from mCyclinG2 locus
TCCAATAAA
GAGCTGAG
6 0 2.41E-02 No exact hit in rat genome
TGCACGACT
ATGTTATT
6 0 2.41E-02 8266 Rattus norvegicus transcribed
sequences
unique hit, 3kb from novel transcript with similarity
to RING1 and YY1 binding protein (Rybp)
TGGTCTCTT
AATCCAGT
6 0 2.41 E-02 98823 Rattus norvegicus similar to
KIAA1064 protein (LOC308385),
mRNA
unique hit- no assigned gene locus within 5kb
TTCCTGACT
AAATGTAG
6 0 2.41E-02 65930 notch gene homolog 2,
(Drosophila)
unique hit, 2.5 kb from Notch2 locus
TTGATTGTCT
ATGTTGT
6 0 2.41 E-02 12498 Rattus norvegicus transcribed
sequences




6 0 2.41 E-02 9376 Rattus norvegicus transcribed
sequences







Tag VMP vsu fold P-value Unigene Description genomic BLAST
AAAATTTCT
TGGCAAAA
5 0 3.95E-02 6532 Rattus norvegicus transcribed








5 0 3.95E-02 53915 PV-1 no hits
AACTACACC
TGCTGTAA
5 0 3.95E-02 9609 cystatin N maps to cystatin E/M locus
AACTCCCCG
TGTCTGTC
5 0 3.95E-02 27227 Rattus norvegicus transcribed
sequences
unique hit, 5kb from bcl-2 locus
AAGTAGTGT
GACTCGGG
5 0 3.95E-02 6570 Rattus norvegicus similar to
vaccinia related kinase 3
(LOC361565), mRNA
unique hit, close to hVRK3
AATAAAGAT
AATATAAC





5 0 3.95E-02 61277 Rattus norvegicus similar to
hypothetical protein D930024B17
(LOC303552), mRNA
unique hit, close to novel transcript
ACAGACAGA
ACATTCCC
5 0 3.95E-02 No exact hit in rat genome
ACCCTGGTG
GGAGACAA
5 0 3.95E-02 16016 Rattus norvegicus putative eps
protein (MGEPS) mRNA, partial
cds
unique hit, 2kb from transcript homolog to EHD2
ACTGGAGTT
TGCTTTGT
5 0 3.95E-02 unique hit 2kb from polyA polymerase alpha
AGAATGAAG
TTCACAAG
5 0 3.95E-02 2918 Rattus norvegicus similar to
MUM2 protein (LOC287427),
mRNA
unique hit, close to mVoltage gated K channel
AGATAAGCA
GGAAGTTC











Tag VMP vsu fold P-value Unigene Description genomic BLAST
AGGAGATGG
AGAACTTT
5 0 3.95E-02 93304 Rattus norvegicus similar to
TRAF-binding protein
(LOC293571), mRNA
unique hit, close to novel transcript with homology to
TRAF binding protein (TRABID)
AGTGTGTAC
AAGCTTAG




5 0 3.95E-02 No exact hit in rat genome
ATGCTGAGA
GGAAGCTT
5 0 3.95E-02 52627 Rattus norvegicus similar to
hypothetical protein
(LOC366980), mRNA
unique hit, close to novel transcript with homolgy to
mRIKEN cDNA 4432409D24 = Arid rfx like
ATTAGTTAA
CAAACATC
5 0 3.95E-02 3111 Rattus norvegicus similar to
semaphorin cytoplasmic domain-
associated protein 3A
(LOC312607), mRNA = PDZ
domain containing RING finger 3
unique hit, close to mRIKEN cDNA 1110020C07,
SemaF cytopl dom ass protein 3A
ATTCTTTTGG
AATGTAT
5 0 3.95E-02 2342 mannosyl (alpha-1,6-)-
glycoprotein beta-l,2-N-
acetylglucosaminyltransferase
unique hit- close to named gene
ATTTAAGAC
AGTATTTT
5 0 3.95E-02 29900 Rattus norvegicus transcribed
sequences
unique hit, no assigned locus in neigbourhood
CAAAAGGCT
CTCCTAAT





unique hit- in wrong direction
CAAGGCCTC
CCTAAAAG
5 0 3.95E-02 unique hit, no assigned locus in neigbourhood
CACTCCTGC
TGAAGAAT
5 0 3.95E-02 14510 Rattus norvegicus transcribed
sequences




5 0 3.95E-02 11189 Ras-related associated with
diabetes
unique hit (GTP binding protein RAD 1)
Tag VMP vsu fold P-value Unigene Description genomic BLAST
CAGCAGCCT
CTGGAAGA






5 0 3.95E-02 116313 Rattus norvegicus transcribed
sequence with moderate similarity







5 0 3.95E-02 8133 Rattus norvegicus similar to
RIKEN cDNA 1110038M16
(LOC313529), mRNA
unique hit close to novel transcript with homology to
mRIKEN cDNA 1700012A05 (=1110038M16)
CCTTGGGGG
AGGGTGGG
5 0 3.95E-02 unique hit, lkb from to mSlit2 homolog
CCTTTTGTTA
TAATAAA
5 0 3.95E-02 8458 Rattus norvegicus transcribed
sequences
No exact hit in rat genome
CTCCTTTATC
TTCTACT
5 0 3.95E-02 91975 Rattus norvegicus transcribed
sequences




5 0 3.95E-02 98420 Rattus norvegicus similar to
RIKEN cDNA 1700027N10
(LOC316238), mRNA




5 0 3.95E-02 17732 Rattus norvegicus transcribed
sequences
unique hit, lkb from mSOX7 locus
GAGAAGCCG
GAGGTCGT
5 0 3.95E-02 118492 Rattus norvegicus transcribed
sequence with strong similarity to
protein sp:Pl 1174 (H.sapiens)
RS15_HUMAN 40S ribosomal
protein S15 (RIG protein) multiple hits
GAGGAGAGT
GAAAATGC




5 0 3.95E-02 23241 Rattus norvegicus transcribed
sequences
unique hit, 1.5kb from ZF13 locus (Zfpl 10, Zfp274)
Tag VMP vsu fold P-value Unigene Description genomic BLAST
GCCGAAATG
TCTGTGTT
5 0 3.95E-02 1078 Rattus norvegicus transcribed
sequences




5 0 3.95E-02 28360 Rattus norvegicus transcribed
sequences
uniquey hit, 3.5kb from mADAMTS12 locus
TGGGCCAAG
TCTGGG
5 0 3.95E-02 33523 Rattus norvegicus similar to A301
protein (LOC308592), mRNA
unique hit, close to novel transcript with homolgy to
glutamate rich WD containing 1 (Grwdl = A301)
GCTTCTCCCT
TCTTCCC
5 0 3.95E-02 8046 casein kinase 1, delta unique hit
GGAGATACC
TGTTCAAA
5 0 3.95E-02 11567 nel-like 2 homolog (chicken) unique hit
GGCAAGCCC
CAGCGTNT
5 0 3.95E-02 multiple genomic hits (for 19bp)
GTCTATTTAT
ACATTGG
5 0 3.95E-02 41830 Rattus norvegicus transcribed
sequences




5 0 3.95E-02 121231 Rattus norvegicus transcribed
sequences




5 0 3.95E-02 36521 Rattus norvegicus similar to
FGFR1 oncogene partner
(LOC365103), mRNA




5 0 3.95E-02 1868 beta-2 microglobulin
TAAAGTACT
CACTCCTG
5 0 3.95E-02 117190 Rattus norvegicus transcribed
sequence
unique hit, beta 2 microglobulin
TAATTAAAC
ACTTGTGA
5 0 3.95E-02 103231 Rattus norvegicus transcribed
sequences
unique hit, 4kb from novel transcript with homology
to mSCUBEl (contains CUB domain, mostly found
in developmentally reg proteins)
TAATTTGAT
TTTGGAAT





5 0 3.95E-02 66545 Rattus norvegicus transcribed
sequences
uniqueh hti, 4.5kb from novel transcript similar to
PLAG1 (pleiomorphic adenoma gene)
TATTTACTCT
GCCAAGT










Tag VMP vsu fold P-value Unigene Description genomic BLAST
TGACCATAT
TGTCAAAA
5 0 3.95E-02 56603 amine oxidase, copper containing








5 0 3.95E-02 16844 Rattus norvegicus similar to
amyotrophic lateral sclerosis 2
chromosome region candidate 9;
putative GTPase regulator
(LOC363239), mRNA
unique hit, no assigned loci in same direction
TGTGGCATA
CATACACT
5 0 3.95E-02 62699 Rattus norvegicus transcribed
sequences
unique hit, no assigned locus within 5kb
TTCACAATG
CCTTGTGT
5 0 3.95E-02 24283 Rattus norvegicus transcribed
sequences
No exact hit in rat genome
TTCATTAATT
ATTGTGG
5 0 3.95E-02 103261 Rattus norvegicus similar to
retinoid x receptor interacting
protein (LOC290997), mRNA
unique hit, close to novel transcript with similarity to
retinoid x receptor interacting protein (=RAP 80)
TTCCTGCAA
TAAAGGCT
5 0 3.95E-02
